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Influenza A virus (IAV) is a zoonotic pathogen which consists of a large
genetically and antigenically diverse viral population. Swine IAVs not only cause disease
outbreaks among swine, but can also be transmitted to humans, causing sporadic 
infections and even pandemic outbreaks apart from human seasonal IAV. Antigenic 
variant identification is fundamental for an effective vaccination program. Red blood cell
based immunological tests have been used to identify antigenic variants among
circulating IAV strains. Because these assays require viral isolation, they are time 
consuming and labor intensive. Thus only limited numbers of virus isolates are subjected 
to antigenic characterization in influenza surveillance studies and much of this important
information is lost. In this project, a novel polyclonal antibody based proximity ligation 
assays (polyPLA) was developed and validated to characterize IAV antigenic variants 
directly using clinical samples. The application of this method with clinical samples from 
influenza surveillance had aided in the understanding of the antigenic evolution of IAV in 
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INTRODUCTION
Influenza viruses and diseases
Currently, there are four genera of influenza viruses that belong to the family
Orthomyxoviridae: Influenza virus A, B, C, and D (IAV, IBV, ICV, and IDV, 
respectively). IAV and IBV have genomes that consists of 8 negative-sense, RNA
segments that encode at least 11 proteins: RNA polymerase subunit 2 (PB2), RNA
polymerase subunit 1 (PB1 and PB1-F2), RNA polymerase unit (PA), hemaggluinin 
(HA), nucleoprotein (NP), neuraminidase (NA), matrix proteins (M1 and M2), and 
nonstructural proteins (NS1 and NS2). ICV and IDV have 7 negative-sense, RNA
segments that encode at least 9 proteins. IAV is a zoonotic pathogen which consists of a
large genetically and antigenically diverse viral population that, to date has subtypes from 
18 HA and 11 NA. 
The influenza virus is a perpetual threat to public health. Seasonal influenza
infections are associated with 30,000 deaths a year in the United States (1); additionally, 
influenza epidemics, every few years, increase the annual mortality level to 40,000 to 
45,000 deaths. Unpredictably, global pandemics of influenza occur, infecting 20% to 
40% of the population in a single year, dramatically raising death rates above normal 
levels. The influenza vaccine is the most viable option in counteracting and reducing the 





















   
continuously changing, new strains can potentially escape the immunity of previously
exposed hosts(3, 4).  Therefore, the vaccine strains need to be updated almost annually to 
obtain antigenic matches between the vaccine strain and the strain potentially causing
future outbreaks(5, 6). 
Host range and zoonosis of influenza A viruses
While aquatic waterfowl are the major natural reservoir for IAV, swine can serve as a
host for both human and avian origin IAV(7). Avian- and human-origin IAVs typically
preferentially bind to receptor saccharides containing terminal α2,3-linked sialic acid-
galactose (SA2,3Gal) or α2,6-linked sialic acid-galactose (SA2,6Gal), respectively(8, 9). 
Swine tracheal epithelium expresses both SA2,3Gal and SA2,6Gal receptors(10), and 
swine are therefore proposed as the intermediate host for avian IAV adaptation and as a
“mixing vessel” for generating novel viruses by reassortment between avian-origin and 
human-origin IAVs(11-13). Subtypes which have been isolated from global swine
populations include: H1, H2, H3, H4, H5, H7, and H9(14). 
Humans have been reportedly infected with swine IAV since 2005(15), and such 
viruses are referred to as “variants”. Many cases of variant IAV have been traced back to 
swine exposure at agricultural fairs within the United States(16-19); with the most
notorious of these viruses being the 2009 H1N1 pandemic(20-22). As of 2011, there have
been 364 reported human disease cases caused by H3N2 variant (H3N2v) IAV in 14 
states(15, 19, 23); many of the infected people reported direct or indirect contact with 
swine at agricultural fairs and only rarely was human-to-human transmission of the virus



















Also, swine have been shown to be susceptible to human influenza virus strains(26). 
In the past five decades, genomic analyses suggested at least 20 introductions of IAVs 
from humans to swine, the majority being human seasonal subtype H3N2 viruses(27). 
Human-to-swine transmission, also referred to as reverse zoonosis, of influenza
A(H1N1)pdm09 virus was found in swine approximately one month after the virus was 
detected in humans(28). The A(H1N1)pdm09 virus co-circulated with endemic swine
influenza virus, including triple-reassortant H3N2, human-origin H1N2 (H1 δ1), and 
classical H1N1 (H1 γ) swine influenza viruses(29), resulting in reassortment events(30-
33). (H3N2)v swine influenza viruses with matrix gene segments from A(H1N1)pdm09 
virus were isolated in humans in 2011(25). 
Evolution of Influenza A viruses
Mutations, reassortment, and recombination
The RNA polymerase of IAV lacks a proofreading mechanism, leading to a mutation 
rate that ranges from 0.4 x 10-3 to 2.0 x 10-6 per nucleotide per year, depending on strain 
and gene (34-38). The rapid evolution of the surface glycoproteins, HA and NA, leads to 
antigenic drift (39). Genetic and antigenic diversity is also accomplished through mixed 
infection of two or more viruses within the same host and the generation novel viruses by
reassortment of gene segments, which can result in antigenic shift. Recombination, rare
in IAV, can also occur in a mixed infection in which the polymerase switches templates, 
creating a novel mosaic structure(40).  Novel antigenic variants enable influenza viruses 
to cause epidemics in humans on almost a yearly basis, with potentially serious medical 

















Viral quasispecies Selection and fitness
Infection within a host is not limited to one identical viral genome; the proliferating
population of viruses is closely related, yet is not identical(42-45). The viral quasispecies 
of IAV within a host is due to the rapid virus diversification because of the error-prone
genome replication and are these quasispecies are subject to continuous competition (44, 
46). Some mutations can be positively selected in order for a virus to escape from host 
antibody neutralization or to replicate more efficiently, leading to virus variants, which 
could become predominant in the population (47). Population-level fitness has also been 
shown to be increased by cooperative interactions between variants within a
quasispecies(48-52). 
Influenza vaccination
Influenza vaccination in humans
Vaccination is the primary approach for the control and treatment of human
seasonal influenza outbreaks(2). Antigenic variant identification and antigenic match 
between vaccine strain and epidemic strain is the key to a successful vaccination 
program(35). The global influenza surveillance network coordinated by the World Health 
Organization(53) characterizes antigenic properties of influenza viruses using the golden 
standard antigenic characterization method of hemagglutination inhibition assay (HI) and 
sequencing of HA1 domain(54, 55). Antigenic, genetic, and epidemiological data are
examined to make recommendations for candidate vaccine strains. Data collection also 
aids policy makers in understanding the risk factors for severe disease, variation of
influenza severity from season to season and its relationship to virus types or subtypes, 



















   
    
 
decision-making(53). One major limitation for implementing changes to the influenza
vaccine is the time restriction on current virus strain assessment. Recommendations are
based on predicting the future impact of circulating viruses, most notably, emerging
antigenic variants, before full epidemiological significance is known(36).
Accuracy in deciding vaccine composition is important because typically this 
must be completed almost a full year before the peak of seasonal influenza activity(5). 
Worldwide epidemiological surveillance is necessary in order to monitor IAV vaccine 
effectiveness; this is accomplished by the isolation and characterization of currently
circulating viruses. Additionally, the early detection of IAV infection by reliable
laboratory results can prevent spread of disease and assist with optimal treatment 
decisions. 
Influenza vaccination in domestic swine
Vaccination is commonly used in the United States for IAV control in swine. 
Swine vaccines typically, available as licensed commercial products, consist of culture-
derived virions in crude allantoic fluid from SPF chicken eggs, which are then chemically
inactivated, and formulated into a mineral oil emulsion vaccine(56). Current swine
influenza vaccines are strain specific, consisting of two or more H1 and H3 isolates, and 
fail to induce cross-protection against genetic and antigenic virus variants(57). Unlike 
human vaccines, this process avoids costly purification steps for enrichment of the
surface glycoproteins hemagglutinin (HA) and neuraminidase (NA)(58), but booster





















Because vaccines are produced locally and autogenously, each geographic region 
differs in vaccine strain, exact adjuvant formulation, and antigen dose. Vaccines that are
antigenically inaccurate for circulating viruses can lead to vaccine-induced immune 
pressure, causing antigenic drift(60). The generation of novel escape mutants gradually
replace circulating virus strains(61, 62). Such antigenic drift events in swine populations
have been documented(57, 63, 64).
Influenza vaccination in domestic poultry
In domestic poultry, influenza vaccines are not only used for the prevention of disease
and death, but for the prevention of infection or reduction of viral replication in 
respiratory and digestive tracts to limit viral spread to uninfected flocks(65-68). 
Currently, vaccines are available against H5 or H7 in live IAV vaccines, that are only
available for chickens, or inactivated avian IAV vaccines, that are available for a wider 
range of species, including chickens, turkeys, ducks, geese, and zoo birds(67).  
Antigen diversity of IAVs in different hosts
Antigenic diversity of IAVs in domestic swine
Swine may play a role in the reassortment and adaptation of novel zoonotic
viruses; it is possible that a novel virus with pandemic potential could cause a spill-over 
event into the human population(11, 69, 70). Influenza surveillance in swine is seen as 
important for the protection of public health and pandemic prevention. Swine IAVs not
only cause outbreaks among swine, but can also be transmitted to humans, causing
sporadic infections and even pandemic outbreaks apart from human seasonal IAV. 




















   
 
viruses for their adaptation before these viruses can infect humans(71-74). Both avian-
like H1N1 and H3N2 viruses have been isolated from domestic swine(74-76); avian 
origin influenza A viruses of subtypes H1 to H13 have been shown to infect and replicate 
in swine under experimental conditions(74), as well as direct avian H2N3, H3N1, and 
H4N6 to swine transmission of influenza in nature(12, 57, 77-84). 
Influenza surveillance studies in domestic swine from 2009 to 2012 identified the
co-circulation of H1N1, H1N2, and H3N2 IAVs, which are genetically and antigenically
diverse, with different amounts of cross-reactivity in serological assays(80-83). The H1 
subtypes form four genetic clusters: swH1α (classic H1N1), swH1ß (reassortant H1N1-
like), swH1γ (H1N2-like), and swH1δ (human-like H1); swH1γ are further divided into 
subclusters swH1γ and swH1γ2; swH1δ are further divided into subclusters swH1δ1 
(human-like H1N2) and swH1δ2 (human-like H1N1) (20). Additionally, the 2009 H1N1 
(A(H1N1)pdm09) virus emerged from swH1γ, a classic H1N1 virus, but has evolved into 
a distinct genetic and antigenic lineage after being introduced back to the swine 
population(77).  There are four genetic clusters of H3N2 subtype IAV present in the 
United States swine population: clusters I-IV(7, 78, 79); cluster IV is currently
predominant in domestic swine, and can be further divided into two antigenic clusters: 
H3N2-α and H3N2-ß(80). Antigenic characterization studies demonstrate that these
genetically diverse H1 and H3 viruses are antigenically distinct, showing different 
amounts of cross-reactivity in serologic assays(85, 86).
Antigenic diversity of IAVs in feral swine
Migratory waterfowl are the major natural reservoir of IAVs(7, 87) but avian 

















   
 
 




swine, Sus scrofa, in the United States, are domestic swine that escaped from commercial 
operations or were intentionally released, descendants of Eurasian wild boar introduced 
for hunting purposes, or hybrids of the two(88). The feral swine have an estimated 
population size of 5 million across 35 states, which is ever-increasing. Although the same 
species as domestic swine, feral swine are free ranging, with capabilities to come in 
contact with wild waterfowl, domestic swine, poultry, and humans, making feral swine a
potential vector for the bi-directional transmission of influenza viruses. 
H1N1 and H3N2 IAVs have been recovered from feral swine, and a recent 
serological surveillance in feral swine revealed 9.15% IAV seropositive samples from 31 
states(80). Feral swine have opportunities to encounter wild waterfowl by frequenting the
same bodies of water, feeding in the same areas, and preying or scavenging on wild 
waterfowl, which can provide potential for IAV transmission from wild birds to feral 
swine. Because feral swine are highly mobile, they can also have opportunities to come 
into contact with IAVs from infected domestic swine, poultry, and even humans via
contaminated fomites or aerosol dispersal(89).
Antigenic diversity of IAVs in domestic poultry
Domestic poultry can be infected with nonpathogenic, low pathogenic, and highly
pathogenic IAV. There are a variety of HA subtypes that are less virulent and do not 
cause death in experimental infection. In contrast, H5 and H7 subtypes are highly virulent 
and cause 100% death in experimental infection. The emergence of antigenic variants in 







   
   
  











Antigenic diversity of IAVs in wild birds
IAVs have been recovered from at least 105 wild bird species of 26 different 
families(91). Migratory waterfowl, such as the birds in the orders Anseriformes (e.g. 
ducks, geese, swans) and Charadriiformes (e.g. gulls, terns, and waders), are considered 
the major natural reservoirs of IAVs(7). Sixteen IAV HA (H1–H16) and NA (N1-N9) 
subtypes have been recovered from migratory waterfowl. The prevalence of IAV
infection is up to 30% among wild birds(7), and virus transmission typically occurs via
exposure to virus shed in the feces of infected animals(92, 93).  It has been conceptually
proposed that antigenic evolution in migratory waterfowl could be static(94); for
example, this theory is supported by recent studies indicating a lack of antigenic diversity
among H3 and H7 IAVs in migratory waterfowl in North America(95, 96).
Influenza vaccine strain selection and challenges
Current WHO strain selection
Human seasonal vaccines need to be updated almost every year due to frequent 
antigenic drift events in the epidemic viruses. On the other hand, recommendations of 
influenza vaccine strains are based on the prediction of circulating viruses, most notably, 
possibly emerging antigenic variants, before full epidemiological significance is 
known(97). One major challenge for selecting an influenza vaccine strain is the time 
restriction that at least six months are required for vaccine manufacture before the next 
influenza season begins. For example, for the Northern Hemisphere, the vaccine strain 
for the fall season has to be determined early spring (usually on Feb 15 each year). Thus, 
to create a successful influenza vaccination program, a rapid antigenic variant 











   
  
 
Since 1993, antigenic and biochemical differences in the HA proteins of influenza
viruses have been noted after passage in both Madin-Darby canine kidney (MDCK) cell
and eggs(100). There are altered patterns of agglutination for influenza viruses 
propagated in eggs and after growth in cell culture spiked with non-immune horse serum 
in comparison to the original isolate(98, 100-108). Additionally, sequence analysis has 
shown that changes in the H3 HA residues occur in the antigenic sites (residue 137 
(antigenic site A), 156 (B), 186 (B), 248 (D), 276 (C))(101). Both monoclonal and 
polyclonal antisera can detect a difference in the antigenicity between HAs before and 
after passage in eggs(100). The altered viruses will negate the goal of choosing vaccine 
viruses which are likely to be circulating during the impending influenza seasons. 
Alternatively, vaccine effectiveness, in the 2012-13 influenza season, was affected by
egg-adapted mutations in the A/Victoria/361/2011 vaccine strain (IVR-165)(109). 
Antigenic profiles
Reference ferret sera are used to determine antigenic properties of currently
circulating viruses for influenza surveillance and vaccine strain selection(97, 109-114). 
Variant viruses are identified to have ≥8-fold reduction of cross-reactivity to the ferret 
sera as compared to that of the homologous vaccine virus. Vaccines are also evaluated 
with human post-vaccination sera for cross-reactivity with circulating variants; a
reduction of ≥50% in geometric mean titers significantly indicates low vaccine 
efficiency(115). In a comparison between ferret and human sera, it has been shown that 
ferret sera does not always represent vaccine-induced responses in humans(111, 115-
117). One such example of vaccine mismatch occurred in the 2014-2015 Northern 



















H3 antigenic differences in 2014 with H3N2 subclades 3C.2a and 3C.3a 
In the 2014-2015 influenza season, two H3N2 subclades mutated independently
and rapid spread of the novel antigenic mutations occurred due to a lack of immune 
protection. Previously, in the HA of genetic clade 3C.1, phenylalanine (F) was at residue
159 and asparagine (N) was at residue 225. Both subclades mutated residue 225 first to 
aspartic acid (D), followed by mutation of residue 159 to serine (S) or tyrosine (Y) for 
clades 3C.3a or 3C.2a, respectively. 
Low or undetectable hemagglutination activity was common, particularly for 3C.2a, 
which caused antigenic characterization of the novel viruses to be more difficult (118). 
Ferret sera from cell-propagated 3C.3a and 3C.2a inhibited most circulating viruses, so
the WHO concluded that 3C.3a and 3C.2a were antigenically related. The majority of the 
viruses analyzed were antigenically related to 3C.3a and  A/Switzerland/9715293/2013-
like virus (3C.3a) was chosen as the 2015-2016 vaccine virus(118, 119). 
The following season, 2015-2016, the majority of viruses analyzed were 3C.2a with 
3C.3a co-circulating but at a lower proportion(118). Like the previous year, antigenic 
characterization was technically challenging due to low or undetectable hemagglutination 
activity. Reference sera for 3C.2a were able to inhibit the majority of viruses from both 




Clinical signs and symptoms of influenza can include: fever, muscle aches,





















nose(120). Influenza diagnosis based on clinical signs and symptoms alone is difficult 
because they are similar to other pathogens. There are several diagnostic tests available 
for the detection of influenza virus, including viral culture, serology, rapid antigen testing
reverse transcription polymerase chain reaction (RT-PCR), immunofluorescence assays, 
and rapid molecular assays. Sensitivity and specificity of these tests depend on type of 
test used, time from onset of illness until sample collection, type of sample collected, 
sample handling, and test performance. 
Serological assays
Routinely, immunological tests, such as HI (86) assays and microneutralization 
(121) assays, have been relied upon to identify antigenic variants among the circulating
strains(122). The HI assay is an experiment to measure how a test influenza antigen and a
reference antigen (e.g. a current vaccine strain) match through the immunological 
reaction between the test antigen and the reference antiserum. This reference antiserum is 
usually generated in ferrets using the reference antigen. However, the data from HI
assays are notoriously noisy, and HI experiments are affected by many factors. For 
example, red blood cells (RBCs) used from different species, which could have different 
sialic acid receptors, can produce varied results(122). Both HI and MN require viral
isolation, thus are labor intensive and for highly pathogenic viruses, a BSL-3 facility is 
required. The data are subject to interpretations and the HI assays are difficult to
automate and standardize. 
More importantly, mutations of the receptor binding site in HA(4) (antigenic drift) are
causing human seasonal H1N1(100, 123) and H3N2 influenza A viruses(124) to lose the 


















the human epidemic H1N1 influenza A viruses in 1988 or later caused the loss of their 
abilities to agglutinate chicken RBCs due to four amino acid changes(125). For H3N2 
viruses, the Gly190Asp substitution has been correlated to the loss of the ability to 
agglutinate chicken erythrocytes(122, 124, 126-130). Since 2000, human seasonal H1N1 
and H3N2 influenza A viruses have been losing their binding abilities to turkey
RBCs(122, 131). This may be attributed to a reduced affinity for sialic acid-linked 
receptors (particularly α2-6-linked receptors), which are at lower levels on chicken and 
turkey RBCs compared to levels on guinea pig RBCs(122, 131). In addition, 
heterogeneous populations which contain minor antigenic variants cannot be detected 
with HI assays(132).
In addition, both HI and MN require viruses to be isolated and propagated from the
original clinical samples. The virus isolation process is not only time-consuming but also 
can change the antigenic properties of the viruses in the patients due to the laboratory
adaptation in cells or embryonated eggs(121, 133-135). Furthermore, some viruses 
cannot even be recovered from the specimen. The virus isolation and propagation may
require a high-level biocontainment, e.g. for highly pathogenic influenza A viruses. Thus, 
there is a critical need for a viral isolation-free and RBC independent assay to assess 
antigenic changes in influenza viruses in order to further expand influenza surveillance. 
Antigen detection
When a patient has an influenza like illness (ILI), it is important that throat, nasal and 
nasopharyngeal secretions or tracheal aspirate and washings are properly collected, 
stored, and transported for laboratory detection of influenza virus. Laboratory


















PCR(136) for influenza-specific RNA(137). Immunofluorescence antibody (IFA) 
staining of original clinical samples or isolates can be completed with commercially
available monoclonal antibodies. Viral isolation is preferred for a larger quantity of 
antigen to be present yet suitable clinical specimens can be used. The sensitivity of IFA 
depends on sample quality, specificity of reagents used, and the level of experience for
test performance, reading, and interpretation.
Commercially available rapid influenza antigen detection tests (RIDTs) are used 
within the first 4 days of ILI symptom onset. RIDTs are used for: detection of influenza
A only, detection of both influenza A and B, or detection and differentiation between 
influenza A and B(137). For detection of nucleoprotein (NP) for pandemic H1N1 2009, 
RIDTs, compared to RT-PCR, has a sensitivity range of 10-69%(138-142); detection of
NP from seasonal influenza with RIDTs, compared to RT-PCR or viral culture, has a
sensitivity range of 10-96%(143-146). The use of RIDTs is not encouraged if RT-PCR of 
immunofluorescence assays are available and the WHO recommends IFA, viral culture, 
or RT-PCR should be used in conjunction to confirm and extend results(147).  
The proximity ligation assay utilizes quantitative real time PCR (qRT-PCR) for 
the detection of antigen-antibody interaction(148). For this assay: (1) oligonucleotide-
linked monoclonal antibodies are incubated with the analyte in question; (2) if in close
proximity, the oligonucleotides can be ligated together; and (3) presence of analyte will
be shown by amplification of ligated products with qRT-PCR. The assay reporter signal 























Genomic sequencing and data analyses
Sequencing of IAV is useful to identify the origin of novel reassortant viruses as 
well as identify molecular characteristics of a virus, such as host range, replication 
efficiency, transmissibility, or virulence(150-153). The traditional method of Sanger 
sequencing is widely used in influenza surveillance and research(154). Next-generation 
sequencing (NGS) can sequence the entire genome(155, 156) and is helpful in the 
identification of genetic variation within a viral quasispecies and to monitor vaccine
composition(157). The massively parallel sequencing of influenza virus by the NGS
platforms allow for increased sensitivity of the study of the populations. This is in 
contrast to the traditional method and NGS is a highly sensitive sequencing method that 
does not require molecular cloning or plaque generation for phenotypic selection(158-
160) for an output of multiple gigabases of DNA(161). Because the whole IAV genome 
is only 13,000 nucleotide bases of RNA, coverage is high, yet the segmented nature of 
the genome is challenging to achieve full genome coverage(155, 162-166). In the analysis
of NGS data for IAV, it is important to accurately assemble the short reads into the 8 
genomic sequences while retaining the polymorphisms within the quasispecies or true
mixed infection of multiple viruses.  
Phylogenetic analyses
Genetic differences can be visualized by relatedness with other influenza viruses by
phylogenic trees, typically HA and NA gene segments. The length of the horizontal 
branches indicates the number of nucleotide differences and the vertical distance of the
branches indicate the genetic difference. Phylogenic analysis can determine a common 

















Genetic differences, alone, are unreliable in the determination of antigenic 
differences in novel viruses. Additionally, antigenic properties through immunological 
datasets are not always straightforward. The relative antigenic relationship and evolution 
can be visualized with the production of two- or three- dimensional maps, known as 
antigenic cartography(168). The antigenic map produced can quantify antigenic
differences between viruses; antigenically similar viruses cluster closely while
antigenically different viruses are farther away.
Objectives, hypotheses, and specific aims of this study
The goal of this study is to understand antigenic evolution of influenza A virus 
directly using clinical samples. The hypotheses of this study are that antigenic variants 
can be detected directly from clinical samples and that antigenic characterization from 
clinical samples, especially uncultivable samples, would provide new knowledge of the
antigenic evolution of influenza A viruses. To test the hypotheses of this study, a novel 
polyclonal antibody based proximity ligation assays (polyPLA) was developed and 
validated to characterize influenza antigenic variants directly using clinical samples and 
further to apply this method in clinical samples from influenza surveillance to understand  







   
   
       
 
  




   
  
   
        
  
 
US FERAL SWINE WERE EXPOSED TO BOTH AVIAN AND SWINE IFNLUENZA 
A VIRUSES
Influenza A viruses (IAVs) in swine can cause sporadic infections and pandemic
outbreaks among humans, but how avian IAV emerges in swine is still unclear. Unlike 
domestic swine, feral swine are free ranging and have many opportunities for IAV
exposure through contacts with various habitats and animals, including migratory
waterfowl, a natural reservoir for IAVs. During 2010–2013, 8,239 serum samples were
collected from feral swine across 35 US states and tested against 45 contemporary
antigenic variants of avian, swine, and human IAVs; of these, 406 (4.9%) samples were
IAV-antibody positive. Among 294 samples selected for antigenic subtyping, 271 cross-
reacted with ≥1 testing virus whereas the other 23 did not cross-react with any testing
virus. Of the 271 IAV-positive samples, 236 cross-reacted with swine IAVs, 1 with avian 
IAVs, and 16 with avian and swine IAVs, indicating that feral swine were exposed to 
both swine and avian IAVs but predominantly to swine IAVs. Our findings suggest that 
feral swine could potentially be infected with both avian and swine IAVs, generating
novel IAVs by hosting and reassorting IAVs from wild birds and domestic swine and 
facilitating adaptation of avian IAVs to other hosts, including humans, before their











   
 
   
   
  
  
   
  
   
   
   
IAVs in feral swine is necessary to increase our understanding of the natural history of 
IAVs.
Introduction
Influenza A virus (IAV), a negative-stranded RNA virus with 8 genomic
segments, can infect a wide range of hosts, including humans, wild birds and domestic
poultry, swine, canines, felines, equines, mink, ferrets, sea mammals, and bats. IAVs 
have been recovered from at least 105 wild bird species of 26 different families (91). 
Migratory waterfowl, such as Anseriformes spp. birds (e.g., ducks, geese, and swans) and 
Charadriiformes spp. birds (e.g., gulls, terns, and waders), are considered the major
natural reservoirs of IAVs (7). Sixteen IAV HA (H1–H16) and NA (N1-N9) subtypes 
have been recovered from migratory waterfowl. The prevalence of IAV infection is up to 
30% among wild birds (7), and virus transmission typically occurs via exposure to virus 
shed in the feces of infected animals (92, 93).  It has been conceptually proposed that 
antigenic evolution in migratory waterfowl could be static (94); for example, this theory
is supported by recent studies indicating a lack of antigenic diversity among H3 and H7 
IAVs in migratory waterfowl in North America (169, 170). 
IAVs in domestic swine are genetically and antigenically diverse. In the past 
decade, the predominantly circulating domestic swine strains in the United States were
IAV subtypes H1N1, H1N2, and H3N2 (57, 84). Subtypes such as H4N6, H2N3, and 
H3N1 were also identified in North American domestic swine (82, 171, 172), but these
viruses did not become endemic. The H1 subtypes circulating in domestic swine form 
four genetic clades: swH1α (classic H1N1), swH1ß (reassortant H1N1-like), swH1γ






     
 
  




     
 
      
    
    




       
  
swH1γ1 and swH1γ2, and clade swH1δ is subdivided into swH1δ1 (human-like H1N2) 
and swH1δ2 (human-like H1N1) (173). In addition, the 2009 H1N1 pandemic virus,
A(H1N1)pdm09 emerged from a classic H1N1 virus and evolved into a distinct genetic
and antigenic lineage (173). There are 4 genetic clusters (I-IV) of the H3N2 subtype of 
IAVs present in the US swine population (174-176). Cluster IV, currently the 
predominant IAV cluster circulating among domestic swine, can be further divided into 2 
antigenic clusters H3N2-α and H3N2-ß (85). Antigenic characterization suggests that 
these genetically diverse H1 and H3 viruses are antigenically distinct, showing different 
extents of cross-reactivity in serologic assays (85, 177). Influenza surveillance studies in 
domestic swine from 2009 through 2012 identified the co-circulation of H1N1, H1N2, 
and H3N2 IAVs, including 6 H1 genetic clades (H1α, H1ß, H1γ, H1δ1, H1δ2, 
A[H1N1]pdm09) and 2 H3 cluster IV antigenic clusters (H3SIVα and H3SIVß) (29, 
178).  
Avian- and human-origin IAVs typically preferentially bind to receptor 
saccharides containing terminal α2,3-linked sialic acid-galactose (SA2,3Gal) or α2,6-
linked sialic acid-galactose (SA2,6Gal), respectively (8, 9). Swine tracheal epithelium 
expresses both SA2,3Gal and SA2,6Gal receptors (10), and swine are therefore proposed 
as the intermediate host for avian IAV adaptation and as a “mixing vessel” for generating
novel viruses by reassortment between avian-origin and human-origin IAVs (11, 12, 
179). In addition to avian-origin H2N3 and H4N6 IAVs, which were identified in 
domestic swine in North America, avian-origin H1N1(77, 78), H1N2 (180), H3N3 (83), 
H5N1 (81), H6N6 (181), and H9N2 (79, 80). IAVs were also identified in domestic




    






   
   
     
    
  
   
 
 
   
  
become endemic in domestic swine; the other avian-origin IAVs caused only low 
seroconversion rates and has been transient in domestic swine. Nevertheless, under
laboratory conditions, avian-origin IAVs of subtypes H1-H13 can infect and replicate in 
swine (12).
Feral swine in the US are domestic swine that escaped from commercial 
operations or were intentionally released, descendants of Eurasian wild boar introduced 
for hunting purposes, or hybrids of the two (182). In 2013, an estimated 5 million feral 
swine were found in at least 35 US states, with both numbers and geographic range
increasing. H1N1 and H3N2 IAVs have been recovered from feral swine, and serologic
surveillance conducted during 2011–2012 showed that 9.2% of 1,983 serum samples 
from feral swine in 31 states were IAV-seropositive (85). Similar to domestic swine, feral 
swine can be infected with IAVs under laboratory conditions (183).  Feral swine have
opportunities to encounter wild waterfowl by frequenting the same bodies of water, 
feeding in the same areas, and preying or scavenging on wild waterfowl, which can 
provide potential for IAV transmission from wild birds to feral swine. Because feral 
swine are highly mobile, they can also have opportunities to come into contact with IAVs 
from infected domestic swine, poultry, and even humans via contaminated fomites or 
aerosol dispersal (89). 
Our objective was to conduct a serological survey of feral swine for IAV
exposure and to assess the role of feral swine at the interface between wild birds and 
domestic swine. Utilizing 8,239 serum samples collected from feral swine in 35 US states 















   
 
   
   
  
  
   
seropositive samples’ cross-reaction to 45 antigenically diverse prototype IAVs from 
avian, domestic swine and human hosts.
Materials and Methods
Sample collection and serology testing. 
From October 1, 2009–September 30, 2013, the United States Department of 
Agriculture (USDA) Animal and Plant Health Inspection Service’s Wildlife Services
collected 8,239 serum samples from 8,239 individual feral swine, postmortem, across 35 
US states. This collection period included fiscal years (FY) 2010 (October 1, 2009– 
September 30, 2010; 1,818 samples), 2011 (October 1, 2010–September 30, 2011; 2,467
samples), 2012 (October 1, 2011–September 30, 2012; 1,846 samples), and 2013 
(October 1, 2012–September 30, 2013; 2,108 samples) (Table 1). Serum samples from 
October 1, 2011–September 30, 2012, were previously reported as 1,989 totally, yet 143 
serum samples had duplicate information and were ignored for this study. The date of
collection, geographic location, age (juvenile, subadult, adult, and unknown), and sex
were recorded. Antibody status was determined with the IDEXX AI MultiS-Screen Ab 
Test (IDEXX, Westbrook, Maine, USA). Serum samples with a sample-to-negative
control ratio of ≤0.681 were determined to be IAV-positive (183). The ELISA results for
a subset of feral swine samples (76 of 111) from FY2012 are reported elsewhere (85) in 
an assessment of the seropositivity rate of subtype H3 IAV in feral swine. To ensure
complete results, we included all feral swine serum samples collected for the study. Of 
the samples tested, 406 were identified as IAV-positive; to make this study more cost-















      
    
    
     
    
 
 
   
   
 
  
   
  
  
    





Table 1 Summary of feral swine serum samples used to determine the predominant 
source of feral swine exposure to endemic influenza A virus (IAV) in the
United States. 






samples (% positive)b 
selected for testing by HI 
assayc
2010 1,818 112 (6.2%) 0 d 
2011 2,467 95 (3.9%) 95
2012 1,846 111 (6.0%) 111
2013 2,108 88 (4.2%) 88
Total 8,239 406 (4.9%) 294
aFiscal years run from October 1st of one year through September 30th of the next year; 
the FY is named according to the second year.
bSerum samples were considered IAV-positive if the sample-to-negative control ratio was
≤0.681by ELISA (IDEXX AI MultiS-Screen Ab Test; IDEXX, Westbrook, Maine, USA)
(183). 
cHI, hemagglutinin inhibition.
d Not analyzed to make more cost effective.
Viruses and Ferret Reference Sera.
A total of 45 IAVs were selected to represent the following antigenic groups of 
contemporary IAVs: endemic swine IAVs H1 (α, ß, γ1, γ2, δ1, δ2) and H3 cluster IV (α
and ß); human influenza viruses (A[H1N1]pdm09, swine-origin influenza viruses 
A[H3N2]v, and seasonal H3N2); and avian influenza viruses H1–H14 (Table 2). These
viruses were used in the serologic characterization. The ferret reference sera used to 






      
  
   
        
        
        
        
        
         
         
          
         
         
         
         
         
        
       
     
         
         
         
         
       
        
        
        
        
       
       
      
     
     
     
       
       
  
 
    
      
     
      
      
     
     
  
 
    
     
  
 
    
 
 
    
 
 
    
 
  
    
   
   
 
Table 2 Cross-reactivities of feral swine serum samples against testing influenza A 
viruses in hemagglutinin inhibition assays
No. seropositive
Virus Antigenic group Source of virus* samples (%)† GMT (LB-HB)‡
A/swine/Minnesota/02093/2008 H1N1-α domestic swine 44 (14.67) 138.85 (40-1280)
A/swine/Minnesota/A01394082/2013 H1N2-α domestic swine 20 (6.67) 80 (40-320)
A/swine/Nebraska/A01399642/2013 H1N1-ß domestic swine 58 (19.33) 124.49 (40-1280)
A/swine/Nebraska/A01240348/2011 H1N1-ß domestic swine 57 (19.00) 146.94 (40-1280)
A/swine/Indiana/13TOSU0832/2013 H1N1-γ domestic swine 54 (18.00) 204.19 (40-1280)
A/swine/Indiana/13TOSU1154/2013 H1N1- γ domestic swine 53 (17.67) 187.19 (40-1280)
A/swine/Illinois/A01076767/2010 H1N1- γ2 domestic swine 5 (1.67) 45.95 (40-80)
A/swine/South Dakota/A01349306/2013 H1N1- γ2 domestic swine 63 (21.00) 271.32 (40-1280)
A/swine/Iowa/15/2013 H1 δ1 domestic swine 12 (4.00) 75.51 (40-160)
A/swine/Iowa/18/2013 H1 δ2 domestic swine 22 (7.33) 600.92 (40-1280)
A/swine/Iowa/19/2013 H1 δ2 domestic swine 12 (4.00) 59.93 (40-320)
A/swine/Iowa/7/2013 H1 2009p domestic swine 91 (30.33) 264.51 (40-1280)
A/swine/Iowa/8/2013 H1 2009p domestic swine 81 (27.00) 301.39 (40-1280)
A/California/04/2009 H1 2009p human 61 (20.33) 212.57 (40-1280)
A/mallard/Wisconsin/A00751454/2009 H1N1 avian 13 (4.33) 75.85 (40-640)
A/mallard/Oregan/A0030758/2007 H2N3 avian 0 0
A/swine/Ohio/09SW96/2009 H3N2 α domestic swine 84 (28.00) 105.04 (40-1280)
A/swine/Ohio/10SW215/2010 H3N2 ß domestic swine 117 (39.00) 140.45 (40-1280)
A/swine/Ohio/11SW347/2011 H3N2 ß domestic swine 93 (31.00) 146.31 (40-1280)
A/swine/Texas/A01104013/2012 H3N2 ß feral swine 123 (41.00) 64.58 (40-1280)
A/Perth/16/2009 H3N2 human 177 (59.00) 109.86 (40-1280)
A/Wisconsin/112/2010 H3N2v domestic swine 119 (39.67) 153.61 (40-1280)
A/Pennsylvania/14/2010 H3N2v domestic swine 89 (29.67) 89.91 (40-640)
A/Minnesota/10/2011 H3N2v domestic swine 105 (35.00) 106.96 (40-640)
A/Iowa/07/2011 H3N2v domestic swine 118 (39.33) 148.24 (40-1280)
A/Victoria/361/2011 H3N2 human 195 (65.00) 154.18 (40-1280)
A/mallard/Wisconsin/A00661715/2009 H3N2 avian 1 (0.33) 80 (±0.00)
A/blue-winged teal/Colorado/A00170379/2006 H3N8 avian 0 0 
A/mallard/Washington/A00714770/2009 H4N6 avian 0 0 
A/mallard/Wisconsin/10os3845/2010 H5N2 avian 0 0 
A/mallard/Oregon/A00571208/2007 H6N1 avian 0 0 
A/mallard/Ohio/648/2002 H6N2 avian 1 (0.33) 40 (±0.00)
A/bufflehead/Virginia/A00120022/2008 H7N2 avian 1 (0.33) 40 (±0.00)
A/American black H7N3 avian 0 0 
duck/Delaware/A00870108/2010
A/northern shoveler/Illinois/10os3632/2010 H8N4 avian 0 0 
A/mallard/Minnesota/10os4670/2010 H9N2 avian 0 0 
A/northern shoveler/Arkansas/11os386/2011 H9N2 avian 0 0 
A/mallard/South Dakota/A00536114/2007 H10N7 avian 0 0 
A/mallard/Illinois/10OS3249/2010 H11N2 avian 0 0 
A/mallard/Wisconsin/10OS2889/2010 H11N9 avian 0 0 
A/American green-winged H12N4 avian 0 0 
teal/Missouri/10OS4622/2010
A/bufflehead/Wisconsin/10OS3204/2010 H12N5 avian 0 0 
A/hooded merganser/New H13N6 avian 0 0 
Brunswick/03750/2009
A/white-winged H14 avian 0 0 
scooter/Wisconsin/10OS3922/2010
A/long-tailed H14N6 avian 0 0 
duck/Wisoconsin/10OS3912/2010
*The host from which the virus was isolated;
†Serum samples were determined to be positive against a testing virus if the associated 
HI titer was ≥1:40;
‡The geometric mean titer (GMT) was calculated for each group of positive samples.










   
 
   
 







Hemagglutination (HA) and Hemagglutination Inhibition (HI) Assays.
HI assays were performed according to the World Health Organization Global 
Influenza Surveillance Network Manual for the laboratory diagnosis and virologic 
surveillance of influenza (184). In brief, we treated 1 volume of feral swine serum with 3 
volumes of receptor-destroying enzyme (RDE) overnight at 37°C and then heat-
inactivated the serum at 56°C for 30 minutes. After returning to room temperature, 
treated antisera were diluted with 6 volumes of 1× PBS (pH 7.4). To minimize
nonspecific agglutination, we treated RDE-treated serum samples with 0.5% turkey red 
blood cells (RBCs) and then incubated them at 4°C for 1 hour, followed by centrifugation
at 1,200 rpm for 10 minutes; we then collected the serum samples without disturbing the 
packed RBCs. RBC absorption was repeated until no nonspecific agglutination was 
associated with any serum sample. In the HI assay, 0.5% turkey RBCs were used for 
absorption; serum samples were determined to be positive against a specific virus if the
HI titer was ≥1:40, as described previously (85). 
Virus neutralization inhibition assays.
RDE-treated feral swine serum was serially diluted 1:2 in a microtiter plate, and 
100 μL of 50% Tissue Culture Infectious Dose (TCID50) virus was added to each well, 
and then the plate was incubated at 37°C for 1 hour. The sera–virus mixture was then 
incubated with Madin-Darby canine kidney (MDCK) cells for one hour in a 96-well
tissue culture plate (USA Scientific; Ocala, FL, USA), washed twice with 1× PBS (pH
=7.4), washed with 200 μL of Opti-MEM (Thermo Fisher; Waltham, MA, USA), and 



















   
 
 
assays with 0.5% turkey RBCs. Serum samples were determined to be positive against a
specific virus if the neutralization inhibition titer was ≥1:40(185).
Data analyses.
Chi-square tests were used to assess the differences of IAV seropositivity rate 
between sex, age group, and month, year, and state of sample collection. We developed a
multilevel multivariable logistic regression model to test potential risk factors associated 
with IAV seropositivity rate in feral swine, focusing on the population sizes of domestic 
swine and poultry. The logistic regression model was developed using generalized 
estimation equations with binomial distribution and logit link function and accounted for
clustering of swine samples on the same date and location. Variables were manually
selected if they contributed significance to the likelihood ratio statistic for Type 3 
analysis at an alpha level of <0.05. IAV seropositivity rate for sex and age group of feral 
swine, month, fiscal year, and state of sample collection were analyzed as individuals and 
feral swine groups and best fit was assigned based on QIC (Quasilikelihood under the 
Independence model Criterion). Feral swine groups were defined to eliminate 
confounding variables; we grouped samples if collected on the same date at the same 
location; in theory, swine from the same group would be exposed to the same virus. In 
addition, an odds ratio (OR) was estimated using the GLIMMIX procedure for
generalized linear mixed models with binomial distribution and logit link function. 
Observations from states with less than 100 samples were excluded from the analysis. We
obtained population data for domestic swine and poultry per state from the 2012 USDA 
Census of Agriculture (https://www.agcensus.usda.gov/Publications/2012/). Small 













swine.  All statistical analyses were conducted in SAS9.5 (SAS Institute Inc., Cary, NC, 
USA).
Results
IAVs exposure in feral swine.
To evaluate the overall seropositivity rate of IAVs among feral swine, we used 
8,239 serum samples collected across 35 US states during October 1, 2009–September 
30, 2013; this collection period included FY2010–FY2013 (Figure 1; Table 1). Serologic 













     
   
 
Figure 1 Geographic distribution of swine and of influenza A virus (IAV)–positive
and IAV-negative serum samples per county collected from feral swine
across the United States during fiscal years (FY) 2010–2013.
A) Distribution of feral and domestic swine, and the density unit was 1,000,000. B–D)
Distributions of IAV ELISA–negative and –positive feral swine serum samples collected 
in FY2011 (October 1, 2010–September 30, 2011) (B), FY2012 (October 1, 2011– 
September 30, 2012) (C), and FY2013 (October 1, 2012–September 30, 2013) (D).
An association was identified between fiscal years and IAV seropositivity rate (p 
= 0.0002) and months and IAV seropositivity rate (p < 0.0001) for individual feral swine
but not for groups (p = 0.1717 and p = 0.1184 respectively). An analysis of seropositivity
rate by month determined that during FY2010 (October 1, 2009–September 30, 2010), 











     
      
  
   
 
 
   
 
April (12.3%, 20 of 162 swine) and September (1.8%, 1 of 57 swine), respectively. This 
temporal pattern, with a relatively higher IAV seropositive rate in spring and winter, was 
similar to the patterns seen in FY2011 and FY2012 and to those seen in FY2013 in our 
previous report (85) (Figure 2A).
To understand variables that are associated with IAV seropositivity among feral 
swine, we analyzed our results by swine age group and sex. IAV seropositivity rate was 
highest among the adult swine (5.8%, 350/5,984) and lowest among juvenile swine
(1.6%, 3/190); this pattern was consistent for all years; 2010 had the largest percent 
positives only due to having the smallest sampling of juveniles (14.29%; 1/7 samples), 
(Table 3). We identified an association between swine age group and IAV seropositivity
rate (p < 0.0001) for both individual swine and groups. In addition, IAV seropositivity
rate was higher among female (5.4%, 233/4,333) than male (4.5%, 173/3,871) swine; this 
pattern was consistent for all fiscal years except FY2011 (Table 3), in which 
seropositivity rate was higher among male (4.1%; 48/1,170) than female (3.7%; 
47/1,287) swine. However, no association was identified between sex and IAV-positive
samples for individual swine (p = 0.0583) and groups (p = 0.0665). Overall, most IAV-









                 
                
                
Figure 2 Epidemiologic analyses of the percentage of influenza A virus–positive feral 
swine serum samples collected across the United States during fiscal years
(FY) 2010–2013.
Samples were determined to be positive by ELISA. A) Temporal distribution of positive serum samples. B) Age distribution of feral
swine with positive serum samples. C) Sex distribution of feral swine with positive serum samples. FYs run from October 1st of one







    
      
           
           
           
           
           
           
           
           
           
           
           
           
      
           
           
           
           
 
           
           
           







Table 3 Total number of influenza A virus-positive (N=406) and total number of
feral swine serum samples collected during fiscal years 2010-2013* for
month, age group, and sex.
No. positive samples/total no. samples† (%)
Month 2010 2011 2012 2013 Total
January 13/220 (5.91) 16/373 (4.29) 4/80 (5.00) 10/188 (5.32) 43/861 (4.99)
February 16/235 (6.81) 19/337 (5.64) 25/208 (12.02) 9/274 (3.28) 69/1054 (6.55)
March 14/250 (5.60) 18/378 (4.76) 8/245 (3.27) 3/364 (0.82) 43/1237 (3.48)
April 20/162 (12.35) 7/253 (2.77) 1/159 (0.63) 16/218 (7.34) 44/792 (5.56)
May 5/162 (3.09) 2/234 (0.85) 1/131 (0.76) 22/185 (11.89) 30/712 (4.21)
June 4/81 (4.94) 4/134 (2.99) 1/153 (0.65) 2/99 (2.02) 11/467 (2.36)
July 9/133 (6.77) 5/184 (2.72) 0/86 (0.00) 0/101 (0.00) 14/504 (2.78)
August 9/246 (3.66) 4/170 (2.35) 47/309 (15.21) 2/201 (1.00) 62/926 (6.70)
September 1/57 (1.75) 0/112 (0.00) 18/280 (6.43) 0/67 (0.00) 19/516 (3.68)
October 6/107 (5.61) 6/110 (5.45) 1/91 (1.10) 18/187 (9.63) 31/495 (6.26)
November 6/80 (7.50) 9/56 (16.07) 1/26 (3.85) 4/83 (4.82) 20/245 (8.16)
December 9/85 (10.59) 5/126 (3.97) 4/78 (5.13) 2/141 (1.42) 20/430 (4.65)
Age group 2010 2011 2012 2013 Total
Juvenile 1/7 (14.29) 0/63 (0.00) 1/97 (1.03) 1/23 (4.35) 3/190 (1.58)
Subadult 15/526 (2.85) 17/658 (2.58) 17/451 (3.77) 3/406 (0.74) 52/2041 (2.55)
Adult 98/1281 (7.49) 78/1737 (4.49) 93/1288 (7.22) 83/1678 (4.95) 350/5984 (5.85)
Unknown 0/0 (0.00) 0/9 (0.00) 0/10 (0.00) 1/1 (100.00) 1/24 (4.17)
Sex
Female 63/968 (6.51) 47/1287 (3.65) 64/977 (6.55) 59/1101 (5.36) 233/4333 (5.38)
Male 46/843 (5.81) 48/1170 (4.10) 47/858 (5.48) 29/1000 (2.90) 173/3871 (4.47)
Unknown 0/7 (0.00) 0/10 (0.00) 0/11 (0.00) 0/7 (0.00) 0/35 (0.00)
Total 112/1818 (6.16) 95/2467 (3.85) 111/1846 (6.01) 88/2108 (4.17) 406/8239 (4.93)
* Fiscal years run from October 1st of one year through September 30th of the next year; 
the FY is named according to the second year.
†A total of 8,239 samples were tested using the IDEXX AI MultiS-Screen Ab Test 
(IDEXX, Westbrook, Maine, USA).
Although our data set is comprised of samples collected from 35 states, sample
sizes were not evenly distributed since the feral swine populations vary widely between 







































seropositivity rate of IAV was highest in North Carolina (16.1%, 34/211 samples) and 
Texas (10.5%, 164/1,561 samples) (Table 4).
Table 4 Total number and number of influenza A virus–positive feral swine serum 
samples collected from each of 35 US states during fiscal years 2010–2013.*




















North Dakota 0/5 (0.00)
New 0/20 (0.00)Hampshire
New Jersey 0/8 (0.00)
New Mexico 2/224 (0.89)
Nevada 0/16 (0.00)




















    
 
      
  
      
      










West Virginia 1/15 (6.67)
Total 406/8,239 (4.93)
* Fiscal years run from October 1st of one year through September 30th of the next year; 
the FY is named according to the second year.
†A total of 8,239 samples were tested using the IDEXX AI MultiS-Screen Ab Test 
(IDEXX, Westbrook, Maine, USA).
Of 438 counties, 112 (25.56%) were IAV-positive (Figure 1). Texas had the most
IAV-positive samples (40.4%; 164/406 total). Of 31 counties sampled in Texas, the 
highest seropositivity rates were in Dickens County (36.2%; 42/116 total), Hall County
(42.3%; 22/52 total), and Freestone County (35.7%; 5/14 total). The number of IAV-
positive samples varied by year, Hall County for example: in 2010, 0 of 1 samples were
positive; in 2011, 0 of 12 were positive; in 2012, 6 (30.0%) of 20 were positive; and in 
2013, 16 (84.2%) of 19 were positive. 
Distinction between swine and avian IAVs.
HI assays were performed on 294 ELISA positive samples and tested against 45 
IAVs, including HA subtypes H1–H14 and diverse antigenic clusters of contemporary
avian-, swine-, and human-origin IAVs (Table 2). Of note, among the testing strains, 







viruses although most of these viruses are antigenically different with ≥4-fold loss in HI










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of the 294 feral swine serum samples tested, 271 from 71 counties within 21 
states tested positive by HI assay for at least one virus in the reference panel, and 23
samples from 17 counties within 13 states tested negative to all viruses in the reference
panel. Of the feral swine samples tested 38.4% were positive against H1 swine IAVs (113 
out of 294), and 53.7% were positive against H3 swine IAVs (158 out of 294).  Totally, 
52 (17.7%) were positive to both H1 and H3 swine IAVs; among these H1- and H3-
positive samples, 106 (36.1%) and 233 (79.3%) were also positive against H1 and H3 
human IAVs, respectively (Figure 3). The serologic characterization suggests that the
swine-origin IAVs in H3α and H3ß clusters cross-reacted with the ferret reference sera















Figure 3 Geographic distribution of domestic and feral swine across the United States 
and distribution of influenza A virus (IAV)–positive serum samples (by
hemagglutination [HA] subtype) collected from feral swine during fiscal 
years (FYs) 2011–2013.
A) Distribution of feral and domestic swine, and the density unit was 1,000,000. HA 
subtypes were determined by hemagglutination inhibition assay for FY2011 (B), FY2012 
(C), and FY2013 (D). FYs run from October 1st of one year through September 30th of 
the next year; the FY is named according to the second year. Dots (pie charts) indicate 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Although 271 of the 294 feral swine serum samples tested HI positive to swine
and human IAV, only 16 (5.4%) cross-reacted to one of the four avian IAVs included in 
the reference panel: 13 (4.4%) samples cross-reacted to subtype H1 virus, one (0.3%) 
cross-reacted to H3 virus, and one (0.3%) each cross-reacted to H6 or H7 virus (Table 2).  
HI with reference sera showed H1 avian IAVs cross-reacted with ferret reference sera
against H1N1 human IAVs and that avian subtypes H3N2, H6N2, and H7N3 did not 
cross-react with the reference sera against the testing human and swine IAVs. To confirm
the HI results, we performed neutralization inhibition assays, which also showed that the 
16 feral swine serum samples were indeed cross-reactive against avian IAVs (Table 6). 
Distribution of avian subtypes detected in feral swine.
Sixteen feral swine serum samples from 10 counties in six US states were positive
for avian IAV (Figure 3). The states with the highest number of positive samples were
Texas (5), California (4), and Hawaii (4); the remaining samples were from Iowa, 
Kansas, and Ohio. The surveillance year with the highest number of avian IAV–positive 
samples was 2013 (7 samples), followed by 2011 (6 samples) and 2012 (3 samples). 
Thirteen samples were positive for avian subtype H1. Linn County, Iowa, was the only
location with an avian H3 subtype. Colusa County, California, was the only location with 
an avian H6 subtype, and Jefferson County, Oklahoma, was the only place where an
avian H7 subtype was identified. 
Factors associated with IAV seroprevalance in feral swine.
Using manual forward variable selection to determine factors that affect the






   
  
 
   
 
   
  
     
   
 
variables using a multivariable model: the number of domestic swine farms, small
domestic swine farms, poultry farms, and human population per state. We considered 
farms with 1,000 or fewer domestic swine to be small farms. Small farms were of interest 
due to less biosecurity and increased chance for contact with feral swine. Individually, 
the number of domestic swine farms, small domestic swine farms, and poultry farms 
were significant (p <0.05) but the number of small domestic swine farms had a better fit 
based on QIC (2.29). The number of domestic swine farms was highly correlated with the
other variables and were confounded, making each not significant. There were more IAV 
seropositive samples from states with more small domestic swine farms.
Discussion
Feral swine are a potential reservoir for infectious pathogens of domestic swine, 
including IAVs, because bidirectional transmission of pathogens occurs through direct 
and indirect contact between feral and domestic swine, primarily through backyard 
farming operations with poor biosecurity (186). A previous study suggested that IAV 
circulating among feral swine are antigenically and genetically similar to those 
circulating among domestic swine (85). Laboratory experiments have demonstrated that 
swine IAV can infect feral swine and transmit efficiently among them (183). In addition, 
feral swine may be exposed to avian IAVs through direct and indirect contact with wild 
birds via scavenging or preying and by using common sources of water and forage. Our
study findings confirm that although feral swine may be exposed to swine or avian IAVs, 
exposure to swine IAVs is much more common, especially with subtypes H1 and H3.
















   




feral swine could have a mixed IAV infection, and generate reassortants between swine
and avian IAVs that could ultimately be transmitted to domestic swine or humans. 
Based on serological evidence, our findings suggest that IAV-positive feral swine
in the United States were predominantly exposed to subtypes H1 and H3. H3N2 and 
H1N1 IAVs have been isolated from feral swine and are genetically close to endemic
domestic swine IAVs. It is unclear if there is an epidemiological link; however, this 
finding is consistent with a scenario where domestic swine IAV’s occasionally spill over 
into feral swine populations. Feral swine may be more likely to have contact with 
domestic swine in backyards or small farming operations that have less biosecurity than 
large swine operations and it is possible that direct or indirect (i.e. through fomites)
transmission occur between feral swine and domestic swine. Another possible source of 
domestic-like IAVs in feral swine could be from escaped infected domestic swine,
however, the recruitment rate of domestic swine into the feral swine population is not 
clear. Additionally, some feral swine serum samples cross-reacted with both H1 and H3 
subtypes of IAVs. These findings indicate that these swine could have been exposed to 
more than one IAV and is consistent with previously reported findings (85). These
possibilities need to be investigated by isolating IAVs currently circulating in feral swine
and comparing their genetics to those of nearby IAVs circulating in the domestic swine
populations.
A significant portion of the tested feral swine serum samples (78.57%; 231/294) 
cross-reacted with human-origin IAVs, including H1N1 and H3N2 viruses. The source of 
feral swine exposure to human H1N1 and H3N2 viruses is unknown. In 1934, Elkeles 




















five decades, genomic analyses suggested at least 20 introductions of IAVs from humans 
to swine, the majority being human seasonal subtype H3N2 viruses (27). Human-to-
swine transmission of influenza A(H1N1)pdm09 virus was determined in domestic swine
approximately one month after the virus was detected in humans (28). After this “reverse
zoonosis” event, A(H1N1)pdm09 virus co-circulated with endemic swine influenza virus, 
including triple-reassortant H3N2, human-origin H1N2 (H1 δ1), and classical H1N1 (H1 
γ) swine influenza viruses (29), resulting in reassortment events (30-33). Additionally, in 
our reference sera panel, H3N2 seasonal viruses did not cross-react with any reference
sera against any contemporary H3 swine IAVs, this is consistent with the H3 human-like
viruses found in domestic swine(187). As early as 2010, within the domestic swine
population, novel HAs of H3 viruses emerged and were most genetically similar to 
human H3N2 strains from the 2010-2011 season; this spillover event of human H3N2 
into swine is currently being sustained within the domestic swine population. 
In this study, only 4.9% of sera samples were IAV-positive, which is less than 
previously reported(85), yet a more stringent ELISA cutoff (S/N ≤0.681) was used 
among 4 years of sample collection; we believe this more truly represents the true
seropositivity rate of IAV in the feral swine population. The nucleoprotein for influenza
of different species can have up to 18.5% nucleotide differences(188). Therefore, the
IDEXX AI MultiS-Screen Ab Test may not be appropriate for use in feral swine due to 
the low seropositivity rate of avian influenza in feral swine and the IDEXX Swine
Influenza Virus Ab Test may be used for further studies. 
In summary, feral swine were predominantly exposed to H1 and H3 swine IAV, 





   
 
    
  
 
still potential for feral swine to generate novel IAVs by hosting and reassorting IAVs 
from wild birds with those from domestic swine and facilitating adaptation of avian IAVs 
before their spillover to other hosts, including humans. Continued surveillance is
warranted to monitor the distribution and genomic/antigenic diversity of IAVs in feral 















   
DETECTION OF INFLUENZA ANTIGENIC VARIANTS DIRECTLY FROM 
CLINICAL SAMPLES USING POLYCLONAL ANTIBODY BASED 
PROXIMITY LIGATION ASSAYS
Identification of antigenic variants is the key to a successful influenza vaccination 
program. The empirical serological methods to determine influenza antigenic properties 
require viral propagation. Here a novel quantitative PCR-based antigenic characterization 
method using polyclonal antibody and proximity ligation assays, or so-called polyPLA, 
was developed and validated. This method can detect a viral titer that is less than 1,000 
TCID50/mL. Not only can this method differentiate between different HA subtypes of 
influenza viruses but also effectively identify antigenic drift events within the same HA 
subtype of influenza viruses. Applications in H3N2 seasonal influenza data showed that 
the results from this novel method are consistent with those from the conventional 
serological assays. This method is not limited to the detection of antigenic variants in 
influenza but also other pathogens. It has the potential to be applied through a large-scale 
platform in disease surveillance requiring minimal biosafety and directly using clinical 
samples.
Introduction
The influenza virus is a perpetual threat to public health. Seasonal influenza



















worldwide pandemic could increase the death toll to millions in a short period of time. 
The hallmark of the influenza virus is antigenic variation, which comes in two forms: 
antigenic drift and antigenic shift; leading to the recurrence of influenza virus infections
(98). Mutations in the hemagglutinin and neuraminidase glycoproteins cause antigenic 
drift. Meanwhile, antigenic shift is caused by the replacement of a new subtype of 
hemagglutinin and sometimes neuraminidase through genetic reassortment.  
The influenza vaccine is the most viable option in counteracting and reducing the 
impact of influenza outbreaks (189). Since influenza viruses are continuously changing
their antigenicity in order to escape the host immunity (3, 4), the vaccine strains need to 
be updated almost annually to obtain antigenic matches between the vaccine strain and 
the strain potentially causing future outbreaks (6, 190). Identification of influenza
antigenic variants is the key to a successful influenza vaccination program for both 
pandemic preparedness as well as seasonal influenza prevention and control (98). 
Routinely, immunological tests, such as hemagglutination inhibition (HI) assays 
and microneutralization (MN) assays, have been relied upon to identify antigenic variants 
among the circulating strains (122). The HI assay is an experiment to measure the level to 
which a test influenza antigen and a reference antigen (e.g. a current vaccine strain) 
match through the immunological reaction between the test antigen and the reference
antiserum. This reference antiserum is usually generated in ferrets using the reference
antigen. HI assays are limited due to their use of red blood cells (RBCs), e.g. turkey red 
blood cells, as indicators for the binding affinity of antigen and antiserum (191). A higher 
interaction between antigen and antisera will lead to less hemagglutination of RBCs















   
 
much more time-consuming. Moreover, for influenza viruses requiring biosafety-level 3 
(BSL-3) or higher, MN assays are difficult to perform (193). For this reason, HI assays 
have been one of the routine procedures used to identify influenza antigenic variants for
vaccine strain selection while MN assays are generally used to validate the results from 
HI assays.
However, the data from HI assays are notoriously noisy, and HI experiments are
affected by many factors. For example, RBCs used from different species and even 
variation in RBC sialic acid receptors can produce varied results (122). The data are
subjective interpretations and the HI assays have difficulty in automating and 
standardizing operations. Minor antigenic variants within a heterogeneous population 
cannot be assessed by the serological method of HI (132). More importantly, mutations 
of the receptor binding site in HA (4) (antigenic drift) are causing human seasonal H1N1
(100, 123) and H3N2 influenza A viruses (124) to lose the ability to bind to RBCs. For 
example, the mutations at residue 193, 196, 197, and 225 in the human epidemic H1N1 
influenza A viruses in 1988 or later caused the loss of their abilities to agglutinate 
chicken RBCs due to four amino acid changes (125). For H3N2 viruses, the Gly190Asp 
substitution has been correlated to the loss of the ability to agglutinate chicken 
erythrocytes (122, 124, 126, 128-130, 194). Since 2000, human seasonal H1N1 and 
H3N2 influenza A viruses have been losing their binding abilities to turkey red blood 
cells (122, 131). This may be attributed to a reduced affinity for sialic acid-linked 
receptors (particularly α2-6-linked receptors), which are at lower levels on chicken and 



















demand exists for the development of a red blood cell independent assay for influenza
antigenic variation.
Proximity ligation assay utilizes quantitative real time PCR (qRT-PCR) for the
detection of antigen-antibody interaction (148). For this assay: (1) oligonucleotide-linked 
monoclonal antibodies are incubated with the analyte in question; (2) if in close 
proximity, the oligonucleotides can be ligated together; and (3) presence of analyte will
be shown by amplification of ligated products with qRT-PCR. The assay reporter signal 
is dependent on a proximal and dual recognition of each target analyte providing high 
specificity (149).
In this study, we developed a novel antigenic characterization method using
polyclonal antibody-based proximity ligation assays (polyPLA). This method was found 
to be useful in detecting influenza antigenic variants in clinical samples. 
Materials and Methods
Viruses and antibodies
The H3N2 viruses used in this study were obtained from the Centers of Disease
Control and Prevention, Department of Health & Human Services and BEI Research 
Resources Repository (http://www.beiresources.org/) (Table 7), and the monoclonal 
antibodies against nucleoprotein (NP) from Millipore, the United States.  The viruses 
were propagated at Madin-Darby Canine Kidney (MDCK) cells and stored at -80 °C
before usage. The polyclonal antisera were generated using 4- to 6-month-old ferrets 
(Triple F Farm, PA). The ferrets were anesthetized with isoflurane and inoculated 




   
 
  
   
   
   
   
   
   
   
   
 
 
   
 
 
   
  
 
sera were collected three weeks post-infection. The viral isolation was performed using
MDCK cells.
Table 7 The H3N2 influenza A viruses used in this study.








athe antigenic cluster was described in Sun et al. (195), and ND, not determined.
Labeling of antibodies.
The IgG was purified from ferret polyclonal antisera and mice monoclonal
antibodies using Pierce Chromatography Cartridges Protein A/G according to the 
manufacturer’s instruction (Pierce, Rockford, IL) and then biotinylated with Biotin-XX 
Microscale Protein Labeling Kit according to manufacturer directions (Life
Technologies, Carlsbad, CA). To remove the free biotin, Slide-A-Lyzer Dialysis
Cassettes (Thermo Scientific Pierce, Rockford, IL) were used; dialysis was performed at 



















Forced proximity probe test.
An aliquot of biotinylated antibody stock solution was diluted to 200 nM (30 
µg/mL); 2 µL of diluted biotinylated antibody was added to 2 µL of equal mixture of 200 
nM 3’ and 5’ TaqMan Prox-Oligo, designated probe A and probe B (Life Technologies, 
Carlsbad, CA), and incubated at room temperature for 60 minutes. A negative control 
was made replacing diluted biotinylated antibody with 2 µL antibody dilution buffer. 
After incubation, 396 µL of assay probe dilution buffer was added and incubated for 
another 30 minutes at room temperature. Then 96 µL of ligation solution was added to 4 
µL of the probe and virus mixture, incubated again at 37 ºC for 10 minutes, and cooled at 
4 ºC for 10 minutes. After incubation, 9 µL were transferred to a new 0.2 mL 
microcentrifuge tube with 11 µL qPCR mix (10 µL Fast Master Mix, 2x plus 1 µL
Univeral PCR Assay, 20x) and was briefly centrifuged. The qPCR cycling was as 
follows: 95 ºC for 2 minutes, 40 cycles of 95 ºC for 15 seconds, and 60 ºC for 1 minute.
The change in threshold cycle (ΔCt) values was calculated for each biotinylated 
antibody: Average Ct (negative control) – Average Ct (forced proximity probe). If the
ΔCt ≥ 8.5, the test biotinylated antibody was considered suitable for use in the PLA.
Probe preparation.
Two assay probes for each antibody were prepared by combining the biotinylated 
antibodies with either 3’ or 5’ TaqMan Prox-Oligo (probe A and probe B). For example, 
for each probe, 2.5 µL 200 nM biotinylated antibody was combined with 2.5 µL of either 
200 nM 3’ prox-Oligo or 200 nM 5’ prox-Oligo, and the mixture was incubated at room 
temperature for 60 minutes. Then, 45 µL Assay Probe Storage Buffer was added, briefly


















PLA and quantification of polyΔCt and monoΔCt.
The Taqman PLA was performed by first diluting equal parts of probes A and B
mixture 1:10 with phosphate-buffered saline (PBS, pH 7.4). For the non-protein control 
(NPC), 2 µL were combined with 2 µL diluted virus (virus lyzed for NP detection) or 2 
µL 1x PBS, pH 7.4. The mixture was centrifuged briefly and incubated at 37ºC for one
hour. Then, 96 µL of ligation solution was added to 4 µL of the probe and virus mixture, 
incubated again at 37 ºC for 10 minutes, and cooled at 4 ºC up to 10 minutes. After
incubation, 2 µL of 1x protease was added to each ligation reaction and incubated at 37ºC
for 10 minutes, 95 ºC for 5 minutes, and 4ºC for holding. Lastly, 9 µL of the product was 
transferred to a new 0.2 mL microcentrifuge tube with 11 µL qPCR mix (10 µL Fast 
Master Mix, 2x plus 1 µL Universal PCR Assay, 20x) and was briefly centrifuged. The
qPCR cycling was as follows: 95 ºC for 2 minutes, 45 cycles of 95 ºC for 15 seconds, and 
60 ºC for 1 minute.
The NPC was used as a reference background and the threshold cycle (Ct) value 
given dictated the non-target ligation signal noise of the assay. A total of three replicates 
for each sample and control were performed. To calculate the ΔCt values: Average Ct 
(NPC) – Average Ct (sample), which represented the true target-mediated signal above
background. The cutoff of ΔCt  ≥ 3.00 was used for qualitative analysis of viral and 












   












HI and virus neutralization assays.
In the HI assay, the receptor destroying enzyme (RDE, Denka Seiken Co., Japan) 
was used to treat the ferret sera in the ratio of 1:3 (RDE : sera, volume : volume) for 18
hours at 37 ºC, then heat inactivated at 56 ºC for 30 minutes. The treated ferret sera were
diluted to 1:10 with phosphate-buffered saline (PBS) then 2-fold serial diluted and 
reacted with 4-hemmagglutination-units viruses. The HI titers were expressed as the 
reciprocal of the highest dilution at which virus binding to the 0.5% turkey red blood 
cells (RBC) was blocked.
For the virus neutralization assay, serially diluted ferret sera were first incubated 
with 100 TCID50 viruses at 37 ºC for 1 hour. The virus-sera mixtures were then adsorbed 
to MDCK cells for 1 hour. The infected cells were washed twice with PBS buffer and 
replenished with Opti-Mem Reduced Serum Media (Life Technologies, US). The
supernatants from the infected cells were harvested 4 days post-infection and were
analyzed using hemagglutination assay.
Data analysis.
To compare the antigenic properties across the testing antigens (viruses), we
computed the polyPLA unit between antigen (virus) and antibody using the following
equation:
polyPLA = a * (polyΔCtmonoΔCt) + b (1)
To improve our computation, we simply used a =1.00 and b=10.00. The b=10.00 enabled 
us to avoid negative numbers. If monoΔCt < 3.00, polyPLA will be assigned as “<0”,
meaning that the viral loads were too low for analyses. As mentioned above, in general, 








     
        
  










Genomic sequencing and GenBank accession number.
The HA genes of 21 H3N2 isolates recovered from human clinical specimens 
were sequenced using Sanger Sequencing, and they were deposited in Genbank with the
accession numbers KM244531-KM244551. 
Molecular characterization and phylogenetic analyses.
The multiple sequence alignments were conducted using the MUSCLE software
package (197). The phylogenetic analyses were performed using maximum likelihood by
GARLI version (198), and bootstrap resampling analyses were conducted with 1,000 runs 
using PAUP* 4.0 Beta (199) with a neighborhood joining method, as previously
described (200). 
Results
polyPLA for influenza antigenic variant detection.
polyPLA quantifies the antibody antigen binding avidity using the amplification 
signals in quantitative PCR (qPCR) from the pairs of primers attached to a reference
polyclonal antiserum. The first step of this experiment is to biotinylate a reference
polyclonal antiserum (Figure 4A), which will be then labeled with sodium azide-linked 5’ 
and 3’ oligonucleotides (Figure 4B). The ligation efficiency will be assessed with qPCR. 
A labeled polyclonal antiserum with ΔCt ≥ 8.5 in the ligation efficiency test is then 
incubated with a reference antigen (virus) or a testing antigen (Figure 4C), followed by
the proximity ligation of the two oligos (Figure 4D). The antibody antigen binding
avidity is quantified using the amplification signals ΔCt in qPCR (Figure 4E). The ΔCt 















differences among these tested antigens. These ΔCt values can be viewed as similar to the
serological titers, such as HI and neutralization titers, from conventional serological 
assays (Figure 4F).
To make the ΔCt values comparable across reference sera, we have to ensure the 
testing antigens have the same quantities across quantification assays. In HI assays, we
usually standardize the antigens to be 4 or 8 units of hemaglutinnation titer before HI; in 
neutralization assays, we usually standardize antigen quantities using TCID50(196). In 
this assay, we use the quantities of nucleoproteins (NPs) to normalize the amount of 
viruses in the analyses. For data consistency, we used a monoclonal antibody targeting
conserved regions of NPs in the proximity ligation assay (148). Thus, for a test antigen, 
the polyPLA units were normalized by its ΔCt values for polyclonal antiserum (polyΔCt) 













   
  
  
Figure 4 The simplified diagram of polyPLA.
polyPLA quantifies the antibody antigen binding avidity using the amplification signals 
in quantitative PCR (qPCR) from the pairs of primers attached to a reference polyclonal 
antiserum. First, the IgG purified from a reference polyclonal antiserum is biotinylated 
(A), which will be then labeled with sodium azide-linked 5’ and 3’ oligonucleotides (B). 
A labeled polyclonal antiserum with ΔCt ≥ 8.5 in the ligation efficiency test is then 
incubated with a reference antigen (virus) or a testing antigen (C), followed by the 
approximate ligation of the two oligos (D). The antibody antigen binding avidity is 
quantified using the amplification signals ΔCt in qPCR (E). The ΔCt values among the 
polyclonal antisera and antigens can be compared to assess antigenic differences among
these tested antigens, and these ΔCt values can be viewed as similar as the serological 
titers, such as HI and neutralization titers, from conventional serological assays (F). The
polyPLA units were normalized by its ΔCt values for polyclonal antiserum (polyΔCt) 
with its ΔCt values for monoclonal antibody against NP (monoΔCt) (G).
Viral particles must be completely lysed to release NPs and allow for an accurate
measure of these protein quantities. We compared two commonly used methods for viral 
lysis: freeze/thaw and treatment with lysis buffer. The results showed that lysis buffer 
treated virus has a significantly higher ΔCt value of 7.46 (± 0.45) for A/Sydney/05/1997 



















for A/Sichuan/2/1987 (SI/2), lysis buffer treated virus did not have a significantly
different ΔCt value compared to the freeze/thaw method of viral lysis. In the following
assays, all the samples used in normalization were treated with lysis buffer.
Figure 5 Optimization of the methods in detecting NP proteins using proximity
ligation assays.
OV denotes the control the control viruses, which were harvested directly after viral 
propagation in MDCK cells; F-T denotes the viruses, which were frozen and thawed 5 
times; L denotes the viruses, which were treated with lysis buffer.
HA specific IgG predominates polyclonal antisera.
PolyPLA quantifies the interactions between influenza viral proteins and all IgG 
present in the polyclonal antisera. To assess the impacts of NA and other internal proteins 
on PolyPLA, we constructed three reassortants between SY/05 and PR8, including
SY/05xPR8(H3N2), SY/05xPR8(H3N1), and SY/05xPR8(H1N2). The signals from NPC
were used as the control to calculate ΔCt value from proximity ligation assays. Our
results showed that SY/05, SY/05xPR8(H3N2), and SY/05xPR8(H3N1) had ΔCt values 
of 5.40(± 0.74), 5.67(± 0.17), and 5.26(± 0.34), respectively (Figure 6). The ΔCt values 



















   
Figure 6 PolyPLA detects predominant IgG against HA gene.
The ∆Ct of proximity ligation assays for SY/05(H3N2), PR8(H1N1), and three
reassortants SY05xPR8(H3N2), SY05xPR8(H1N2), and SY05xPR8(H3N1) were
measured using reference polyclonal sera against SY/05(H3N2).
Viral quantities are linearly correlated with ∆Ct values.
To assess the sensitivity of polyPLA, we performed PLA on influenza A viruses 
with serial dilutions. Regression analyses demonstrated that the poly∆Ct values are
linearly correlated with the influenza viral quantities, with Pearson’s coefficient R = 0.98
for the testing strain SY/05 (p<0.001) (Figure 7). The cutoff ∆Ct value 3.00 was 
equivalent to 4.90 x 104 TCID50/mL against its homologous polyclonal antibodies. 
Similarly, the mono-∆Ct values were also linearly correlated with HA titers, and the R
was 0.92 for SY/05 (p<0.001). The cutoff ∆Ct value was equivalent to 9.80 x 104 
TCID50/mL against the NP-specific monoclonal antibody. Similar linear correlations
were also observations in A/Johannesburg/33/1994(H3N2) (JO/33) and 
A/Nanchang/933/1995(H3N2) (NA/933) (data not shown). Linear correlation between 
viral quantities and ∆Ct allows us to normalize the viral titers by using a simple equation 

















   
normalization method enables us to compare the antigenic properties between the testing
antigens (viruses) without justifying the viral quantities before measuring poly∆Ct, 
having been used in HI and neutralization assays to ensure the equivalency of the viral 
quantities before assays.
Figure 7 The linear correlation of poly∆Ct (R = 0.98) and mono∆Ct  (R = 0.92) with 
viral quantities.
The cutoff ∆Ct value 3.00 was equivalent to 4.90 x 104 TCID50/mL against its 
homologous polyclonal antibodies and 9.80 x 104 TCID50/mL against NP specific
monoclonal antibody.
Sensitivities of polyPLA.
To test the sensitivity of polyPLA, we evaluated the viral loads from nasal swabs 
collected from ferrets infected with A/swine/K6/2011(H6N6). After only the first day of 
infection, a poly∆Ct titer of 3.20 (± 0.06, standard deviation) was obtained, 
corresponding to a TCID50 titer of 1.00 x 103 for the infected ferret (Figure 8). After two 
days of infection, a poly∆Ct value of 5.19 (± 0.06) was obtained, corresponding to a 














among the nasal wash samples post-infection. All the samples collected from the control 
ferrets had poly∆Ct titers of less than 3.00, and no viruses were recovered from these
control ferrets (Figure 8). Thus, this method is sensitive sufficiently to detect not only the 
viruses propagated from the laboratory, but also those in animal specimens. The detection 
limit is approximately 103 TCID50/mL, which is much less than the viral loads from most 
patients at the peak time of virus shedding. For example, man can shed 2.6, 5.0, 5.1, 4.9, 
3.8, and 1.9 TCID50/mL from one through six days post inoculation of H1N1 seasonal 
influenza virus, respectively (201).
Figure 8 Sensitivity of polyPLA.
Comparison of poly∆Ct and mono∆Ct titers with viral culture titers using the nasal swabs 
collected from the ferrets infected with A/swine/Guangdong/K6/2010(H6N6). After only
the first day of infection, a poly∆Ct value of 3.20 (± 0.06, standard deviation) was
obtained, corresponding to a TCID50 titer of 1.00 x 103 for the infected ferret. After two 
days of infection, a poly∆Ct value of 5.19 (± 0.06) was obtained, corresponding to a 
TCID50 titer of 1.00 x 104.
Detecting antigenic variants of H3N2 historical seasonal influenza viruses.
The H3N2 viruses have been causing seasonal epidemic outbreaks since its first 
introduction into the human population, resulting in the pandemic of 1968. During the
















occurred from 1997 to 2010 (195, 202). In this study, six historical H3N2 isolates, JO/33, 
NA/933, SY/05, A/Brisbane/10/2007 (BR/10), A/Perth/16/2009 (PE/16), 
A/Victoria/361/2011(VI/361) representing antigenic cluster BE92, WU95, SY97, BR07, 
PE09, and VI11 (195), and their corresponding homologous ferret antisera were used to 
validate polyPLA. Our method was expected to identify significant differences in 
homologous and heterologous polyPLA titers.
Our results showed that the homologous titers were approximately 10.00 
polyPLA units. The polyPLA titers for NA/933 and SY/05 against JO/33 antisera were
9.37 (±0.22) and 6.725 (±0.32) polyPLA units, which were significantly less than the 
homologous JO/33 titer 11.43 (±0.01) units, p<0.0001 (Figure 9A). The homologous titer 
for NA/933 was 11.71 (±0.28) whereas the titers for JO/33 and SY/05 against NA/933 
antisera were 8.44 (±0.32) and 8.16 (±0.43) units, respectively; the titers for JO/33 
against NA/933 antisera were significantly less than the homologous titers for JO/33, 
p<0.001. The homologous titer for SY/05 was 13.19 (±0.06) units whereas the titers for 
JO/33 and NA/933 against SY/05 antisera were 10.59 (±0.15) and 8.21 (±0.07) units, 
respectively; the titers for both JO/33 and NA/933 against SY/05 antisera were
significantly less than the homologous titers for SY/05, p<0.0001.  
Similarly, the homologous titers for BR/10 were 9.91 (±0.16) whereas the titers 
for PE/16 and VI/361 against BR/10 sera were 7.97 (±0.12) and 7.72 (±0.21), 
respectively (Figure 9B); the titers for PE/16 and VI/361 against BR/10 sera were
significantly less than the homologous titers for BR/10, p<0.001. PE/16 had the highest 
poly∆Ct value of 12.00 (±0.20) against PE/16 sera whereas the titers for BR/10 and 














for BR/10 and VI/361 against PE/16 sera were significantly less than the homologous 
titers for PE/16, p<0.001. The homologous titer for VI/361 was 10.87 (±0.22) whereas 
the titers for BR/10 and PE/09 against VI/361 sera were 5.90 (±0.10) and 7.93 (±0.15), 
respectively; the titers for BR/10 and PE/09 against VI/361 sera were significantly less 
than the homologous titers for VI/361, p<0.001.
Figure 9 Detecting antigenic variants of H3N2 historical seasonal influenza viruses.
JO/33, NA/933, SY/05, BR/10, PE/16, VI/361 representing antigenic cluster BE92, 
WU95, SY97, BR07, PE09, and VI11. The homologous polyPLA titers were
significantly higher than the heterologous titers for both the antigenic drift event BE92-
>WU95->WY97 (A) and BR07->PE09->VI11(B). These results were consistent with 













Table 8 The correlation among the titers from polyPLA and those from HI and MN 
assays for JO/33, NA/33, and SY/05.
a the number in bold is the homologous titer.
Table 9 The correlation among the titers from polyPLA and those from HI and MN 
assays for BR/10, PE/16, and VI/361.













   
  
Detecting antigenic variants in human clinical specimens. 
To test the applicability of polyPLA in clinical samples, we applied this same 
method to characterize antigenic profiles of H3N2 influenza A viruses, which came 
directly from clinical samples collected in the 2012-2013 influenza season. A total of 100 
nasal swabs were collected from September of 2012 to April of 2013, and confirmed as 
H3N2 positive using quantitative RT-PCR.
About 50% of these samples had at least a 3-polyPLA-unit decrease compared to 
BR/10 homologous titers and that about 18% and 1% of these samples had at least 3-
polyPLA-unit decrease when compared to PE/16 and VI/361 homologous titers, 
respectively (Figure 10A). The polyPLA titers of the majority clinical samples were
highest when using VI/361 sera, followed by PE/16 and BR/10. We compared the 
poly∆Ct titers of the clinical samples with the HI titers for these 21 isolates, and the HI
titers were positively correlated with poly∆Ct titers (Figure 10B). 
To better understand the antigenic and genetic background of the H3N2 viruses in 
these samples, 21 samples were randomly selected and subjected to viral isolation using
MDCK cells. A total of 21 viruses were recovered, and the HA sequences of these
viruses were sequenced. The sequence analyses showed that no consistent mutations at 
the reported antibody binding sites (203) were observed in the isolates we recovered from 


































                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
  
Table 10 Molecular characterization of amino acid changes in the HA1 proteins of 
H3N2 isolates recovered from 2012-2013 season.
Amino acid positiona 
2 8 33 45 48 53 94 128 142 144 145 158 198 199 223 278 280 312
Isolate (C) (C) (C) (E) (B) (A) (A) (A) (B) (B) (C) (C) (C)
WI/67 K N Q S T D Y T R N N K A S I N E N
BR/10 K N Q S T D Y T R N N K A S V N E N
PE/16 K N Q S T D Y T R K N N A S V N E N
VI/361 K N Q N I D Y T R N N N S S I N E S
TX/50 K N R N I D Y N R N N N P S I K E S
MS/3 K N R N I D Y T R N S N S S I K E S
MS/4 K N R N I D Y A G N S N S S I K E S
MS/17 K N R N I D Y A G N S N S S I K E S
MS/20 K N R N I D Y T R N S N S S I K E S
MS/27 N N R N I D Y T R N S N S S I K E S
MS/29 K N R N I D Y T R N S N S S I K E S
MS/32 K N R N I D Y T R N S N S S I K E S
MS/33 K N R N I D Y T R N S N S S I K E S
MS/35 E D Q S T N H T R N N N A S V N A N
MS/36 E D Q S T N H T R N N N A S V N A N
MS/40 E D Q S T N H T R N N N A S V N A N





                   
                   
                   
                   
                   
                   
                   
                   
                   
  





MS/44 E D Q S T N H T R N N N A S V N A N
MS/45 E D Q S T N H T R N N N A S V N A N
MS/47 E D Q S T N H T R N N N A S V N A N
MS/48 E D Q S T N H T R N N N A S V N A N
MS/49 E D Q S T N H T R N N N A S V N A N
MS/51 E D Q S T N H T R N N N A S V N A N
MS/53 E D Q S T N H T R N N N A S V N A N
MS/65 K N R N I D Y T R N S N S S I K E S
MS/6 E D Q S T N H T R N N N A S V N A N
aThe antibody binding sites were annotated based on previous report (203).
Since 2007, the H3N2 seasonal influenza viruses have six genetic clusters (196)
The genetic clusters 1 and 2 were PE/16 like-viruses. The viruses from 2010 were
scattered into genetic clusters 3, 4, 5, and 6. The phylogenetic analyses showed that these















Figure 10 Detecting antigenic variants in human clinical specimens. 
(A) The percentile of antigenic variants (white portion) compared to their corresponding
homologous titers, and a 3-polyPLA-unit threshold was used; (B) the correlation between 
polyPLA units and HI titers, which were measured using PE/16 polyclonal antisera;  (C) 
phylogenetic tree of HA protein sequences of H3N2 seasonal influenza viruses. The 21 
isolates recovered from the 2012-2013 influenza season from Mississippi were marked in 
red, and the antigenic variants proposed by polyPLA assays using clinical samples 
against PE/16 were marked with stars. The phylogenetic tree was constructed by
maximum parsimony based on HA protein sequences, and genetic clusters were defined 
based on the reports from Community Network of Reference Laboratories (CNRL) for 




















Identification of antigenic variants in disease surveillance is essential, and an ideal 
antigenic characterization platform should meet the following four criteria: (1) robust, the
results should be repeatable; (2) simple and economic, the methods can be carried out in a
common diagnosis laboratory; (3) high throughput, the method should be able to perform 
on a large-scale; and (4) sensitive, the method will have optimal performance in 
identifying antigenic variants directly from clinical samples, avoiding viral isolation. For 
many diseases, the pathogen isolation process is not only time-consuming but also can 
change virus antigenic properties, resulting in data that does not accurately represent 
those antigenic properties in circulating viruses. Furthermore, some pathogens cannot 
even be recovered from the specimen. The polyPLA developed in this study was 
designed to meet these four criteria, as confirmed in influenza antigenic variant 
identification in this study.
The polyPLA quantifies antibody-antigen interactions for influenza viral proteins, 
including both HA and NA, against their corresponding antibodies in the antisera. The
principle of this method is more similar to neutralization assays rather than HI assays. 
More importantly, it can avoid the red blood cell binding problems usually seen in HI
assay. For example, egg-adaptation substitutions affect the architecture of the HA
receptor-binding site and alter the interactions of the HA with the terminal sialic acid 
moiety(133).
The high concentration of influenza A viruses could lead to the saturation of 
viruses over antibody, which is 200 nM used in this study. For example, when the 




















differences between the ∆Ct values against NA/933 antibody and those against JO/33 
antibody (data not shown). After the NA/933 viruses were diluted to 1:40, there was a 
significant difference between the ∆Ct values against NA/933 and those against JO/33 
antibodies (Table 8 and Figure 9). However, we do not believe this potential limitation 
will affect the application of this method in clinical samples, from which the virus loads 
are much smaller than a single isolate.
Compared to seasonal influenza virus surveillance, the antigenic characterization 
of emerging pathogens for pandemic preparedness, especially those pathogens in areas 
without sufficient biosafety facilities, has been challenging. Propagation of these
emerging viruses usually requires a higher biosafety containment such as BSL-3 and even 
BSL-4. In most cases, the specimens need to be shipped to a laboratory with appropriate 
biosafety containment, and sometimes even the paperwork for such collaborative
agreements, especially among countries, can cause delays when an outbreak occurs. 
Because the polyPLA can use the clinical samples directly and also use a common qRT-
PCR platform, it can perform large-scale analyses with minimal biosafety requirements in 
laboratory conditions. For example, Biosafety Level 2 level will be sufficient for the use
of the polyPLA in influenza surveillance(196)   Thus, this method will be very useful in 
detecting antigenic variants for the H5N1 highly pathogenic avian influenza viruses and 
emerging H7N9 low pathogenic avian influenza viruses. In resource limited areas, 
although the RBCs in conventional serological assays such as HI can be more accessible, 
it would be much easier and more economical to set up a qRT-PCR platform than a high 










In summary, polyPLA is a simple method quantifying the binding avidity of
antibody-antigen interactions. Beyond influenza applications, this method can also be 






    
  
 
   
  
 







GENETIC AND ANTIGENIC VARIATIONS AMONG SUBTYPE H3N2 
INFLUENZA A VIRUSES IN HUMAN NASOPHARYNGEAL AND
VIRAL ISOLATES
Influenza A virus (IAV) is a zoonotic pathogen which consists of a large
genetically and antigenically diverse viral population. Swine IAVs not only cause disease
outbreaks among swine, but can also be transmitted bi-directionally between swine and 
humans, causing sporadic infections and even pandemic outbreaks apart from human 
seasonal IAVs. Antigenic variant identification is fundamental for an effective
vaccination program. Conventional red blood cell based immunological tests have been 
used to identify antigenic variants among circulating IAV strains. Because these assays 
require viral isolation, they are time consuming and labor intensive. Thus only limited 
numbers of virus isolates are subjected to antigenic characterization in influenza
surveillance studies and much of this important information is lost. In this project, a novel 
polyclonal antibody based proximity ligation assays (polyPLA) was developed and 
validated to characterize IAV antigenic variants directly using clinical samples. The
application of this method with clinical samples from influenza surveillance had aided in 
the understanding of the antigenic evolution of IAV in human and swine populations. In 
the comparison of clinical sample and their isolates, both can antigenically and 

















properties between swab and isolates showed that polymorphisms were identified in the
isolates, including those in the antibody binding sites. This study demonstrated polyPLA 
can be effective in characterizing antigenic profiles in clinical samples and culture
adapted mutations can lead to antigenic variations in human clinical samples and skew 
the antigenic data. polyPLA would be useful influenza vaccine strain selection by the 
antigenic characterization of viruses directly with the use of clinical samples. 
Introduction
Antigenic variants 
The surface glycoprotein of influenza A virus (IAV), hemagglutinin (HA) and 
neuraminidase (NA), are under positive selection in order to evade the host’s 
immunological responses (204). The most common antibodies against influenza target 
the highly variable head of HA; such antibodies prevent reinfection with similar antigenic
properties. Variability of IAV is a product of adaptation to host cell factors as well as 
change of antigenicity to escape from host immune response (3, 4). Evasion tactics of the
host acquired immune system are 1) antigenic drift (204), which is mainly caused by
accumulative mutations in HA and/or NA of IAVs, and 2) antigenic shift, which is 
caused by acquiring a new HA and/or NA by reassortment (205). 
Surveillance of human clinical samples 
Worldwide epidemiological surveillance is necessary in order to identify and 
monitor the emergence and spread of novel antigenic variants, to project their impacts on 
population health, and to provide scientific evidence for making decision vaccine 

















   
  
  
currently circulating viruses. Human IAV continually circulate in yearly epidemics, with 
most frequency in the months from late fall through the spring. Many speculate that the 
infectious virus is transmitted mainly by small-particle aerosols, which are maintained at 
low temperature (7ºC to 8ºC) and low relative humidity (< 50%) due to lower osmotic
pressure on the influenza virus particles (Reviewed in (206, 207)).
Early detection of IAV infection by reliable laboratory results can prevent spread 
of the virus by providing information to public health authorities about early intervention 
as well as assist with optimal treatment decisions. The use of molecular diagnostic 
methods, RT-PCR, rapidly decreases after one week from onset of symptoms (208). 
Diagnostics through viral cultures are more likely to obtain a positive result if the clinical 
sample is collected within three days of onset of symptoms (208). Specimens from nasal 
and nasopharyngeal specimens (e.g. nasal swab, nasopharyngeal swab, nasopharyngeal 
aspirate, nasal wash, combined nasal and throat swab, and throat swab) have a higher 
yield of virus detection than oropharyngeal specimens (208).
The global influenza surveillance network coordinated by the World Health 
Organization (WHO) characterizes antigenic properties of influenza viruses using the 
golden standard antigenic characterization method of hemagglutinin inhibition assay and 
sequencing of HA1 domain (54, 55). Antigenic, genetic, and epidemiological data are
examined to make recommendation of candidate vaccine strains.
Pandemic preparedness 
Typically, 30,000 deaths, a year in the United States, are caused by seasonal IAV. 
Influenza epidemics, every a few years, increase annual mortality level to 40,000 to 




















the infection of 20% to 40% of the population within a single year, dramatically raising
death rates above normal levels. There was incomplete historical surveillance information 
before the 2009 H1N1 pandemic which lead to a limited ability to evaluate the severity of 
the novel virus within the human population (208). 
With the standardization of influenza data collection by the WHO, the policy
makers can better understand risk factors for the potential severity of a pathogen, 
variation of influenza severity from season to season and its relationship to virus types or 
subtypes, the burden of disease related to influenza, and other factors critical to public
health decision-making (208). Rapid comparative assessment of each influenza season is 
necessary for preparation of future pandemics locally and globally (208).
Human H3 3c.3a and 3c.2a
In the 2014-2015 influenza season, two H3 genetic subclades mutated 
independently and the rapid spread of novel antigenic mutations occurred due to a lack of 
herd immunity to the novel viruses. Previously, in the H3 genetic clade 3C.1, 
phenylalanine (F) was at residue 159 and asparagine (N) was at residue 225. Both clades 
mutated at residue 225 first to aspartic acid (D), followed by the mutation of residue 159 
to serine (S) or tyrosine (Y) for clades 3C.3a or 3C.2a, respectively. 
A/Switzerland/9715293/2013-like virus (3C.3a) was chosen as the 2015-2016 vaccine 
virus because the majority of viruses analyzed were antigenically related to those viruses 
in 3C.3a (118, 119). The following season, 2015-2016, the majority of viruses analyzed 
were of the genetic subclade 3C.2a with 3C.3a co-circulating but at a lower proportion




















Viral isolation is not only time-consuming, but also can change the antigenic 
properties of the original viruses due to the laboratory adaptation in cells or embryonated 
eggs(121, 133-135, 209). Egg-adaptation substitutions have been shown to affect the HA
receptor-binding site and to change the interactions between influenza HA and the 
terminal sialic acid of the host cell(133). Isolated H3N2 viruses can potentially have
mutations across the whole genome level when cultured in Madin-Darby Canine Kidney
(MDCK) cells(196). Within the HA itself, most residue changes were within to near 
receptor binding sites (A138S, G218R, R221L, V223I), altering receptor binding, and 
one residue change (N165K) was within an antigenic site.
Uncultivable (low viral titer) clinical samples
Only a small quantity of influenza infections can be laboratory confirmed per 
season. Recommendations of influenza vaccine strains are based on the prediction of 
circulating viruses, before full epidemiological significance is known (97). A real-time 
surveillance system for influenza outbreaks is necessary to produce earlier interventions 
for a decrease of morbidity and mortality (210-214). Influenza surveillance is not fully
complete without the inclusion of clinical samples, which are uncultivable (low viral 
titer) in both cells and eggs. In a previous study, influenza A and B, as well as subtypes 
H1, H3, and H5, were detected with RT-PCR in uncultivable clinical samples with a
sensitivity of 90.4%(215). Although subtype can be distinguished by PCR and 















   
 




Viral quasispecies Selection and fitness
Infection within a host is not limited to one identical viral genome; the
proliferating population of viruses is closely related, yet is not identical (42-45). The viral 
quasispecies of IAV within a host are subject to continuous competition because of the
error-prone genome replication (44, 46). Some mutations can be positively selected in 
order for a virus to escape from host-antibody neutralization or to replicate more
efficiently, leading to virus variants, which could become predominant in the population 
(47). Population-level fitness has also been shown to be increased by cooperative
interactions between variants within a quasispecies(48-52).
Genomic sequencing and data analyses
Sequencing of IAV is useful to identify origin of novel reassortant viruses as well
as identify molecular characteristics of a virus, such as host range, replication efficiency, 
transmissibility, or virulence (150-153). The traditional method of Sanger sequencing is 
widely used in influenza surveillance and research (154). Next-generation sequencing
(NGS) can sequence the entire genome (155, 156) and is helpful in the identification of
genetic variation within a viral quasispecies and to monitor vaccine composition (157). 
The massive parallel sequencing of influenza virus by the NGS platforms allow for 
increased sensitivity of the study of the original populations. This is in contrast to the 
traditional method that requires molecular cloning or plaque generation (158-160) for an 
output of multiple gigabases of DNA (161). Because the whole IAV genome is only
13,000 nucleotide bases of RNA, coverage is high, yet the segmented nature of the
genome can be challenging to achieve full genome coverage (155, 162-166). In the 
















the 8 genomic sequences while retaining the polymorphisms within the quasispecies or
true mixed infection of multiple viruses.
Antigenic Cartography
Most retrospective studies only use a partial sequence of the HA gene to 
understand and predict, the evolution of H3N2 strains (126, 168, 216-218). Genetic
differences, alone, are unreliable in the determination of antigenic differences in novel 
viruses and antigenic properties through immunological datasets are not always 
straightforward. The relative antigenic relationship and evolution can be visualized with 
the production of two- or three- dimensional maps, known as antigenic cartography
(168). The antigenic map produced can quantify antigenic differences between viruses; 
antigenically similar viruses cluster closely while antigenically different viruses are
farther away. 
the polyclonal sera–based proximity ligation assay (polyPLA)
Proximity ligation assay utilizes quantitative real time PCR (qRT-PCR) for the
detection of antigen-antibody interaction (148). For this assay: (1) oligonucleotide-linked 
monoclonal antibodies are incubated with the analyte in question; (2) if in close 
proximity, the oligonucleotides can be ligated together; and (3) presence of analyte will
be shown by amplification of ligated products with qRT-PCR. The assay reporter signal 
















The 11 reference H3N2 viruses were received from the Food & Drug Administration, 
Health and Human Services, to represent the past 9 influenza vaccine reformulations of 
the Northern Hemisphere winter seasons of November 2008-April 2009 until November
2016-April 2017. The twelve viruses represent 6 genetic clades, including 1-Brisbane/10, 
1-Perth/16, 2-3c.1, 1-3c.2, 3-3c.2a, 3-3c.3a. Additionally, 30 H3N2 clinical samples were
received from the Mississippi Department of Health (MSDH) from the 2014-2015 
influenza season and 60 H3N2 clinical and isolated samples were received from the
Centers of Diseases Control and Prevention, Department of Health & Human Services 
(CDC) from 2014-2015 and 2015-2016 seasons. All viruses were isolated and propagated 






    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
Table 11 Paired sample information.
Reference Viruses Genetic Clade Clinical Isolate
A/Brisbane/10/2007 (BR/10) BR/10 no yes
A/Perth/16/2009 (PE/16) PE/16 no yes
A/Victoria/361/2011 (VI/361) 3c.1 no yes
A/Texas/50/2012 (TX/50) 3c.1 no yes
A/Costa Rica/4700/2013 (CR/4700) 3c.2 no yes
A/Utah/07/2013 (UT/07) 3c.3a no yes
A/Switzerland/9715293/2013 (SW/9715293) 3c.3a no yes
A/Palau/6759/2014 (PA/6759) 3c.3a no yes
A/Hong Kong/4801/2014 (HK/4801) 3c.2a no yes
A/Victoria/503/2015 (VI/503) 3c.2a no yes
A/Fiji/2/2015 (FI/2) 3c.2a no yes
A/Brisbane/82/2015 (BR/82) 3c.2a no yes
MSDH Viruses Genetic Clade Clinical Isolate
A/Mississippi/161/2014 3C.2a yes yes
A/Mississippi/162/2014 3C.3a yes yes
A/Mississippi/163/2014 3C.3a yes yes
A/Mississippi/164/2014 3C.3a yes yes
A/Mississippi/165/2014 3C.3a yes yes
A/Mississippi/166/2014 3C.3a yes yes
A/Mississippi/167/2014 3C.3a yes no
A/Mississippi/168/2014 3C.3a yes yes
A/Mississippi/169/2014 3C.3a yes yes
A/Mississippi/180/2014 3C.3a yes yes
A/Mississippi/181/2014 3C.3a yes yes
A/Mississippi/182/2014 3C.3a yes yes
A/Mississippi/183/2014 3C.3a yes yes
A/Mississippi/198/2014 3C.3a yes yes
A/Mississippi/199/2014 3C.3a yes yes
A/Mississippi/200/2014 3C.3a yes yes
A/Mississippi/201/2014 3C.3a yes yes
A/Mississippi/202/2014 3C.3a yes yes
A/Mississippi/203/2014 3C.3a yes yes
A/Mississippi/204/2014 3C.2a yes yes
A/Mississippi/205/2014 3C.3a yes yes
A/Mississippi/206/2014 3C.2a yes yes





    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
Table 11 (Continued)
A/Mississippi/223/2014 3C.3a yes yes
A/Mississippi/224/2014 3C.3a yes yes
A/Mississippi/225/2014 3C.2a yes yes
A/Mississippi/226/2014 3C.3a yes yes
A/Mississippi/227/2014 3C.2a yes yes
A/Mississippi/228/2014 3C.3a yes yes
A/Mississippi/229/2014 3C.3a yes no
CDC Viruses Genetic Clade Clinical Isolate
A/Missouri/04/14 3C.3 yes yes
A/Alaska/05/2014 3C.3 yes yes
A/Louisiana/9/13 3C.3 yes yes
A/Hawaii/2/14 3C.3 yes yes
A/Washington/14/14 3C.3 yes yes
A/Maryland/10/14 3C.3 yes yes
A/New Mexico/20/14 3C.3 yes yes
A/New York/1/15 3C.3 yes yes
A/Florida/3/15 3C.3 yes yes
A/Utah/1/15 3C.3 yes yes
A/Colorado/1/15 3C.3 yes yes
A/Ohio/11/15 3C.3 yes yes
A/Iowa/6/15 3C.3 yes yes
A/Massachusetts/1/15 3C.3 yes yes
A/Arkansas/10/14 3C.3 yes yes
A/Wisconsin/37/13 3C.3 yes yes
A/Indiana/29/14 3C.3 yes yes
A/Wyoming/19/14 3C.3 yes yes
A/California/4/14 3C.3a yes yes
A/North Carolina/12/14 3C.3a yes yes
A/North Carolina/14/14 3C.3a yes yes
A/California/18/14 3C.3a yes yes
A/Mississippi/3/14 3C.3a yes yes
A/Hawaii/49/14 3C.3a yes yes
A/Texas/11/16 3C.3a yes yes
A/California/2/16 3C.3a yes yes
A/Montana/13/16 3C.3a yes no
A/Oklahoma/2/16 3C.3a yes yes





    
    
    
    
    
    
    
    
    
    
    
    
    
     
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    





A/Colorado/22/16 3C.3a yes yes
A/Idaho/10/15 3C.3a yes yes
A/Nebraska/3/15 3C.3a yes yes
A/Pennsylvania/6/15 3C.3b yes yes
A/Washington/53/14 3C.3b yes yes
A/Montana/3/15 3C.3b yes no
A/Hawaii/34/15 3C.3b yes yes
A/Pennsylvania/1/15 3C.3b yes yes
A/Pennsylvania/27/14 3C.2 yes yes
A/New Mexico/23/13 3C.2 yes yes
A/California/58/13 3C.2 yes yes
A/Vermont/3/14 3C.2a yes yes
A/Minnesota/7/14 3C.2a yes yes
A/Rhode Island/11/14 3C.2a yes yes
A/Connecticut/4/14 3C.2a yes yes
A/New Jersey/13/14 3C.2a yes yes
A/New Mexico/11/14 3C.2a yes yes
A/Florida/1/16 3C.2a yes yes
A/Minnesota/54/15 3C.2a yes yes
A/North Carolina/4/16 3C.2a1 yes yes
A/Texas/73/14 3C.2a yes yes
A/Maine/4/15 3C.2a yes yes
A/Florida/5/15 3C.2a yes yes
A/West Virginia/1/15 3C.2a yes yes
A/Washington/19/16 3C.2a1 yes yes
A/Wyoming/19/15 3C.2a yes no
A/Colorado/27/15 3C.2a yes no
A/Oregon/1/15 3C.2a yes yes
A/Utah/2/15 3C.2a yes yes
A/Delaware/44/14 3C.2a yes yes
A/Hawaii/49/15 3C.2a yes yes
Serum generation with ferrets
Twenty-two 4-month old female ferrets were confirmed to be seronegative for


















USA). All animal experiments described here were approved by Mississippi State
University Institutional Animal Care and Use Committee. Animals were anesthetized by
intramuscular administration of Ketamine 20mg/kg and Xylazine 1mg/kg (by body
weight) prior to all procedures, including infection, bleeding, and nasal swabbing. The
ferret sera were collected three weeks post-infection. Briefly, there were 11 groups 
consisting of 2 ferrets each, each group was inoculated with one reference virus. 
Monoclonal antibodies anti-nucleoprotein (NP) were obtained from BEI Resources 
(Bethesda, MD, USA).
Nasal swabs
Nasal swabs were taken for two groups of ferrets infected with viruses BR/10 and 
HK/4801, representing two antigenically distinct viruses, on 0, 3, 5, 7, and 10 days post
infection, stored in 1.5 mL tubes with 1 mL Opti-MEM Reduced Serum Media (Thermo 
Fisher; Waltham, MA, USA), and titrated by TCID50 in MDCK cells. TCID50 was 
calculated by the Reed-Muench method(219). 
HI
Hemagglutinin inhibition assay (HI) was performed for all 11 viruses and ferret 
sera as well as the 28 isolated Mississippi clinical samples. Briefly, ferret sera, were
treated at a 1:3 ratio with receptor destroying enzyme (RDE, DenkaSeiken Co.; Japan) 
overnight at 37ºC, then heat inactivated at 56ºC for 30 minutes, and diluted 1:10 with 1x
phosphate-buffered saline (PBS; pH 7.4). The treated and diluted ferret sera were 2-fold 



















were expressed as the reciprocal of the highest dilution in which virus binding to 0.5% 
turkey red blood cells (RBCs) were blocked. Each experiment was repeated in triplicate.
polyPLA 
polyPLA, was completed as previously described (220). Briefly, Pierce protein 
A/G chromatography 1 mL cartridge (Thermo Scientific Pierce, Rockford, IL, USA)
were used to purify IgG from ferret polyclonal antisera. Monoclonal antibodies anti-NP 
and purified IgG were biotinylated with Biotin-XX miscroscale protein labeling kit, as 
according to manufacturer’s directions (Life Technologies, Carlsbad, CA, USA). Excess 
biotin was removed with Slide-A-Lyzer dialysis cassettes (Thermo Scientific Pierce, 
Rockford, IL, USA) in cold 1X PBS (pH 7.4) at 4ºC overnight. 
Two assay probes for each antibody were prepared by incubating the biotinylated 
antibodies with either 3’ or 5’ TaqMan Prox-Oligos (Thermo Scientific Pierce, Rockford, 
IL, USA). For example, for each probe, 2.5 µL 200 nM biotinylated antibody was 
combined with 2.5 µL of either 200 nM 3’ prox-Oligo or 200 nM 5’ prox-Oligo, 
incubated at room temperature for 60 minutes, and 45 µL Assay Probe Storage Buffer 
was added, briefly centrifuged, and incubated at room temperature for 20 minutes.
Antigenic cartography
The antigenic maps of H3N2 swine IAVs were constructed using AntigenMap 
(http://sysbio.cvm.msstate.edu/AntigenMap) and data derived from the HI assay or the
polyPLA (25, 26). The data entry with an HI titer of <1:10 or a polyPLA unit of <5.0 
















   
 
Sequencing
Viral RNA was extracted from both clinical samples (n=30) and viral isolates (n=28) 
with the GeneJet Viral DNA/RNA Purification Kit (Thermo Scientific Pierce, Rockford, 
IL, USA) according to manufacturer’s instructions. Using previously described primers
(221, 222), full-length cDNA for the eight influenza A gene segments was amplified with 
SuperScript One-Step RT-PCR (Invitrogen). Amplified viral DNA products were
quantified with use of High Sensitivity DNA kit (Agilent Technologies; Santa Clara, CA, 
USA) on Agilent 2100 Bioanalyzer (Agilent Technologies; Santa Clara, CA, USA). 
Sequencing libraries were prepared with equal amounts of each sample for the Illumina
Nextera DNA Sample Prepartion kit (Illumina, San Diego, CA, USA), quantified, 
normalized, and pooled together. Sequencing was completed with MiSeq Reagent kit v2 
(Illumina, San Diego, CA, USA) with the MiSeq sequencing system (Illumina, San 
Diego, CA, USA), according to the manufacturer’s suggested protocol. 
Next Generation Sequence Data Analyses
All the pair-end reads were trimmed according to their sequence quality with
Trimmomatic (version 0.36)(223). For assembly, a hybrid assemble pipeline was 
implemented to assemble pair-end reads using either reference or de novo method. Using
Bowtie2 (version 2.3.1)(224), the pipeline maps all assembled reads against template 
sequences and then generates consensus sequences as the results. In order to detect co-
infection in our sample, samples were assembled using the de novo method by Velvet
(version 1.2.10)(225). Different from reference method, Velvet will generate contigs 
from all reads, which is able to identify different HA/NA genes from the same sample.














   
  
 
sequences using Bowtie2. After mapping steps, we generate all polymorphisms under a
10% cutoff using SAMtools (version 1.4)(226) and igvtools (version 2.3)(227).  
Molecular characterization and phylogenetic analyses. 
Full length consensus sequences for 12 HA and 16 NA clinical and 58 HA and 48 
NA isolate were downloaded for CDC samples from GISAID EpiFlu database
(http://platform.gisaid.org/). The multiple sequence alignments of the consensus HA and 
NA gene segments, from GISAID and MSDH, were conducted using the MUSCLE 
software package (197). The phylogenetic analyses were performed using maximum 
likelihood by GARLI version (198), and bootstrap resampling analyses were conducted 
with 1,000 runs using PAUP* 4.0 Beta (199) with a neighborhood joining method, as 
previously described (200). 
Statistical Analysis
Linear regression analyses were performed using the HI titers of the isolated viruses 
(n=84) versus the 11 reference antisera and polyPLA units of these 84 virus isolated 
verses polyclonal antibodies of TX/50, SW/9715293, PA/6759, FI/2 and HK/4801. The
90 clinical samples were assessed for mono∆CT and ∆polyPLA cutoffs by the frequency
procedure using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) to determine sensitivity
and specificity for detection of IAVs and antigenic variants with confidence intervals at 
95%. The mathematical product of sensitivity × specificity, given the term efficiency, 
was calculated and graphed for each polyPLA value to provide the probability of correct 











(MedCalc; Ostend, Belgium) was used to test for significant difference in residue 
changes of the HA protein of clinical and isolate samples.
Results
Sensitivity of nasal swabs
To determine whether polyPLA is sensitive enough to identify H3N2 human 
IAVs in clinical samples, we used 20 nasal swabs from 2 ferrets infected with BR/10 and 
2 ferrets infected with HK/4801. Of the 20 samples, 6 had virus titers up to 2.8 × 108 
TCID50/mL and both swabs and virus isolates for each sample were IAV-positive (ΔCT ≥ 
3.00) using NP monoclonal antibodies. Further analyses using polyclonal antibodies from 
BR/10, PE/16, and TX/50 were used to detect BR/10 infected ferrets and TX/50, 
SW/9715293, and HK/4801 were used to detect HK/4801 infected ferrets. polyPLA 
detected viral shedding from 3 and 5 days after virus challenge and titers ranged from 6.0 
























Table 12 Virus titration and polyPLA of nasal swab from ferrets challenged with 
A/Brisbane/10/2007 and A/Hong Kong/4801/2014.
a Ferret identification number.
b Days post infection.
c 50% tissue culture infectious dose per mL.
d Standard deviation.
e Polyclonal antibodies used against original samples and isolates. BR/10 – 
A/Brisbane/10/2007; PE/16 – A/Perth/16/2009; TX/50 – A/Texas/50/2012; SW/9715293 
– A/Switzerland/9715293/2013; HK/4801 – A/Hong Kong/4801/2014.
f Nasal swabs directly from ferrets.
g Virus isolated from nasal swabs.
h Homologous titers in bold.
Detecting antigenic variants of H3N2 historical seasonal influenza viruses.
The 11 reference viruses were tested against the polyclonal antibodies for TX/50, 
SW/9715293, PA/6759, HK/4801, and FI/2 as well as the monoclonal NP antibody. The
results from polyPLA indicated that the titers for these five testing isolates ranged from 
2.80 to 12.38 polyPLA units. In support of the HI cartography–derived data, polyPLA-
based cartography also showed that the two genetic subclades 3C.2a and 3C.3a were
grouped in two antigenic clusters. The average distance between genetic subclusters was 












   
 
Fig. 11b) in HI and polyPLA cartography, respectively. Correlation association analyses 
through linear regression showed the fold increment titers from homologous virus 
isolates and fold increment in polyPLA values had a coefficient of R2 = 0.82 (p<0.0001; 
Fig. 11c). An 8-fold increment in HI titer was correlated with a 1.57-fold increment in 
polyPLA units.  
Figure 11 Comparison of antigenic characterization of H3N2 reference IAVs using
hemagglutination inhibition (HI) assays and polyclonal sera–based 
proximity ligation assay (polyPLA).
(A) Antigenic map derived from HI data; 3C.2a are marked in green and 3C.3a are
marked in blue. (B) Antigenic map derived from polyPLA data; 3C.2a are marked in 
green and 3C.3a are marked in blue. (C) Correlation of the fold increments in HI titers 
and those in polyPLA values; fold increment in polyPLA values can be predicted from 
fold increment in HI titers by the following formula: ΔpolyPLA values = 0.21  Δlog2(HI











   




   
  




Correlation with golden standard assay 
To assess the effectiveness of the polyPLA, we compared the antigenic data for
the same set of viral isolates derived from the HI assay and the polyPLA. The total of 84 
H3N2 IAVs isolates used for testing in our study had cross-reaction titers ranging from 
<1:10 to 1:1,280 against all reference sera (Table 13). HI-based antigenic cartography
showed that these 84 isolates can be grouped in two antigenic clusters, each is 
corresponding to genetic cluster 3C.2a and 3C.3a, respectively (Fig. 12a). 
The results from polyPLA using five reference sera against TX/50, SW/9715293, 
PA/6759, FI/2, and HK/4801 indicated that the titers for these 84 testing isolates ranged
from 2.58 to 15.43 polyPLA units. polyPLA-based cartography also showed that these 84 
isolates were could be grouped according to genetic subclade (Fig. 12b). The average
distance between genetic subclusters was 1.14 units (± 0.62 standard deviation) and 2.78 
units (± 1.06 standard deviation) in HI and polyPLA cartography, respectively. 
Correlation association analyses through linear regression showed the fold increments in 
HI titers and polyPLA values had a coefficient of R2 = 0.82 (p<0.0001) (Fig. 12c). An 8-
fold increment in HI titer was correlated with a 3.60-difference in polyPLA units.
a. Clinical samples
To measure the sensitivity of polyPLA on the clinical samples, we used the assay
on the 95 samples with three reference polyclonal antibodies against TX/50, 
SW/9715293, PA/6759, FI/2, and HK/4801. The frequency distribution of ΔCT values for
NP monoclonal antibodies for the 90 IAV positive– and 5 IAV negative–clinical samples 
showed that the greatest efficiency (98.9%) was observed at a ∆CT cutoff of 3.0 (Fig. 




   
 
 





       








sensitivity of 98.9% (95% CI = 93.1%, 99.9%) and specificity of 100.0% (95% CI =
46.3%, 100.0%).
Figure 12 Comparison of antigenic characterization of H3N2 IAVs using
hemagglutination inhibition (HI) assays and polyclonal sera–based 
proximity ligation assay (polyPLA).
(A) Antigenic map derived from isolate HI data; 3C.2a are marked in red and 3C.3a are marked 
in blue. (B) Antigenic map derived from isolate polyPLA data; 3C.2a are marked in red and
3C.3a are marked in yellow. (C) Correlation of the fold increments in HI titers and the difference 
in polyPLA values; difference in polyPLA values can be predicted from fold increment in HI
titers by the following formula: difference in polyPLA values = 1.09  Δlog2(HI titers) – 0.38, R2 
= 0.82. (D) Distribution of IAV-positive samples (white bars, N = 90) vs. IAV-negative samples
(grey bars, N = 5) obtained using NP monoclonal antibody and various ∆CT values. A total of 12 
representative H3N2 swine influenza A viruses (IAVs) were selected to represent the past 9 
influenza vaccine reformulations of the Northern Hemisphere winter seasons of November 2008-
April 2009 until November 2016-April 2017 (Table 11). The homologous ferret antisera for these 
viruses were used to perform the HI assay and polyPLA. The HI assays were performed using
0.5% red blood cells. Antigenic maps were constructed using AntigenMap 












polyPLA units for the paired 84 clinical samples ranged from 2.80 to 16.73 
polyPLA units. The clinical samples had larger polyPLA values against the polyclonal 
antibodies from the same genetic subclade. With the data from five reference polyclonal 
antibodies, the antigenic map of clinical samples with polyPLA showed variation in the
samples but with little distinction of genetic subclusters grouping together (Fig. 13). The
average distance between subclusters was 2.45 units (± 0.78 standard deviation) in 
polyPLA cartography, respectively.
Figure 13 Antigenic map derived from 90 clinical samples polyPLA data.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Totally, six clinical samples were unable to be isolated with MDCK cells. 
Sequence analyses of isolated viral RNA directly from the clinical samples concluded 
that two samples were of the 3C.2a subclade (A/Colorado/27/2015, 
A/Wyoming/19/2015), three samples were of the 3C.3a subclade
(A/Mississippi/167/2014, A/Mississippi/229/2014, A/Montana/13/2016), and one sample
was of the 3C.3b subclade (A/Montana/3/2015). With the use of polyPLA, the samples 
were able to be antigenically characterized. The clinical samples had larger polyPLA 
values against the polyclonal antibodies from the same genetic subclade.  
Phylogenetic analysis
Twenty-eight out of 30 MSDH viruses were isolated from MDCK cells. Of the 58 
total clinical and isolate samples, 24 clinical samples and 28 isolate samples were
sequenced; totally, 23 pairs were sequenced. Additionally, 58 out of the 60 CDC viruses 
were isolated from MDCK cells; from GISAID EpiFlu database
(http://platform.gisaid.org/), full length consensus sequences for 12 HA and 16 NA
clinical and 58 HA and 48 NA isolate were downloaded.  
Since 2007, the H3N2 seasonal influenza viruses have six genetic clusters (231). 
The viruses from 2013 belong to genetic clades 3c.2a and 3c.3a.The phylogenetic
analyses of the consensus sequences for HA gene showed that all 90 viruses belong to 
genetic clusters 3c.2a and 3c.3a (Fig. 14a). For H3, 14 out of 33 (42.4%) pairs differed in 
sequence from clinical to isolate and for N2, 9 out of 27 (33.3%) pairs differed in 





   
 
  






             
             
              
              
         
Figure 14 (Continued)
(A) Phylogenetic tree of HA nucleotide sequences of H3N2 seasonal influenza viruses. (B) Phylogenetic tree of NA
nucleotide sequences of H3N2 seasonal influenza viruses. The 90 pairs of viruses are from 2013-2016 H3N2 IAV from
MSDH and CDC. Unique clinical sequences were marked in blue, unique isolate sequences were marked in red, similar 
clinical and isolate sequences were marked in green, and reference sequences are in bold. The phylogenetic tree was 














Full protein consensus sequences for 23 pairs of clinical and isolate HA proteins 
of the MSDH viruses were analyzed for polymorphism distribution. The average depth of 
coverage for the polymorphic sites identified in HA is 8,275 with a range from 1,186 to 
18,544. Overall, 21 residues had significantly different proportions of amino acids 
between 3C.2 and 3C.3 of both clinical and isolated samples. For 3C.3, 12 residues were
significantly different between clinical and isolate samples but there were no residues 
significantly different between clinical and isolate samples for 3C.2 (Fig. 15).
Figure 15 The polymorphism distribution in 84 clinical and isolate pairs.
Using the comparison of proportions calculator (MedCalc) significant difference between 














polymorphisms in the sequences for the HA protein in the pubic databases 
Totally, protein consensus sequences of HA for 827 original and isolate H3N2 
pairs from 2012 until 2017 were downloaded from GISAID. Of these, 600 pairs were
genetically related to 3C.2 and 227 were genetically related to 3C.3. Totally, 29 residues 
had significantly different proportions of amino acids between 3C.2 and 3C.3 of both 
original and isolated samples. There were no residues that were significantly different 
between original and isolate samples (Fig. 16). 
Figure 16 The polymorphism distribution in human H3N2 from 2012 to 2017, 3C.2 
original and isolate pairs (n=600) and 3C.3 original and isolate pairs (n=227) 
samples downloaded from GISAID.
Using the comparison of proportions calculator (MedCalc) significant difference between 



















All viruses in the genetic subgroup 3C.2a have amino acids changes at residues 
L3I, F159Y, K160T, N335D, Q311H, and D489N. K160T is shown to be an addition of a
glycosylation motif at 158-160. 90% of viruses have the loss of glycosylation motif at 
N144S. 20% of samples have the same amino acid changes at residues N171K I406V, 
and G484E. Genetic subgroup 3C.3 contains amino acid changes at residues T128A, a
loss of glycosylation motif, and R142G. Subgroup 3C.3a has additional residue changes 
at A138S, F159S, N225D, and K326R. 
Using paired data for both clinical and isolate, a genetic and antigenic switch 
occurred in eight MSDH samples; all of these eight clinical samples belonging to 3C.2a
and all the eight corresponding isolates belonging to 3C.3a. Through NGS analysis, two 
clinical samples (A/Mississippi/207/2014, A/Mississippi/226/2014) have polymorphisms 
within the HA protein yet no polymorphisms within the isolate sample, which is what is 
expected. While the other six clinical samples have no polymorphisms, more
interestingly enough, four of those samples have polymorphisms within the isolate HA 
protein. Two samples have no polymorphisms present in either clinical or isolate.
Discussion
In this study, a polyPLA assay was used to detect antigenic variants of 
contemporary human H3 IAVs in the United States. The previously defined detection 
limit for polyPLA is approximately 10^3 TCID50/ mL(220, 232), which is much less 
than the viral loads from most patients at the peak time of virus shedding (201). This 
assay was used to differentiate viruses in genetic clusters 3C.2a from those in 3C.3a




















With the Δ Ct PLA unit of 3.00, this assay can detect antigenic variants with a 
specificity of 100% and a sensitivity of 98.9% in influenza positive samples collected 
during influenza surveillance. Thus, the polyPLA is specific and sensitive enough to be 
used for antigenic variant detection in human H3 IAVs. Because it is developed based on 
a qRT-PCR platform, polyPLA can be used for high-throughput antigenic screening in 
most laboratories; this assay reduces the necessary time of 3-5 days for conventional 
methods to only a few hours after specimen collection for antigenic characterization, 
because there is no need for virus isolation. Detection of possible emerging antigenic
variants can increase effectiveness of vaccination programs. 
Low or undetectable hemagglutination activity was common, particularly for 
3C.2a, which caused antigenic characterization to be more difficult of the novel viruses 
(118). Ferret sera from cell-propagated 3C.3a and 3C.2a inhibited most circulating
viruses, so WHO has concluded that 3C.3a and 3C.2a were antigenically related. With 
the use of polyPLA, antigenic clades could be better distinguished. The antigenic map of 
polyPLA units is in agreement with the antigenic map of HI titers, both show slight 
separation of 3C.2a and 3C.3a.  
In this study, as well as others, have seen a variety of viruses with different HA1 
mutations for both 3c.3a and 3c.2a(119). Additionally, mutations occurred in each 
antigenic site (A-E); typically the accumulation of amino acid changes in HA are
clustered in the antigenic sites located close to the receptor binding sites (233). In a
previous study, 42% of H3N2 viruses isolated from MDCK cells contained substitutions 




   
 









    




    
we saw that in HA and NA gene segments specifically, 42.4% and 33.3%, respectively
contained substitutions in viral isolates as compared to clinical samples. 
It has been well established genetic evolution is a continuous process, hence
relying on consensus sequences alone for influenza genetic analysis can miss information 
about the true population of viruses within a sample. Additionally, it is possible that with 
the use of reverse transcriptase or Taq, template switching can occur during the first 
amplification cycles, leading to artificial chimaeras(234). Even in conventional Sanger 
sequencing, in silico recombination could occur by assembling fragments that have been 
sequenced separately(235). With NGS, the entire genome of influenza can be sequenced
at once and the true genetic variation within a viral quasispecies can be identified (155,
156). Further analysis on NGS of all 84 clinical and isolate pairs is still needed in order to 
analyze polymorphisms within each sample population. 
Additionally, the original viral population is not limited one identical viral 
genome and the cell-propagated population of viruses should be more homogeneous (42-
45). Of the 23 pairs of clinical and isolate HA sequences, eight pairs had polymorphisms 
in clinical samples, yet not in isolates, as expected; nine pairs did not contain 
polymorphisms in either clinical or isolate; six pairs contained polymorphisms in isolates 
but not in clinical samples. The average coverage for NGS was approximately 8,000; the
reason for the eight MSDH samples that have a switch in genetic subclade is still unclear. 
Conclusions
Detection of antigenic variants of H3 human influenza viruses from clinical 
samples can give additional information that can be missed in traditional surveillance










in the human population. The direct use of influenza positive clinical samples can help to 
give better insight into the true circulating population of viruses. In this chapter, we see
both genetic and antigenic differences in original clinical samples as compared to the
isolated viruses with the use of polyPLA and NGS. Further analyses will be completed, 
including sparse machine learning, to establish a connection between genetic and 

















    
DETECTION OF ANTIGENIC VARIANTS OF SWINE SUBTYPE H3 INFLUENZA
A VIRUSES FROM CLINICAL SAMPLES
A large population of genetically and antigenically diverse influenza A viruses 
(IAVs) are circulating among the swine population, playing an important role in 
influenza ecology. Swine IAVs not only cause outbreaks among swine, but they can also 
be transmitted to humans, causing sporadic infections and even pandemic outbreaks. 
Antigenic characterization of swine IAVs are key to understanding the natural history of 
these viruses in swine and to select strains for effective vaccines. However, influenza 
outbreaks generally spread rapidly among swine, and the conventional methods for
antigenic characterization require virus propagation, a time-consuming process that can 
significantly reduce the effectiveness of vaccination programs. We developed and 
validated a rapid, sensitive, and robust method, the polyclonal sera–based proximity
ligation assay (polyPLA), to identify antigenic variants of subtype H3N2 swine IAVs. 
This method utilizes oligonucleotide–conjugated polyclonal antibodies and quantifies 
antibody–antigen binding affinities by quantitative RT-PCR. The results showed that the 
assay can rapidly detect H3N2 IAVs directly from nasal wash or nasal swab samples 
collected from laboratory-challenged animals or during influenza surveillance at county
fairs. In addition, the polyPLA can accurately separate the viruses at two contemporary




















sensitivity of 84.9% and a specificity of 100.0%. The polyPLA can be routinely used in 
surveillance programs to detect antigenic variants of influenza viruses and to select 
vaccine strains for use in controlling and preventing disease in swine.
Introduction
Influenza A virus (IAV) can infect swine, causing typical signs of respiratory
disease (e.g., fever, depression, coughing, nasal discharge, sneezing, and breathing
difficulty) that generally last 5–7 days. IAVs can be transmitted between humans and 
swine, both of which have N-acetylneuraminic acid–α2, 6–linked galactose (NeuAcα-
2,6Gal) serving as receptors for IAVs in their upper respiratory tracks (9). In addition to 
NeuAcα-2,6Gal, swine also have N-acetylneuraminic acid–α2, 3–linked galactose 
(NeuAcα-2,3Gal) serving as receptors for IAVs in their upper respiratory tracks. Thus, 
swine have been proposed to serve as “mixing vessels,” generating novel IAVs by
reassorting avian IAVs and swine IAVs and facilitating adaptation of avian IAVs before
their spillover to the human population (236, 237). Swine IAVs cause sporadic cases of 
influenza among humans as well as a pandemic in human, e.g. by a swine-origin IAV, 
influenza A(H1N1)pdm09 (21). On the other hand, it is not uncommon for IAVs to be
introduced from humans to swine (238). For subtype H3N2 specifically, at least 13 
infections caused by the introduction of virus from humans to swine were identified from 
1965 to 2013 (239). Thus, understanding the genetic and antigenic diversity of IAVs in 
swine is key to developing an effective strategy for influenza prevention and control 
among domestic swine and to protect public health. 
In the United States, surveillance has shown that a genetically diverse population 


















   
 
(57, 84). At least seven genetic clusters of swine subtype H1 IAVs (H1α, H1ß, H1γ1, 
H1γ2, H1δ1, H1δ2) and A(H1N1)pdm09 are circulating in the swine population, and the
viruses in these H1 genetic clusters are antigenically distinct (173). A recent study
suggested the proportion for the number of swine subtype H3N2 IAVs over the total 
number of swine IAVs recovered from domestic swine have increased, and these viruses 
are widely spread across the United States (29). Molecular characterization suggested that 
the hemagglutinin (HA) genes of contemporary swine subtype H3 IAVs belong
genetically to cluster IV, and these viruses can be antigenically separated into two 
groups, H3N2 swine IAV-α and H3N2 swine IAV-ß (abbreviated as H3α and H3ß) (240).
Vaccination has been routinely utilized in the United States to prevent virus
transmission at swine farm operations (241) and swine exhibits at agricultural fairs (239). 
Swine vaccines, which are available as licensed commercial products, are typically
produced from culture-derived virions incubated in crude allantoic fluid from special 
pathogen–free chicken eggs. After incubation, the virus is chemically inactivated and 
formulated into a mineral oil emulsion vaccine (242). Unlike the process for producing
vaccines for humans, this process for producing swine vaccines avoids costly purification 
steps for enrichment of the surface glycoproteins hemagglutinin (HA) and neuraminidase
(NA) (58); however, potential booster vaccinations are necessary to achieve and maintain 
protective levels of systemic HA-inhibiting antibodies (59).
Production of an effective vaccine requires an antigenic match between 
circulating strains and the vaccine strain, but that is not a trivial task. IAV transmission 
occurs rapidly among swine populations, especially on farms with middle- or large-scale 







   
   
 
  







produced and administered (within days of an outbreak) to effectively mitigate the spread 
of disease. However, the conventional methods for antigenic characterization (e.g., 
hemagglutination inhibition [HI]) require virus isolation, which usually takes at least 3 
days to accomplish. Thus, because of the antigenic diversity of swine IAVs, conventional 
methods cannot be used to determine immunologic reactions between circulating viruses 
and available vaccines. Therefore, many vaccines for swine IAVs in the United States 
have been produced locally and autogenously without efficacy testing (243).
It is not uncommon for vaccines that are antigenically inaccurate for circulating
viruses to lead to vaccine-induced immunity, causing antigenic drift and the silent spread 
of virus (244). Moreover, the generation of novel escape mutants could gradually lead to 
the replacement of circulating virus strains (61, 62), further complicating the antigenic 
and genetic evolution of swine IAVs. The occurrence of such antigenic drift events in 
swine is well documented (57, 63, 64). To develop an effective and robust swine IAV
vaccination program, a rapid and robust method for antigenic characterization in swine is 
needed. Ideally, the assay would not require virus isolation but would be sensitive enough 
to directly perform antigenic characterization using clinical samples.
A polyclonal serum–based proximity ligation assay (polyPLA) was developed 
recently to measure antibody–antigen binding affinities without using red blood cells 
(RBCs) (220). The polyPLA attaches probes to antibody, and then quantifies the binding
affinities between antibody and antigen by quantitative RT-PCR. This method is highly
sensitive and was shown to effectively detect antigenic variants for human seasonal 
influenza subtype H3N2 virus in human nasopharyngeal swab samples, thus avoiding the 














quantify the antibody–antigen interaction for swine H3 IAVs. This method would be
useful for vaccine strain selection for swine IAVs.
Materials and Methods
Viruses and serum samples.
Seven contemporary (2009–2011) swine H3N2 IAV isolates  and their
homologous ferret serum samples were chosen to represent the swine IAV antigenic
groups H3α and H3ß (Table 14); antigenic characterization of these isolates is described 
elsewhere (240). The strain of A/California/04/2009(H1N1) (abbreviated as CA/04)
[A(H1N1pdm09] and homologous ferret serum was used as a negative control. The anti-








          
 
 
   
 
   
 
   
 
 































































   
  
    
  
    
  
    
  
 
           
     
     
   
                 
     
                
 









Table 14 Antigenic characterization of H3N2 swine influenza viruses using
hemagglutination inhibition assay and polyPLA
Ferret Antiserum
a 
b b b b
09SW96 10SW215 11SW347 CA/04
Antigenic polyPLA polyPLA polyPLA polyPLA










10.37 6.14 5.20 N/A
A/swine/Ohio/09SW64/2009(H3N2) H3α 1,600 (0.10) 40 (0.69) <10 (0.36) <10 (N/A)
11.06 4.53 1.71 N/A
A/swine/Ohio/09SW96/2009(H3N2) H3α 1,280 (0.72) 40 (0.71) <10 (0.52) <10 (N/A)
6.62 11.87 10.62 N/A
A/swine/Ohio/10SW130/2010(H3N2) H3ß 40 (0.86) 640 (0.33) 640 (0.28) <10 (N/A)
4.12 14.85 9.52 N/A
A/swine/Ohio/10SW156/2010(H3N2) H3ß 20 (0.37) 1,280 (0.36) 640 (0.56) <10 (N/A)
4.01 16.47 11.64 N/A
A/swine/Ohio/10SW215/2010(H3N2) H3ß 40 (1.32) 1,280 (0.11) 640 (0.10) <10 (N/A)
7.24 11.59 12.26 N/A
A/swine/Ohio/11SW208/2011(H3N2) H3ß 40 (0.65) 320 (0.46) 1,024 (0.28) <10 (N/A)
4.99 8.15 12.63 N/A
A/swine/Ohio/11SW347/2011(H3N2) H3ß 20 (0.14) 320 (0.44) 1,280 (0.39) <10 (N/A)
6.66 4.83 N/A 9.70
A/California/04/2009(H1N1)
f 
H1pdm09 10 (0.95) <10 (0.51) <10 (N/A) 1,280 (0.61)
a The viruses were collected from pigs at agricultural fairs in Ohio, USA, 2009–2011 (240)
b Homologous titers are in bold.
c 09SW96, A/swine/Ohio/09SW96/2009(H3N2); 10SW215, A/swine/Ohio/10SW215/2010(H3N2); 11SW347,
A/swine/Ohio/11SW347/2011(H3N2); CA/04, A/California/04/2009(H1N1).
d HI, hemagglutination inhibition assay. Each experiment was repeated two times, and each HI value reported in this table is an
average number from three independent experiments. 
e polyPLA, polyclonal sera based proximity ligation assay; SD, standard deviation. Values represent the average of three replicate
experiments.
fA/California/04/2009 (H1N1) was used as a negative control.
Clinical samples.
A total of 120 nasal wash and nasal swab samples were collected for 10 
consecutive days post infection (dpi) from 8 feral swine infected with 
A/swine/Texas/A01104013/2012 (H3N2) and 4 sentinel feral swine. The details for the 
experimental design and sample collection are available from a prior publication (183). 
Among these samples, 42 were tested with a detectable TCID50, and these samples were
used in this study to test the sensitivity and specificity of the proposed polyPLA method. 
We also tested 81 nasal swab samples that had been collected from swine at the 




   
   
 











   
  
   
  
positive for IAV, using matrix gene–based quantiative RT-PCR (qRT-PCR) (240, 245); 
and 20 of the samples were negative for IAV. A power analysis (OpenEpi, Version 3)
suggested that a sample size of 20 gave 95% probability to detect ±10% with expected 
specificity (246). Of those 61 IAV-positive samples, 50 were subtype H3 and 11 were
subtype H1.
HA and HI assays. 
HI was performed as previously described (247). In brief, receptor-destroying
enzyme (RDE; Denka Seiken Co., Ltd., Tokyo, Japan) was incubated overnight at a 1:3 
ratio (vol:vol) with ferret antisera. After incubation, the mixture was heat-inactivated at 
56ºC for 30 min and then diluted 1:10 with 1 phosphate-buffered saline (PBS, pH 7.4). 
The treated ferret antiserum was then 1:2 serially diluted in 96-well v-bottom plates with 
1 PBS, reacted with 4 HA units of virus, and then incubated for 30 min at 37ºC, after 
which 0.5% turkey RBCs were added to each well and incubated for 30 min at 37ºC. 
Each experiment was repeated two times and each HI value reported is an average
number from three independent experiments; the highest dilution in which virus binding
to the RBCs was blocked was expressed as the reciprocal HI titer.
polyPLA. 
IgG was purified from polyclonal serum and monoclonal antibody and labeled 
separately with 5′ and 3′ TaqMan Prox-Oligos (Thermo Fisher Scientific, Waltham, MA, 
USA) for use in a proximity ligation assay, as described elsewhere (220). In brief, 5′- and 
3′- labeled IgG was diluted (1:10) in assay probe dilution buffer, and 2 µL was added to 2 















       
 
 
96 µL of ligation mixture (0.1 µL of diluted [1:500] ligase, 5 µL of 20X ligation reaction 
buffer, and 90.9 µL of dH2O) was added to each incubation product, incubated at 37ºC
for 10 min, and then put on ice. Diluted protease was then added to the ligation products 
and incubated at 37ºC for 10 min and at 95ºC for 5 min and then put on ice. Last, 4.5 µL
of protease products was added to 5 µL of TaqMan Protein Assays Fast Master Mix (2X) 
(Thermo Fisher Scientific, Waltham, MA, USA) and 0.5 µL 20X Universal PCR Assay
(Thermo Fisher Scientific, Waltham, MA, USA), and quantitative RT-PCR was 
performed as follows: 95ºC for 20 sec, 40 cycles at 95ºC for 1 sec, and 60ºC for 20 sec. 
The threshold was set at 0.2, and change in the cycle threshold (∆CT) were calculated by
[average CT (NPC) – average CT (sample)]; quantitative RT-PCR was performed on each 
sample in triplicate. 
Antigenic cartography.
The antigenic maps of H3N2 swine IAVs were constructed using AntigenMap 
(http://sysbio.cvm.msstate.edu/AntigenMap) for the data derived from the HI assay or the
polyPLA (229, 230). The data entry with an HI titer of <1:10 or a ∆CT of <3.00 were
determined as a low reactor for the data from HI or the polyPLA, respectively.
Data analyses. 
To make the antigenic properties across the testing antigens (viruses) comparable, 
we calculated the polyPLA units between virus and antibody as previously described 
(220): polyPLA = a  (poly∆CT − mono∆CT) + b, in which a = 1.00 and b = 10.00, to 
eliminate negative numbers. A mono∆CT cutoff of <3.00 has been traditionally used to 















     
   
 
 
Linear regression analyses were performed using the HI titers of the 7 swine IAV
isolates (2 to antigenic clade H3α and 5 to H3ß) verses their homologous antisera and 
polyPLA units of these 7 swine IAV isolates verses 3 polyclonal antibodies (1 to H3α and 
2 to H3ß). The 81 nasal swab samples were assessed for mono∆CT and ∆polyPLA cutoffs 
by the frequency procedure using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) to 
determine sensitivity and specificity for detection of IAVs and antigenic variants with 
confidence intervals at 95%, receiver operator characteristic area under the curve, and 
linear regression. The mathematical product of sensitivity × specificity, given the term 
efficiency, was calculated and graphed for each polyPLA value to provide the probability
of correct classification for unknown sample status (228). Kappa analyses and all 
descriptive graphs were created using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, CA, USA).
Results
Comparison of HI assay and polyPLA in antigenic characterization of subtype H3 
swine IAVs.
To assess the effectiveness of the polyPLA, we compared the antigenic data
derived from the HI assay and the polyPLA. The seven H3N2 swine IAVs used for
testing in our study had cross-reaction titers ranging from <1:10 to 1:1,600 (Table 14). 
HI-based antigenic cartography showed that the seven isolates were separated into two 
antigenic clusters: two isolates from 2009 were in cluster H3α, and the five other isolates 
were in cluster H3ß (Figure 17a). The results from polyPLA indicated that the titers for
these seven testing isolates ranged from 1.71 to 16.47 polyPLA units. In support of the HI








isolates were grouped in two antigenic clusters (Figure 17b). The average distances 
between clusters were 5.14 units (± 0.15 standard deviation) and 6.27 units (± 1.22 
standard deviation) in HI and polyPLA cartography, respectively. Correlation association 
analyses through linear regression showed that the titers between these two types of data 
had a coefficient of R2 = 0.82 (p<0.0001) (Figure 17c) and that the fold increments in HI
titers and polyPLA values had a coefficient of R2= 0.85 (p<0.0001) (Figure 17d). Similar 
to HI assay results, polyPLA results suggested that subtype H3N2 swine IAVs did not





   
  
         
              
                 
              
               
               
             
          
       
     
    
    
Figure 17 Comparison of antigenic characterization of H3N2 swine IAVs using
hemagglutination inhibition (HI) assays and polyclonal sera–based 
proximity ligation assay (polyPLA).
(A) Antigenic map derived from HI data. (B) Antigenic map derived from polyPLA data. (C) Correlation of HI titers 
and polyPLA values; polyPLA values can be predicted from HI titers by the following formula: polyPLA values = 1.27
× log2(HI titers) – 0.56, R2 = 0.82. (D) Correlation of the fold increments in HI titers and those in polyPLA values; fold
increment in polyPLA values can be predicted from fold increment in HI titers by the following formula: ΔpolyPLA
values = 0.10  Δlog2(HI titers) – 0.05, R2 = 0.85. A total of 7 representative H3N2 swine influenza A viruses (IAVs) 
were selected to represent antigenic clusters H3 swine IAV-α and H3 swine IAV-ß (abbreviated as H3α and H3ß)
(Table 14). The homologous ferret antisera for these viruses were used to perform the HI assay and polyPLA. The HI 
assays were performed using 0.5% red blood cells. Antigenic maps were constructed using AntigenMap
(http://sysbio.cvm.msstate.edu/AntigenMap) (229, 230). Viral isolates are 09SW64, A/swine/Ohio/09SW64/2009
(H3α); 09SW96, A/swine/Ohio/09SW96/2009 (H3α); 10SW130, A/swine/Ohio/10SW130/2010 (H3ß); 10SW156,
A/swine/Ohio/10SW156/2010 (H3ß); 10SW215, A/swine/Ohio/10SW215/2010 (H3ß); 11SW208,














Detection of H3N2 swine IAVs in clinical samples from feral swine.
To determine whether polyPLA is sensitive enough to identify H3N2 swine IAVs 
in clinical samples, we used 42 nasal swab and nasal wash samples from 8 feral swine
infected with A/swine/Texas/A01104013/2013(H3N2) (belonging to antigenic clade
H3ß) and 4 sentinel feral swine with virus titers up to 5.00  105 TCID50 /mL. Of the 42 
samples, 34 were IAV-positive (ΔCT ≥3.00) using NP monoclonal antibodies. Further 
analyses using polyclonal H3ß antibodies showed that polyPLA can detect H3N2 swine
IAV virus titers of <1,000 TCID50/mL (Figure 18a); this finding is similar to that for 
human IAVs which can detect virus titers of <1,000 TCID50/mL, as previously published
(220). Furthermore, in the animal experiments, polyPLA could detect viral shedding from 
1 to 10 days after virus challenge, and titers ranged from 4.35 to 14.83 polyPLA units







            
            
         
              
           
        
            
 
 
Figure 18 Comparison of sensitivity of cell culture based viral titration and polyclonal 
sera–based proximity ligation assay (polyPLA) in detecting influenza A 
viruses (IAVs) in nasal wash and nasal swab samples collected from feral 
swine infected with A/swine/Texas/A01104013/2012(H3N2).
(A) Variations of TCID50 and polyPLA titers in 12 swine. Horizontal dashed line indicates 1000
TCID50/mL. (B) Average number of days after virus challenge that virus could be detected by TCID50 and
polyPLA. The whiskers of the box-and-whisker plots denote the smallest value to the larger value, while 
the box extends to the 25th and 75th percentiles, with the median in the middle. The infecting virus belongs
to swine influenza A virus (IAV) antigenic cluster H3N2 swine IAV-ß. Swine 1–8 were inoculated nasally
with virus; swine 9–12 were sentinel swine housed in the same room. Among a total of 120 samples 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    
   
  







   
 
Application of polyPLA in detecting H3N2 swine IAV antigenic variants from
clinical samples collected from swine at agricultural fairs.
To measure specificity of polyPLA in the clinical setting, we used the assay on 81 
samples taken from swine at agricultural fairs. The frequency distribution of ΔCT values 
for NP monoclonal antibodies for the 61 IAV positive– and 20 IAV negative–clinical 
samples from domestic swine showed that the greatest efficiency (77.0%) was observed 
at a ∆CT cutoff of 7.0 (Figure 19a). Thus, the optimum combination for detecting IAVs in 
clinical samples is an assay sensitivity of 77.0% (95% CI = 64.5%, 86.8%) and 
specificity of 100.0% (95% CI = 83.2%, 100.0%). Accuracy of the polyPLA was 
measured by the receiver operating characteristic area under the curve, which was 0.90, 
an excellent test for separating IAV-positive from IAV-negative clinical samples (Figure
20). There was 82.7% overall agreement between qRT-PCR and polyPLA, with a kappa
of 62.4% (95% CI = 45.8%, 79.0%), which suggests a good strength of agreement. The
typical ∆CT cutoff of 3.0 showed that the polyPLA had high sensitivity (96.7%; 95% CI =
88.7%, 99.6%) but low specificity (15.0%; 95% CI = 3.2%, 37.9%), and 59 true-positive
and 17 false-positive samples were detected. At the higher ∆CT cutoff of 7.0, false 
positives were eliminated, and 47 true positive samples were detected. 
To distinguish between antigenic group H3α and antigenic group H3ß viruses, we
calculated the frequency distribution of ΔpolyPLA values for H3α and H3ß polyclonal 
antibodies for the 47 IAV-positive clinical samples from domestic swine. At the 
ΔpolyPLA threshold of 3.5, the greatest efficiency was observed at 85.0%, with a 
sensitivity of 85.0% (95% CI = 77.0%, 91.0%) and specificity of 100.0% (95% CI =











regression showed the fold increment titers from homologous virus isolates and fold 
increment in polyPLA values had a coefficient of R2 = 0.88 (p<0.0001; Figure 21). An 8-
fold increment in HI titer was correlated with a 3.26-fold increment in polyPLA units. 
polyPLA was able to distinguish between the two swine IAV H3 antigenic groups with 
complete agreement: 10 samples were H3α-positive (sensitivity 95% CI = 69.2%; 100%), 
and 33 were H3ß-positive (sensitivity 95% CI = 89.4%; 100%); 4 were negative to both 
polyclonal antibodies because they were previously identified as H1 qRT-PCR-positive










      
 
   
Figure 19 Optimization of the polyclonal sera–based proximity ligation assay
(polyPLA) in detecting antigenic variants in clinical samples from swine
infected with IAV.
(A) Distribution of IAV-positive samples (white bars, N = 61) vs. IAV-negative samples 
(grey bars, N = 20) obtained using NP monoclonal antibody and various ∆CT values. (B) 
Distribution of H3 swine IAV-α vs. H3 swine IAV-ß samples at various ∆polyPLA 
values. 09SW, A/swine/Ohio/09SW96/2009(H3N2); 10SW, 
A/swine/Ohio/10SW215/2010(H3N2); 11SW, A/swine/Ohio/11SW347/2011(H3N2); 
shown in dark grey, light grey, and white bars, respectively. Data analyses were















Figure 20 Receiver operating characteristic was performed to assess the accuracy of 
polyPLA results for determining the presence of IAV in clinical samples 
from swine.
The area under the curve was 0.8973, which is a very good test for the separation of IAV-
positive from IAV-negative clinical samples with NP monoclonal antibody.
Figure 21 Correlation of fold change of log2(HI) titer and fold change of polyPLA 
values.
Fold change in polyPLA values can be predicted from the fold change in HI titers by the 
following formula: fold change polyPLA values = 1.1228 × fold change log2HI – 
0.11124, R2=0.8836 (p<0.0001). An 8-fold change of HI titer correlates with a 1.604 (± 
0.125)–fold change of polyPLA value: these fold changes were used to distinguish 10 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
Table 18 Antigenic differences in subtype H3 influenza A virus–positive samples
from swine.
Antigenic Group
Clinical Samplea Subtypeb 
H3αc H3ßd 
TOSU 1 H3 - +
TOSU 2 H3 - +
TOSU 3 H3 - +
TOSU 4 H3 - +
TOSU 5 H3 + -
TOSU 6 H3 + -
TOSU 7 H3 + -
TOSU 8 H3 + -
TOSU 9 H3 + -
TOSU 10 H3 + -
TOSU 11 H3 + -
TOSU 12 H3 + -
TOSU 13 H3 + -
TOSU 14 H3 + -
TOSU 15 H3 - +
TOSU 16 H3 - +
TOSU 17 H3 - +
TOSU 18 H3 - +
TOSU 19 H3 - +
TOSU 20 H3 - +
TOSU 21 H3 - +
TOSU 22 H3 - +
TOSU 23 H3 - +
TOSU 24 H3 - +
TOSU 25 H3 - +
TOSU 26 H3 - +
TOSU 27 H3 - +
TOSU 28 H3 - +
TOSU 29 H3 - +
TOSU 30 H3 - +
TOSU 31 H3 - +
TOSU 32 H3 - +





    
    
    





    
    
    
  
  





    





    
    






















TOSU 34 H3 - +
TOSU 35 H3 - +
TOSU 36 H3 - +
TOSU 37 H3 - +
TOSU 38 H3
TOSU 39 H3
TOSU 40 H3 - +
TOSU 41 H3 - +
TOSU 42 H3 - +
TOSU 43 H3
TOSU 44 H3 - +
TOSU 45 H3
TOSU 46 H3
TOSU 47 H3 - +
TOSU 48 H3 - +
TOSU 49 H3
TOSU 50 H3
TOSU 51 H1 - -
TOSU 52 H1 - -
TOSU 53 H1 - -
TOSU 54 H1
TOSU 55 H1






























      
         
      
          
       
         
           




   
 














a Swine clinical samples from Ohio, USA, agricultural fairs; samples were given arbitrary names of The 
Ohio State University (TOSU) 1 to 81.
b Of the 81 samples, 61 were positive for IAV using matrix gene-based quantitative RT-PCR; this includes
50 that were subtyped as H3 and 11 that were subtyped as H1(2).
cResults of polyPLA (polyclonal sera–based proximity ligation assay) using 09SW96 polyclonal antibodies 
to determine samples positive (+) or negative (-) for antigenic group H3-α swine influenza virus (SIV).
d polyPLA results distinguishing SIV H3-ß positive (+) and negative (-) antigenic group with 10SW215 and
11SW208 polyclonal antibodies.
Effectiveness of polyPLA in detecting H1 swine IAV antigenic variants.
To evaluate whether polyPLA was effective in identifying antigenic variants for
subtype H1 IAVs, cross-activities were measured using both the polyPLA and HI assays 
between the CA/04 polyclonal serum and a panel of H1N1 isolates, which belong to 8 
antigenically distinct clades, including clade H1α , H1ß, H1γ, H1γ1, H1γ2, H1δ1, H1δ2, 
and A(H1N1)pdm09. Results from polyPLA showed that CA/04 polyclonal serum cross-
reacted with the homologous virus CA/04 and A/swine/Iowa/8/2013(H1N1) (both to 
clade A(H1N1)pdm09) with two highest polyPLA units, 13.83 and 15.87, respectively; 
this serum cross reacted to A/swine/Nebraska/A01240348/2011(H1N1) (H1ß) with 12.02 
polyPLA unit, to A/swine/Indiana/13TOSU1154/2013(H1N1) (H1γ) with 11.01 polyPLA 
unit, to A/swine/Indiana/13TOSU0832/2013(H1N1) (H1γ1) with 10.22 polyPLA unit.  






   
 
 








than 10.00 (Table 17). Such results were consistent with the corresponding HI titers, 
validating that this method is effective in antigenic characterization of H1 viruses. 
Furthermore, we performed polyPLA assays using CA/04 serum against the 47 IAV-
positive clinical samples. Results showed that CA/04 serum did not cross-react with 43 
H3 IAV positive samples but did to 4 H1 IAV positive samples to different extents. 
Among these 4 H1 viruses, 2 were sequenced, 1 genetically belong to H1γ and the other 
one to H1δ1 (Table 17). 
Discussion
In this study, a polyPLA assay was used to detect antigenic variants of 
contemporary subtype H3 IAVs in swine in the United States. This assay was validated to 
differentiate viruses in antigenic cluster H3α from those in H3ß directly in clinical 
samples, such as swine nasal swab or nasal wash samples. With the optimized ΔpolyPLA 
unit of 3.500, this assay can detect antigenic variants with a specificity of 100% and a
sensitivity of 84.9% in samples collected during influenza surveillance. Thus, the 
polyPLA is specific and sensitive enough to be used for vaccine strain selection for swine 
IAVs. Because it does not require virus isolation, this assay shortens the time needed for
antigenic characterization using conventional methods (3–5 days) to only a few hours 
after specimen collection and, therefore, can increase effectiveness of vaccination 
programs on swine farm operations and at agricultural fairs. In addition, because it is 
developed based on a qRT-PCR platform, polyPLA can be used for high-throughput 
screening and for clinical diagnosis in most laboratories.
The HI assay is used routinely in influenza antigenic characterization because of 


















is based on the competition of the glycan receptors on animal RBCs and antibody against
surface glycoproteins, especially hemagglutinins of IAVs. Thus, antigenic 
characterization results can be affected not only by changes at antibody binding sites, but
also by the source of the RBCs and the variation of receptor binding sites. In addition, HI
requires a large amount of virus particles, so, in general, it is necessary to recover and 
propagate viruses using cells or chicken eggs, which can lead to unwanted adaptive
mutations, especially those at the receptor binding sites of viral hemagglutinin proteins. 
These mutations can skew HI data and even cause loss of binding affinity to some RBCs 
(122, 124). In addition, because no standard RBCs are used in HI assays, the variation in 
the binding affinities of IAVs to different sources of RBCs make it difficult to interpret 
those results across HI assays using different RBCs. Unlike the HI assay, polyPLA does 
not use RBCs and is not affected by variations in receptor binding sites. Instead, polyPLA 
utilizes oligonucleotide-labeled antibodies and quantifies the binding affinities between 
antibody and antigen through qRT-PCR. More strikingly, this method can be applied 
directly in clinical samples and can minimize biases due to virus adaptation in virus 
isolation. Results showed that polyPLA values are similar to those in HI assays, although 
the scale of fold increments are different (Figure 21). In this study, both HI and polyPLA 
clearly separated swine IAVs in antigenic cluster H3α from those in antigenic cluster 
H3ß. Furthermore, an eight-fold increment in HI titer was approximately equal to a
3.256-fold increment in polyPLA (Figure 21). 
Compared with clinical samples from laboratory animals, samples derived from 
the field could be complicated with high background in qRT-PCR due to low quantities 












   
  






viral inhibitor, and/or presence of proteins from other viruses or bacterial pathogens 
(248). Nevertheless, for vaccine strain selection in the clinical setting, it is critical to use
assays with 100% specificity and relatively high sensitivity. Relatively low assay
sensitivity can be overcome by using a larger number of samples in the assays; in general, 
the availability of multiple samples from swine herds will not be an issue, especially
during an outbreak. Based on the 81 samples we tested, polyPLA has a sensitivity of 
77.0% (95% CI of 55.7%, 80.1%) and specificity of 100.0% (95% CI of 83.2%, 100.0%) 
when the ∆Ct cutoff is set at 7.0 (Figure 19a).
The number of polyPLAs conducted in experiments can be reduced if the IAV 
subtype in samples is known prior to testing. Thus, the performance of polyPLA can be
maximized and the cost can be reduced if the assay is coupled with subtype-specific IAV
antigen assays, such as qRT-PCR. The recommended procedure for polyPLA application 
includes three steps: 1) determine whether the testing sample is IAV-positive by using a
matrix gene–based qRT-PCR (245) rapid influenza antigen detection test (249) or an 
influenza test strip; 2) use qRT-PCR to determine the subtype of IAV in the sample; and 
3) perform antigenic characterization by using subtype-specific polyPLA. As with the 
conventional methods for antigenic characterization, polyPLA can be used with a panel 
of reference sera to quantify antigenic diversity among the viruses; thus, polyPLA would 

















MULTIPLEX POLYPLA FOR ANTIGENIC CHARACTERIZATION OF
INFLUENZA VIRUSES USING CLINICAL SAMPLES
Introduction
For the past six influenza seasons in the United states, 2010-2011 until 2015-
2016, the estimated deaths associated with influenza have ranged from low of 12,000 
(2011-2012 season) to high of 56,000 (2012-2013 season)(250). Influenza vaccination is 
the basis for the control and treatment of the influenza virus(2). To create a successful 
influenza vaccination program for pandemic preparedness and seasonal influenza
prevention and control, antigenic variant identification is crucial (98). One major
limitation for implementing changes to the influenza vaccine is the time restriction on 
current virus strain assessment. Currently, recommendations are based on the future
impact of circulating viruses, most notably, emerging antigenic variants, before their full 
epidemiological significance is known (97).
Clinical signs and symptoms of influenza can include: fever, muscle aches,
headache, lethargy, dry cough, sore throat, nasal congestion, and possible runny nose
(120). Influenza diagnosis based on clinical signs and symptoms alone is difficult 
because they are similar to those caused by many other pathogens. There are several 
diagnostic tests available for the detection of influenza virus, including: viral culture, 






















fluoroimmunoassay, rapid influenza antigen detection tests (RIDTs), and reverse
transcription polymerase chain reaction (RT-PCR). Sensitivity and specificity of these
tests depend on type of test used, time from onset of illness until sample collection, type
of sample collected, sample handling, and test performance. 
Detection of influenza virus alone is not useful for vaccine preparation and 
identification of novel, circulating antigenic variants is crucial. Antigenic variant 
detection is conventionally dependent upon the serological assays such as 
hemagglutination inhibition (HI) assay and microneutralization (MN) assays (122). The
use of red blood cells (RBCs) as an indicator for binding affinity of antigen and 
antiserum is a limitation of the HI assays (251). Compared to HI assays, MN assays seem 
to be more sensitive and specific but are much more time-consuming and have
predominantly been used to validate the results from HI assays. Another drawback of the
HI assay is that it is notoriously noisy due to variation in types of RBCs used in the
assays (122) and subjective interpretations due to difficulty in automation and 
standardization of the operation.
The conventional serological assays require a large quantity of viruses, and thus 
viral isolation from clinical sample is a must. The pathogen isolation process is not only
time-consuming but also can change the antigenic properties of the original infecting
virus due to culture adaptation. This will result in data that does not accurately represent 
those antigenic properties in the circulating viruses in the hosts. Additionally, 
heterogeneous populations which contain minor antigenic variants can be skewed by cell



















Therefore, there is a critical need for a viral isolation-free and RBC independent assay to 
assess antigenic changes in circulating viruses.
As shown in earlier chapters, the novel antigenic variant detection method of
polyPLA was developed to address this need (220). Proximity ligation assay uses 
quantitative real time PCR (qRT-PCR) to detect antigen-antibody interactions (148). The
polyPLA assay quantifies antibody-antigen interactions for influenza viral proteins, 
including both HA and NA, against their corresponding antibodies in the polyclonal 
antisera. This novel method avoids the use of viral isolation with the direct use of clinical 
samples. Therefore no adaptation substitutions are created which can affect the
architecture of the HA receptor-binding site, thus avoiding altering interaction of the HA
protein with terminal sialic acid moiety (133).
With the scalability of qRT-PCR, an ideal polyPLA assay shall be able to
characterize viruses using a panel of reference sera, which can be either for a single HA
subtype, multiple HA subtypes or both. A multiplex polyPLA will be able to use a small
volume of samples to achieve the testing results for multiple sera. In addition, mixed 
infections of influenza viruses are not uncommon, presenting a great challenge in 
antigenic characterization because viral propagation could skew the viral population. A 
multiplex polyPLA assay can potentially detect antigenic variants in clinical samples 
with mixed infections, providing antigenic profiles for multiple variants in a single assay. 
The objective of this chapter is to develop and validate a multiplex assay to detect H1 and 





















Viruses and Sera. 
Isolates and their homologous ferret serum for human influenza a virus (IAV)
A/California/04/2007 (H1N1; CA/04) and A/Switzerland/9715293/2013 (H3N2; 
SW/9715293) were chosen to represent IAV vaccine virus strains. The anti-NP 
monoclonal antibody was obtained from BEI Resources (Manassas, VA, USA).
Biotinylation of monoclonal and polyclonal antibodies.
IgG, purified from polyclonal serum, and monoclonal antibody were separately
biotinylated with Biotin-XX Microscale Protein Labeling Kit (Invitrogen; Carlsbad, CA, 
USA), according to manufacturer’s specifications, at a protein molar ratio (MR) of 18. To 
remove excess biotin, dialysis was performed for 12 hours with 1X phosphate buffered 
saline (1X PBS, pH 7.2) at 4°C with Slide-A-Lyzer MINI dialysis device (7 kDa
molecular weight cut off, Thermo Fisher Scientific; Waltham, MA, USA). 
Random oligonucleotide generation.
Using the PLA oligonucleotide design program (252), which uses RNAfold and 
RNAplex from the ViennaRNA package(253), oligonucleotides of 40 nucleotides (nt)
were designed (Table 19). Each of the 40 nt DNA oligos (Eurofins; Louisville, KY, 
USA) has 20 nt sequence for primer targeting in PCR pre-amplification and qRT-PCR
(CAATCGAGAGGTGAGTGCAT and TACAGCGGCGTCTATATCAG; Eurofins; 
Louisville, KY, USA) and 20 bp unique connector sequence. Two 40 nt oligonucleotides, 
Probe B and Probe D, contain 5’-thiol labeled free 3’ -OH and one 40 bp oligonucleotide 








   
   
   
   
    
    
    
    
   





   
     
 
    
   
ligation. Two RNA connector oligos (CC1, CC2; IDT; Coralville, IA, USA) of 20 nt 
were included to make ligation of the two 40 bp oligos more specific. Additionally, two 
TaqMan probes of the homologous DNA sequence include different reporter dyes FAM 
or HEX for TaqMan probe A or TaqMan probe B, respectively (Eurofins; Louisville, KY, 
USA).  
Table 19 Multiplex polyPLA oligonucleotides, RNA connectors, primers, and 
TaqMan probes.
Sequence Name Sequence 5' to 3'
Probe A CTCAAAGAAAGTTGGCCGGACTGATATAGACGCCGCTGTA 5' free
Probe B CAATCGAGAGGTGAGTGCATGATCCCTGTCCAAACTTACG 3' free
Probe C GACACGTCCCTGAATTCGATCTGATATAGACGCCGCTGTA 5' free






TaqMan probe A CAAACTTACGCTCAAAGAAA BHQ1
HEX, 
TaqMan probe B TTCATTGAGGGACACGTCCC BHQ1
Oligonucleotides of 40 nucleotides (nt) were designed using the PLA oligonucleotide design 
program (252), which uses RNAfold and RNAplex from the ViennaRNA package (253), Each of
the 40 nt DNA oligo has 20 nt sequence for primer targeting in PCR amplification and qRT-PCR
(underlined) and 20 bp unique connector sequence. Two 40 nt oligonucleotides, Probe B and 
Probe D, contain 5’-thiol labeled free 3’ -OH and one 40 bp oligonucleotide and two, Probe A
and Probe C, contain 3’ –thiol labeled free 5’-phosphate end for ligation. Two RNA connector
oligos (CC1, CC2) of 20 nt were included to make ligation of the two 40 bp oligos more specific. 
Taqman probes of the homologous DNA sequence include different reporter dyes, FAM or HEX

















Thiol labeled oligos (100 µg) were DTT-reduced (50 mM DTT; Thermo Fisher 
Scientific; Waltham, MA, USA) and excess DTT was removed with Quick Spin 
Columns, Sephadex G-25, fine (Sigma-Aldrich; St. Louis, MO, USA). The eluate was 
directly combined with 0.5 nmol Maleimide-derived streptavidin (STV; Thermo Fisher 
Scientific; Waltham, MA, USA), incubated for 2 hours at 37°C, and reaction quenched 
with 0.5 µL of 0.5 M 2-mercaptoethanol. STV labeled oligos were then purified from free
DNA with protein precipitation, followed by DNA precipitation to remove free protein. 
For quality control, protein concentration was quantified with use of the Quant-iT Protein 
Assay Kit (Thermo Fisher Scientific; Waltham, MA, USA) and oligo concentration was 
measured at A260 on NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific; 
Waltham, MA, USA). Biotinylated antibodies (as prepared previously) were combined 
with STV-oligos in equal molar ratios (100 nM each), and incubated for 1 hour at room 
temperature. Lastly, proximity probes were diluted to 10 nM in 1x PBS with EDTA with 
1% BSA and 0.02% sodium azide and stored separately (5’ and 3’) at 4°C. 
Multiplex polyPLA.
Equal molar concentrations of each proximity probe were combined and 2 µL
proximity probe mixture was incubated with 2 µL antigen (lysed or unlysed virus) or 2 
µL non-protein control (1X PBS) at 37°C for 1 hour to allow the probes to bind to 
analytes. Then 96 µL of ligation mixture will be added to each sample, incubated at 16°C
for 60 minutes, followed by heat inactivation 65°C for 10 minutes. The ligation mixture
is as follows: 1X T4 ligation buffer (New England Biolabs), 10 µM connector 












       
  
   
 
 
a total volume of 25 µL, 20  µL ligation product was added to 5 µL pooled PCR mix (1X
PCR buffer, 1.5 mM MgCl2, 1 mM dNTP, 0.2 µM each forward and reverse
preamplification primer, 2 units Platinum Taq polymerase (Thermo Fisher Scientific; 
Waltham, MA, USA)) and PCR was completed as follows: 95°C for 10 minutes, 2 cycles 
of 95°C for 15 seconds, 46°C for 10 minutes, and 60°C for 2 minutes, followed by 15 
cycles of 95°C for 15 seconds, 54°C for 2 minutes, and 60°C for 2 minutes. Finally, 10 
µL of each sample was added to 1X Fast Universal Master Mix (Thermo Fisher
Scientific; Waltham, MA, USA), 1 µL of 18 µM qRT-PCR primers, 5 µM each of 
TaqMan probes, and H2O to each a total 20 µL. The qRT-PCR cycling was 95°C for 5 
minutes and 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. The threshold was 
set at 0.2, and each change in the cycle threshold (∆CT) was calculated by [average CT 
(NPC) – average CT (sample)]; qRT-PCR was performed on each sample in triplicate.
Data Analysis. 
polyPLA units were calculated to make antigenic properties across the testing
antigens comparable, as previously described polyPLA = a  (poly∆CT − mono∆CT) + b,
in which poly∆CT = polyclonal antiserum ΔCt values, mono∆CT = monoclonal antibody
against NP ΔCt values, a = 1.00, and b = 10.00, to eliminate negative numbers. A
mono∆CT cutoff of <3.00 has been traditionally used to distinguish if virus loads are too 









Polyclonal antibody panel evaluated.
In order to determine if the two polyclonal proximity probe pairs, in multiplex, 
could distinguish the homologous antigen from the heterologous antigen, polyclonal 
antibodies for CA/04 and SW/9715293 were used as proximity probes in multiplex
against CA/04 or SW/9715293 viruses alone. Each of the proximity probes had polyPLA 
units significantly higher for their homologous virus (p < 0.001 [Figure 22; Table 20]). 
CA/04 polyclonal antibodies against CA/04 virus had 12.8 (± 1.3) polyPLA units, 
whereas CA/04 polyclonal antibodies against SW/971293 virus had 2.6 (± 0.5) polyPLA 
units (p < 0.001). SW/971293 polyclonal antibodies against CA/04 virus had 0.4 (± 0.1) 
polyPLA units, while CA/04 polyclonal antibodies against SW/971293 virus had 15.2 (± 














   
      
       
       
 
Figure 22 Oligonucleotide-labeled antibodies for A/California/04/2009 (CA/04;
H1N1) and A/Switzerland/9715293/2013 (SW/9715293; H3N2) tested 
against CA/04, SW/9715293, and equal ratios of CA/04:SW/9715293 viral 
isolates.
Table 20 Oligonucleotide-labeled antibodies for A/California/04/2009 (CA/04;
H1N1) and A/Switzerland/9715293/2013 (SW/9715293; H3N2) tested 
against CA/04, SW/9715293, and equal ratios of CA/04:SW/9715293 viral 
isolates.
Virus
Antibody CA/04 SW/9715293 CA/04 + SW/9715293
polyPLA SD polyPLA SD polyPLA SD
CA/04 12.785 1.265 0.404 0.1 7.46 1.62




















Next, we wanted to determine if each of the polyclonal proximity probe pairs, in 
multiplex, could identify a mixed sample with both CA/04 and SW/9715293 viruses that 
were diluted to 1,000 TCID50/mL and mixed together. CA/04 polyclonal antibodies had 
7.5 (± 1.6) polyPLA units and SW/9715293 had 5.356 (± 0.1) polyPLA units against their
respective homologous viruses. While in the multiplex, each of the polyclonal proximity
probe pairs could identify a mixed sample with no significant difference in polyPLA 
value. 
Discussion
Influenza viruses are continuously changing their antigenicity in order to escape
host immunity (3, 4) causing a need to update the vaccine strains, almost annually, to 
obtain antigenic matches between the vaccine strain and the strain potentially causing
future outbreaks(5, 6). One major challenge for selecting an influenza vaccine strain is 
the time restriction of at least six months are required for vaccine manufacture before the 
next influenza season begins. For the Northern Hemisphere, the vaccine strain for the fall
season has to be determined early spring (usually on February 15th each year). The rapid 
identification of antigenic variants is essential for a successful influenza vaccine (98, 99). 
Although this method has proved its high-throughput capabilities, polyPLA still
has to prove its robustness (220, 232). To further improve the high-throughput 
capabilities of polyPLA, the multiplex assay was generated in order to detect antigenic 
variants from a panel of polyclonal antibodies. In this chapter, both H1N1 and H3N2 
polyclonal antibodies were used for subtype verification and proved the feasibility for a














   





reagents in a single reaction can lead to the detection of a mixed infection or assessing of 
antigenic profiles using multiple sera.  
Historically, both H1 and H3 have lost the ability to bind certain species of RBCs, 
which can impede typical serological assays(100, 123, 124). Rapid subtype verification in 
human clinical samples can be accomplished with the use of the polyPLA multiplex
assay in a panel consisting of H1 and H3 polyclonal antibodies as well as NP monoclonal 
antibodies. Because subtype alone does not fully give knowledge about novel viruses, 
additionally, a panel of contemporary H1 and/or H3 variants can be constructed in order 
to further antigenically characterize circulating virus. 
In the 2014-2015 influenza season, novel antigenic variants from two 
antigenically distinct H3N2 clades (3C.3a and 3C.2a) emerged and rapidly caused 
epidemic outbreaks. Low or undetectable hemagglutination activity was common, 
particularly for 3C.2a, which caused antigenic characterization to be more difficult for the 
novel viruses (118). The majority of the viruses analyzed were antigenically related to 
3C.3a and A/Switzerland/9715293/2013-like virus (3C.3a) that was chosen as the 2015-
2016 vaccine virus (118, 119). However, the following season, 2015-2016, the majority
of endemic viruses were 3C.2a but with 3C.3a co-circulating at a lower proportion (118). 
Like the previous year, antigenic characterization was technically challenging due to low 
or undetectable hemagglutination activity. As a result, A/Hong Kong/4801-like virus 
(3C.2a) remained as the 2016-2017 vaccine virus by the WHO (118). With the multiplex
polyPLA, a panel of polyclonal antibodies consisting of H3N2 variants 3C.2a and 3C.3a


















Mixed infections of influenza viruses are not uncommon, presenting a great 
challenge in antigenic characterization because viral propagation could skew the viral 
population. Infection within a host is not limited to one viral genome and the proliferating
population of viruses is closely related, but not identical (42-45). Additionally, 
cooperative interactions among two distinct variants of human viruses has been shown to 
increase population fitness(254). A panel of currently circulating variants should reveal 
clinical samples that consist of more than just one variant from the same subtype of 
influenza virus. Additionally, as seen in this application, mixed infections with different 
subtypes of influenza can be screened. This novel multiplex assay can detect antigenic
variants in clinical samples with mixed infections, providing a robust detection method 
for antigenic variant identification.
In a natural mixed infection, viral population diversity is in a transient state (254), 
unlike in equal ratios as shown here. Further studies need to be completed to measure the 
sensitivity and specificity at different viral titrations within a mixed infection. A cutoff
will need to be established for the lowest concentration of a single variant within a mixed 
infection that can be detected with this method. 
In summary, a multiplex assay was developed and validated for the detection of 
H1 and H3 antigenic variants in clinical samples in this chapter. The novel multiplex
polyPLA has the potential to give the complete antigenic profile of clinical samples 


















The studies in this dissertation have generated the following conclusions:
First, a novel polyPLA was developed and optimized to detect antigenic variants 
for influenza viruses in clinical samples, including those uncultivable samples. PolyPLA
is a viral isolate- and red blood cell-independent method and has been shown to be a high
throughput, sensitive assay for the identification of antigenic variants in clinical samples 
from human and animals (i.e. swine). A multiplex polyPLA was further developed to 
assess profiles for multiple antigenic variants simultaneously. This method can be used in 
diagnosis and surveillance (i.e. vaccine strain selection) not only for influenza viruses but
also other pathogens with potential antigenic variations. The novel polyPLA also 
provides a useful tool for us to understand antigenic evolution of influenza A viruses 
directly by using clinical samples. Further studies are needed to develop and optimize a
more comprehensive multiplex polyPLA for IAVs and other pathogens.
Second, this study further demonstrated the complexity of the ecology for 
influenza A virus. This study suggested antigenic diversity of IAVs in feral swine, an 
emerging and expanding natural host for IAVs. This study suggested that feral swine of 
the United States were exposed to H1, H3, H6, and H7 subtypes of IAVs, majority of 










Third, this study demonstrated the discrepancy of antigenic profiles for the H3N2 
IAVs in human clinical samples and the corresponding viral isolates, which could be 
generated by culture adaptation in the process of virus isolation. This study indicated the 
potential biases in antigenic data derived from viral isolates, which might not represent 


























1. Centers for Disease C, Prevention. 2010. Estimates of deaths associated with 
seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep 
59:1057-1062.
2. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB, Centers for Disease
C, Prevention Advisory Committee on Immunization P. 2004. Prevention and 
control of influenza: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep 53:1-40.
3. Webster RG, Laver WG, Air GM, Schild GC. 1982. Molecular mechanisms of 
variation in influenza viruses. Nature 296:115-121.
4. Nobusawa E, Nakajima K. 1988. Amino acid substitution at position 226 of the
hemagglutinin molecule of influenza (H1N1) virus affects receptor binding 
activity but not fusion activity. Virology 167:8-14.
5. Group WHOW, Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards 
S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, 
Levandowski R, Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, 
Wairagkar N, Wood J, Zambon M, Zhang W. 2012. Improving influenza
vaccine virus selection: report of a WHO informal consultation held at WHO
headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir 
Viruses 6:142-152, e141-145. 
6. Gerdil C. 2003. The annual production cycle for influenza vaccine. Vaccine
21:1776-1779.
7. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. 
Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179.
8. Rogers GN, D'Souza BL. 1989. Receptor binding properties of human and 
animal H1 influenza virus isolates. Virology 173:317-322.
9. Rogers GN, Paulson JC. 1983. Receptor determinants of human and animal 
influenza virus isolates: differences in receptor specificity of the H3 
























10. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, 
Kida H, Paulson JC, Webster RG, Kawaoka Y. 1998. Molecular basis for the
generation in pigs of influenza A viruses with pandemic potential. J Virol 
72:7367-7373.
11. Ma W, Kahn RE, Richt JA. 2008. The pig as a mixing vessel for influenza
viruses: Human and veterinary implications. J Mol Genet Med 3:158-166.
12. Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Kawaoka Y, 
Webster RG. 1994. Potential for transmission of avian influenza viruses to pigs. 
J Gen Virol 75 ( Pt 9):2183-2188. 
13. Scholtissek C. 1990. Pigs as 'mixing vessels' for the creation of new pandemic
influenza A viruses. Medical Principles and Practice 2:65-71.
14. Brockwell-Staats C, Webster RG, Webby RJ. 2009. Diversity of influenza
viruses in swine and the emergence of a novel human pandemic influenza A 
(H1N1). Influenza Other Respir Viruses 3:207-213.
15. Centers for Disease C, Prevention. 2016. Influenza (Flu): reported infections 
with variant influenza viruses in the United States since 2005.
16. Bowman AS, Sreevatsan S, Killian ML, Page SL, Nelson SW, Nolting JM, 
Cardona C, Slemons RD. 2012. Molecular evidence for interspecies 
transmission of H3N2pM/H3N2v influenza A viruses at an Ohio agricultural fair, 
July 2012. Emerg Microbes Infect 1:e33.
17. Killian ML, Swenson SL, Vincent AL, Landgraf JG, Shu B, Lindstrom S, Xu 
X, Klimov A, Zhang Y, Bowman AS. 2013. Simultaneous infection of pigs and 
people with triple-reassortant swine influenza virus H1N1 at a U.S. county fair. 
Zoonoses Public Health 60:196-201.
18. Wells DL, Hopfensperger DJ, Arden NH, Harmon MW, Davis JP, Tipple 
MA, Schonberger LB. 1991. Swine influenza virus infections. Transmission 
from ill pigs to humans at a Wisconsin agricultural fair and subsequent probable 
person-to-person transmission. JAMA 265:478-481. 
19. Cox CM, Neises D, Garten RJ, Bryant B, Hesse RA, Anderson GA, Trevino-
Garrison I, Shu B, Lindstrom S, Klimov AI, Finelli L. 2011. Swine influenza
virus A (H3N2) infection in human, Kansas, USA, 2009. Emerg Infect Dis 
17:1143-1144.
20. Gray GC, Bender JB, Bridges CB, Daly RF, Krueger WS, Male MJ, Heil GL, 
Friary JA, Derby RB, Cox NJ. 2012. Influenza A(H1N1)pdm09 virus among























21. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions 
WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes 
J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, 
Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, Lopez-Gatell H, 
Olivera H, Lopez I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson 
PD, Jr., Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore
AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, 
Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, 
Donis R, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 
A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
22. Centers for Disease C, Prevention. 2009. Swine influenza A (H1N1) infection 
in two children--Southern California, March-April 2009. MMWR Morb Mortal 
Wkly Rep 58:400-402. 
23. Shu B, Garten R, Emery S, Balish A, Cooper L, Sessions W, Deyde V, Smith
C, Berman L, Klimov A, Lindstrom S, Xu X. 2012. Genetic analysis and 
antigenic characterization of swine origin influenza viruses isolated from humans 
in the United States, 1990-2010. Virology 422:151-160. 
24. Centers for Disease C, Prevention. 2011. Limited human-to-human 
transmission of novel influenza A (H3N2) virus--Iowa, November 2011. MMWR
Morb Mortal Wkly Rep 60:1615-1617.
25. Centers for Disease C, Prevention. 2012. Update: Influenza A (H3N2)v 
transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 
60:1741-1744.
26. Elkeles G. 1934. Experimentelle Untersuchungen zur Aetiologie der Influenza (in 
German). Mededeelingen uit het Instituut vor Praeventieve Geneeskunde:60-79. 
27. Nelson MI, Wentworth DE, Culhane MR, Vincent AL, Viboud C, LaPointe
MP, Lin X, Holmes EC, Detmer SE. 2014. Introductions and evolution of 
human-origin seasonal influenza a viruses in multinational swine populations. J
Virol 88:10110-10119.
28. Howden KJ, Brockhoff EJ, Caya FD, McLeod LJ, Lavoie M, Ing JD, 
Bystrom JM, Alexandersen S, Pasick JM, Berhane Y, Morrison ME, 
Keenliside JM, Laurendeau S, Rohonczy EB. 2009. An investigation into 
human pandemic influenza virus (H1N1) 2009 on an Alberta swine farm. Can Vet 
J 50:1153-1161.
29. Anderson TK, Nelson MI, Kitikoon P, Swenson SL, Korslund JA, Vincent 
AL. 2013. Population dynamics of cocirculating swine influenza A viruses in the


























30. Ducatez MF, Hause B, Stigger-Rosser E, Darnell D, Corzo C, Juleen K, 
Simonson R, Brockwell-Staats C, Rubrum A, Wang D, Webb A, Crumpton 
JC, Lowe J, Gramer M, Webby RJ. 2011. Multiple reassortment between
pandemic (H1N1) 2009 and endemic influenza viruses in pigs, United States. 
Emerg Infect Dis 17:1624-1629. 
31. Lam TT, Zhu H, Wang J, Smith DK, Holmes EC, Webster RG, Webby R, 
Peiris JM, Guan Y. 2011. Reassortment events among swine influenza A viruses 
in China: implications for the origin of the 2009 influenza pandemic. J Virol 
85:10279-10285.
32. Vijaykrishna D, Poon LL, Zhu HC, Ma SK, Li OT, Cheung CL, Smith GJ, 
Peiris JS, Guan Y. 2010. Reassortment of pandemic H1N1/2009 influenza A 
virus in swine. Science 328:1529.
33. Starick E, Lange E, Fereidouni S, Bunzenthal C, Hoveler R, Kuczka A, 
grosse Beilage E, Hamann HP, Klingelhofer I, Steinhauer D, Vahlenkamp T, 
Beer M, Harder T. 2011. Reassorted pandemic (H1N1) 2009 influenza A virus 
discovered from pigs in Germany. J Gen Virol 92:1184-1188.
34. Nobusawa E, Sato K. 2006. Comparison of the mutation rates of human 
influenza A and B viruses. J Virol 80:3675-3678.
35. Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S. 1982. 
Rapid evolution of RNA genomes. Science 215:1577-1585. 
36. Steinhauer DA, Holland JJ. 1987. Rapid evolution of RNA viruses. Annu Rev 
Microbiol 41:409-433. 
37. Buonagurio DA, Nakada S, Parvin JD, Krystal M, Palese P, Fitch WM. 1986. 
Evolution of human influenza A viruses over 50 years: rapid, uniform rate of 
change in NS gene. Science 232:980-982.
38. Martinez C, del Rio L, Portela A, Domingo E, Ortin J. 1983. Evolution of the
influenza virus neuraminidase gene during drift of the N2 subtype. Virology
130:539-545.
39. Hampson A. 2002. Influenza virus antigens and 'antigenic drift', p 49-85. In
Potter C (ed), Influenza, vol 7.
40. Kilbourne ED. 1979. Molecular epidemiology--influenza as archetype. Harvey
Lect 73:225-258.
41. Steinhauer DA. 1999. Role of hemagglutinin cleavage for the pathogenicity of 
influenza virus. Virology 258:1-20.


























43. Eigen M. 1996. On the nature of virus quasispecies. Trends Microbiol 4:216-218. 
44. Lauring AS, Andino R. 2010. Quasispecies theory and the behavior of RNA 
viruses. PLoS Pathog 6:e1001005.
45. Domingo E, Martinez-Salas E, Sobrino F, de la Torre JC, Portela A, Ortin J, 
Lopez-Galindez C, Perez-Brena P, Villanueva N, Najera R, et al. 1985. The
quasispecies (extremely heterogeneous) nature of viral RNA genome populations:
biological relevance--a review. Gene 40:1-8.
46. Nowak MA. 1992. What is a quasispecies? Trends Ecol Evol 7:118-121.
47. Air GM. 2015. Influenza virus antigenicity and broadly neutralizing epitopes. 
Curr Opin Virol 11:113-121. 
48. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. 
Quasispecies diversity determines pathogenesis through cooperative interactions 
in a viral population. Nature 439:344-348.
49. Ciota AT, Ehrbar DJ, Van Slyke GA, Willsey GG, Kramer LD. 2012. 
Cooperative interactions in the West Nile virus mutant swarm. BMC Evol Biol
12:58.
50. Shirogane Y, Watanabe S, Yanagi Y. 2012. Cooperation between different 
RNA virus genomes produces a new phenotype. Nat Commun 3:1235.
51. Ke R, Aaskov J, Holmes EC, Lloyd-Smith JO. 2013. Phylodynamic analysis of 
the emergence and epidemiological impact of transmissible defective dengue
viruses. PLoS Pathog 9:e1003193.
52. Borderia AV, Isakov O, Moratorio G, Henningsson R, Aguera-Gonzalez S, 
Organtini L, Gnadig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, 
Shomron N, Vignuzzi M. 2015. Group Selection and Contribution of Minority
Variants during Virus Adaptation Determines Virus Fitness and Phenotype. PLoS
Pathog 11:e1004838.
53. WHO. 2013. Global epidemiological surveillance standards for influenza.
54. Layne SP, Beugelsdijk TJ, Patel CK, Taubenberger JK, Cox NJ, Gust ID, 
Hay AJ, Tashiro M, Lavanchy D. 2001. A global lab against influenza. Science
293:1729.
55. Kitler ME, Gavinio P, Lavanchy D. 2002. Influenza and the work of the World 
Health Organization. Vaccine 20 Suppl 2:S5-14.
56. Van Reeth K, Ma W. 2013. Swine influenza virus vaccines: to change or not to 






















   
   
 
57. Vincent AL, Ma W, Lager KM, Janke BH, Richt JA. 2008. Swine influenza
viruses a North American perspective. Adv Virus Res 72:127-154.
58. Bruschke CJ, Pittman M, Laddomada A. 2009. International regulations and 
standards for avian influenza, including the vaccine standards of the World 
Organisation for Animal Health. Rev Sci Tech 28:379-389. 
59. Rudolf M, Poppel M, Frohlich A, Breithaupt A, Teifke J, Blohm U, 
Mettenleiter T, Beer M, Harder T. 2010. Longitudinal 2 years field study of 
conventional vaccination against highly pathogenic avian influenza H5N1 in layer 
hens. Vaccine 28:6832-6840.
60. Savill NJ, St Rose SG, Keeling MJ, Woolhouse ME. 2006. Silent spread of 
H5N1 in vaccinated poultry. Nature 442:757.
61. Grund C, Abdelwhab el SM, Arafa AS, Ziller M, Hassan MK, Aly MM, 
Hafez HM, Harder TC, Beer M. 2011. Highly pathogenic avian influenza virus 
H5N1 from Egypt escapes vaccine-induced immunity but confers clinical 
protection against a heterologous clade 2.2.1 Egyptian isolate. Vaccine 29:5567-
5573.
62. Connie Leung YH, Luk G, Sia SF, Wu YO, Ho CK, Chow KC, Tang SC, 
Guan Y, Malik Peiris JS. 2013. Experimental challenge of chicken vaccinated 
with commercially available H5 vaccines reveals loss of protection to some 
highly pathogenic avian influenza H5N1 strains circulating in Hong Kong/China. 
Vaccine 31:3536-3542.
63. Harder TC, Grosse Beilage E, Lange E, Meiners C, Dohring S, Pesch S, Noe
T, Grund C, Beer M, Starick E. 2013. Expanded cocirculation of stable
subtypes, emerging lineages, and new sporadic reassortants of porcine influenza
viruses in swine populations in Northwest Germany. J Virol 87:10460-10476.
64. Vijaykrishna D, Smith GJ, Pybus OG, Zhu H, Bhatt S, Poon LL, Riley S, 
Bahl J, Ma SK, Cheung CL, Perera RA, Chen H, Shortridge KF, Webby RJ, 
Webster RG, Guan Y, Peiris JS. 2011. Long-term evolution and transmission 
dynamics of swine influenza A virus. Nature 473:519-522. 
65. Swayne DE. 2003. Vaccines for List A poultry diseases: emphasis on avian 
influenza. Dev Biol (Basel) 114:201-212.
66. Swayne DE, Beck JR, Garcia M, Stone HD. 1999. Influence of virus strain and 
antigen mass on efficacy of H5 avian influenza inactivated vaccines. Avian Pathol
28:245-255.
67. Swayne DEaK, D. R. 2008. Avian Influenza. In Swayne DE (ed), Vaccines, 


























68. Capua I, Terregino C, Cattoli G, Toffan A. 2004. Increased resistance of 
vaccinated turkeys to experimental infection with an H7N3 low-pathogenicity
avian influenza virus. Avian Pathol 33:158-163.
69. Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF, Williams CS, 
Grenfell BT. 2006. Host species barriers to influenza virus infections. Science
312:394-397.
70. Van Reeth K. 2007. Avian and swine influenza viruses: our current 
understanding of the zoonotic risk. Vet Res 38:243-260. 
71. Yasuda J, Shortridge KF, Shimizu Y, Kida H. 1991. Molecular evidence for a
role of domestic ducks in the introduction of avian H3 influenza viruses to pigs in 
southern China, where the A/Hong Kong/68 (H3N2) strain emerged. J Gen Virol 
72 ( Pt 8):2007-2010.
72. Webster RG, Campbell CH, Granoff A. 1971. The "in vivo" production of 
"new" influenza A viruses. I. Genetic recombination between avian and 
mammalian influenza viruses. Virology 44:317-328.
73. Webster RG, Campbell CH, Granoff A. 1973. The "in vivo" production of 
"new" influenza viruses. 3. Isolation of recombinant influenza viruses under 
simulated conditions of natural transmission. Virology 51:149-162.
74. Kida H, Shortridge KF, Webster RG. 1988. Origin of the hemagglutinin gene
of H3N2 influenza viruses from pigs in China. Virology 162:160-166.
75. Scholtissek C, Burger H, Bachmann PA, Hannoun C. 1983. Genetic
relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated 
from swine and birds. Virology 129:521-523.
76. Shortridge KF, Webster RG, Butterfield WK, Campbell CH. 1977. 
Persistence of Hong Kong influenza virus variants in pigs. Science 196:1454-
1455.
77. Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachmann PA. 1981. 
Evidence for the natural transmission of influenza A virus from wild ducts to 
swine and its potential importance for man. Bull World Health Organ 59:75-78. 
78. Guan Y, Shortridge KF, Krauss S, Li PH, Kawaoka Y, Webster RG. 1996. 
Emergence of avian H1N1 influenza viruses in pigs in China. J Virol 70:8041-
8046.
79. Peiris JS, Guan Y, Markwell D, Ghose P, Webster RG, Shortridge KF. 2001. 
Cocirculation of avian H9N2 and contemporary "human" H3N2 influenza A 



























80. Xu C, Fan W, Wei R, Zhao H. 2004. Isolation and identification of swine
influenza recombinant A/Swine/Shandong/1/2003(H9N2) virus. Microbes Infect 
6:919-925.
81. Choi YK, Nguyen TD, Ozaki H, Webby RJ, Puthavathana P, Buranathal C, 
Chaisingh A, Auewarakul P, Hanh NT, Ma SK, Hui PY, Guan Y, Peiris JS, 
Webster RG. 2005. Studies of H5N1 influenza virus infection of pigs by using
viruses isolated in Vietnam and Thailand in 2004. J Virol 79:10821-10825.
82. Karasin AI, Brown IH, Carman S, Olsen CW. 2000. Isolation and 
characterization of H4N6 avian influenza viruses from pigs with pneumonia in 
Canada. J Virol 74:9322-9327. 
83. Karasin AI, West K, Carman S, Olsen CW. 2004. Characterization of avian 
H3N3 and H1N1 influenza A viruses isolated from pigs in Canada. J Clin 
Microbiol 42:4349-4354.
84. Kaplan BS, DeBeauchamp J, Stigger-Rosser E, Franks J, Crumpton JC, 
Turner J, Darnell D, Jeevan T, Kayali G, Harding A, Webby RJ, Lowe JF. 
2015. Influenza Virus Surveillance in Coordinated Swine Production Systems, 
United States. Emerg Infect Dis 21:1834-1836.
85. Feng Z, Baroch JA, Long LP, Xu Y, Cunningham FL, Pedersen K, Lutman
MW, Schmit BS, Bowman AS, Deliberto TJ, Wan XF. 2014. Influenza A 
subtype H3 viruses in feral swine, United States, 2011-2012. Emerg Infect Dis 
20:843-846.
86. Lewis NS, Russell CA, Langat P, Anderson TK, Berger K, Bielejec F, Burke
DF, Dudas G, Fonville JM, Fouchier RA, Kellam P, Koel BF, Lemey P, 
Nguyen T, Nuansrichy B, Peiris JM, Saito T, Simon G, Skepner E, Takemae
N, consortium E, Webby RJ, Van Reeth K, Brookes SM, Larsen L, Watson
SJ, Brown IH, Vincent AL. 2016. The global antigenic diversity of swine 
influenza A viruses. Elife 5:e12217.
87. Lupiani B, Reddy SM. 2009. The history of avian influenza. Comp Immunol 
Microbiol Infect Dis 32:311-323.
88. Gipson PS HB, Berger T, Lee CD. 1997. Explanations for recent range
expansions by wild hogs into midwestern states. Proceedingsof the Great Plains 
Wildlife Damage Control Workshop 13:148-150.
89. Kristensen CS, Botner A, Takai H, Nielsen JP, Jorsal SE. 2004. Experimental 
airborne transmission of PRRS virus. Vet Microbiol 99:197-202. 
90. Lee CW, Senne DA, Suarez DL. 2004. Effect of vaccine use in the evolution of 

























91. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus AD, 
Fouchier RA. 2006. Global patterns of influenza a virus in wild birds. Science
312:384-388.
92. Stallknecht DE, Kearney MT, Shane SM, Zwank PJ. 1990. Effects of pH, 
temperature, and salinity on persistence of avian influenza viruses in water. Avian 
Dis 34:412-418.
93. Ito T, Okazaki K, Kawaoka Y, Takada A, Webster RG, Kida H. 1995. 
Perpetuation of influenza A viruses in Alaskan waterfowl reservoirs. Arch Virol 
140:1163-1172.
94. Sturm-Ramirez KM, Hulse-Post DJ, Govorkova EA, Humberd J, Seiler P, 
Puthavathana P, Buranathai C, Nguyen TD, Chaisingh A, Long HT, 
Naipospos TS, Chen H, Ellis TM, Guan Y, Peiris JS, Webster RG. 2005. Are
ducks contributing to the endemicity of highly pathogenic H5N1 influenza virus 
in Asia? J Virol 79:11269-11279.
95. Bailey E, Long LP, Zhao N, Hall JS, Baroch JA, Nolting J, Senter L, 
Cunningham FL, Pharr GT, Hanson L, Slemons R, DeLiberto TJ, Wan XF. 
2016. Antigenic Characterization of H3 Subtypes of Avian Influenza A Viruses 
from North America. Avian Dis 60:346-353.
96. Xu Y, Bailey E, Spackman E, Li T, Wang H, Long LP, Baroch JA, 
Cunningham FL, Lin X, Jarman RG, DeLiberto TJ, Wan XF. 2016. Limited 
Antigenic Diversity in Contemporary H7 Avian-Origin Influenza A Viruses from 
North America. Sci Rep 6:20688.
97. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, 
Grohmann G, Hay A, Kelso A, Klimov A, Odagiri T, Smith D, Russell C, 
Tashiro M, Webby R, Wood J, Ye Z, Zhang W, Writing Committee of the 
World Health Organization Consultation on Northern Hemisphere Influenza 
Vaccine Composition f. 2010. Epidemiological, antigenic and genetic
characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: 
basis for the WHO recommendation on the composition of influenza vaccines for
use in the 2009-2010 northern hemisphere season. Vaccine 28:1156-1167.
98. Katz JM, Naeve CW, Webster RG. 1987. Host cell-mediated variation in H3N2 
influenza viruses. Virology 156:386-395.
99. Salk JE, Suriano PC. 1949. Importance of antigenic composition of influenza
virus vaccine in protecting against the natural disease; observations during the 






















100. Azzi A, Bartolomei-Corsi O, Zakrzewska K, Corcoran T, Newman R, 
Robertson JS, Yates P, Oxford JS. 1993. The haemagglutinins of influenza A 
(H1N1) viruses in the 'O' or 'D' phases exhibit biological and antigenic 
differences. Epidemiol Infect 111:135-142.
101. Rocha EP, Xu X, Hall HE, Allen JR, Regnery HL, Cox NJ. 1993. Comparison 
of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly
from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen 
Virol 74 ( Pt 11):2513-2518.
102. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. 1983. 
Single amino acid substitutions in influenza haemagglutinin change receptor 
binding specificity. Nature 304:76-78.
103. Williams SP, Robertson JS. 1993. Analysis of the restriction to the growth of 
nonegg-adapted human influenza virus in eggs. Virology 196:660-665.
104. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, 
Schild GC. 1987. Structural changes in the haemagglutinin which accompany egg
adaptation of an influenza A(H1N1) virus. Virology 160:31-37.
105. Rogers GN, Pritchett TJ, Lane JL, Paulson JC. 1983. Differential sensitivity of 
human, avian, and equine influenza A viruses to a glycoprotein inhibitor of
infection: selection of receptor specific variants. Virology 131:394-408.
106. Rogers GN, Daniels RS, Skehel JJ, Wiley DC, Wang XF, Higa HH, Paulson
JC. 1985. Host-mediated selection of influenza virus receptor variants. Sialic 
acid-alpha 2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-
alpha 2,3Gal-specific wild type in ovo. J Biol Chem 260:7362-7367. 
107. Choppin PW, Tamm I. 1959. Two kinds of particles with contrasting properties 
in influenza A virus strains from the 1957 pandemic. Virology 8:539-542.
108. Choppin PW, Tamm I. 1960. Studies of Two Kinds of Virus Particles Which 
Comprise Influenza A2 Virus Strains : I. Characterization of Stable Homogeneous 
Substrains in Reactions with Specific Antibody, Mucoprotein Inhibitors, and 
Erythrocytes. J Exp Med 112:895-920.
109. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson
JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, 
Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y. 2014. Low 2012-
13 influenza vaccine effectiveness associated with mutation in the egg-adapted 























110. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, 
Hampson AW, Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, 
Kageyama T, Komadina N, Lapedes AS, Lin YP, Mosterin A, Obuchi M, 
Odagiri T, Osterhaus AD, Rimmelzwaan GF, Shaw MW, Skepner E, Stohr 
K, Tashiro M, Fouchier RA, Smith DJ. 2008. Influenza vaccine strain selection 
and recent studies on the global migration of seasonal influenza viruses. Vaccine 
26 Suppl 4:D31-34. 
111. Hensley SE. 2014. Challenges of selecting seasonal influenza vaccine strains for
humans with diverse pre-exposure histories. Curr Opin Virol 8:85-89.
112. Jin H, Zhou H, Liu H, Chan W, Adhikary L, Mahmood K, Lee MS, Kemble 
G. 2005. Two residues in the hemagglutinin of A/Fujian/411/02-like influenza
viruses are responsible for antigenic drift from A/Panama/2007/99. Virology
336:113-119.
113. Belser JA, Katz JM, Tumpey TM. 2011. The ferret as a model organism to 
study influenza A virus infection. Dis Model Mech 4:575-579.
114. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, 
Jones TC, Le NM, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, 
Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, 
Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WE, Le QM, 
Nguyen TH, Wertheim HF, Hurt AC, Osterhaus AD, Barr IG, Fouchier RA, 
Horby PW, Smith DJ. 2014. Antibody landscapes after influenza virus infection 
or vaccination. Science 346:996-1000.
115. Ampofo WK, Al Busaidy S, Cox NJ, Giovanni M, Hay A, Huang S, Inglis S, 
Katz J, Mokhtari-Azad T, Peiris M, Savy V, Sawanpanyalert P, Venter M, 
Waddell AL, Wickramasinghe G, Zhang W, Ziegler T, Group WHOW. 2013. 
Strengthening the influenza vaccine virus selection and development process:
outcome of the 2nd WHO Informal Consultation for Improving Influenza Vaccine
Virus Selection held at the Centre International de Conferences (CICG) Geneva, 
Switzerland, 7 to 9 December 2011. Vaccine 31:3209-3221. 
116. Xie H, Wan XF, Ye Z, Plant EP, Zhao Y, Xu Y, Li X, Finch C, Zhao N, 
Kawano T, Zoueva O, Chiang MJ, Jing X, Lin Z, Zhang A, Zhu Y. 2015. 
H3N2 Mismatch of 2014-15 Northern Hemisphere Influenza Vaccines and Head-
to-head Comparison between Human and Ferret Antisera derived Antigenic 
Maps. Sci Rep 5:15279.
117. Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, 
Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, 
Ahmed R, Wilson PC, Hensley SE. 2013. Immune history shapes specificity of 






















118. WHO. 2015. Recommended composition of influenza virus vaccines for use in 
the 2015-2016 northern hemisphere influenza season.
119. Bedford TN, RA. 2016. Seasonal influenza circulation patterns and projections 
for 2016-2017. 
120. Centers for Disease C, Prevention. 2016. Influenza signs and symptoms and the
role of laboratory diagnostics. 
https://www.cdc.gov/flu/professionals/diagnosis/labrolesprocedures.htm. 
Accessed 
121. Gambaryan AS, Tuzikov AB, Piskarev VE, Yamnikova SS, Lvov DK, 
Robertson JS, Bovin NV, Matrosovich MN. 1997. Specification of receptor-
binding phenotypes of influenza virus isolates from different hosts using synthetic 
sialylglycopolymers: non-egg-adapted human H1 and H3 influenza A and 
influenza B viruses share a common high binding affinity for 6'-sialyl(N-
acetyllactosamine). Virology 232:345-350.
122. Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. 2001. 
Hemagglutinin residues of recent human A(H3N2) influenza viruses that 
contribute to the inability to agglutinate chicken erythrocytes. Virology 289:74-
85.
123. Morishita T, Kobayashi S, Miyake T, Ishihara Y, Nakajima S, Nakajima K. 
1993. Host-specific hemagglutination of influenza A (H1N1) virus. Microbiol
Immunol 37:661-665.
124. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K. 2000. Change in 
receptor-binding specificity of recent human influenza A viruses (H3N2): a single 
amino acid change in hemagglutinin altered its recognition of 
sialyloligosaccharides. Virology 278:587-596.
125. Morishita T, Nobusawa E, Nakajima K, Nakajima S. 1996. Studies on the
molecular basis for loss of the ability of recent influenza A (H1N1) virus strains 
to agglutinate chicken erythrocytes. J Gen Virol 77 ( Pt 10):2499-2506.
126. Fitch WM, Bush RM, Bender CA, Cox NJ. 1997. Long term trends in the 
evolution of H(3) HA1 human influenza type A. Proc Natl Acad Sci U S A 
94:7712-7718.
127. Cox NJ, Bender CA. 1995. The molecular epidemiology of influenza viruses. 
Seminars in Virology 6:359-370.
128. Lindstrom S, Endo A, Sugita S, Pecoraro M, Hiromoto Y, Kamada M, 
Takahashi T, Nerome K. 1998. Phylogenetic analyses of the matrix and non-





















129. Lindstrom S, Sugita S, Endo A, Ishida M, Huang P, Xi SH, Nerome K. 1996. 
Evolutionary characterization of recent human H3N2 influenza A isolates from 
Japan and China: novel changes in the receptor binding domain. Arch Virol 
141:1349-1355.
130. Mori SI, Nagashima M, Sasaki Y, Mori K, Tabei Y, Yoshida Y, Yamazaki K, 
Hirata I, Sekine H, Ito T, Suzuki S. 1999. A novel amino acid substitution at the
receptor-binding site on the hemagglutinin of H3N2 influenza A viruses isolated 
from 6 cases with acute encephalopathy during the 1997-1998 season in Tokyo. 
Arch Virol 144:147-155.
131. Oh DY, Barr IG, Mosse JA, Laurie KL. 2008. MDCK-SIAT1 cells show 
improved isolation rates for recent human influenza viruses compared to 
conventional MDCK cells. J Clin Microbiol 46:2189-2194.
132. Patterson S, Oxford JS. 1986. Analysis of antigenic determinants on internal and 
external proteins of influenza virus and identification of antigenic subpopulations 
of virions in recent field isolates using monoclonal antibodies and immunogold 
labelling. Arch Virol 88:189-202. 
133. Gambaryan AS, Robertson JS, Matrosovich MN. 1999. Effects of egg-
adaptation on the receptor-binding properties of human influenza A and B viruses. 
Virology 258:232-239. 
134. Gambaryan AS, Marinina VP, Tuzikov AB, Bovin NV, Rudneva IA, Sinitsyn
BV, Shilov AA, Matrosovich MN. 1998. Effects of host-dependent glycosylation 
of hemagglutinin on receptor-binding properties on H1N1 human influenza A 
virus grown in MDCK cells and in embryonated eggs. Virology 247:170-177.
135. Govorkova EA, Matrosovich MN, Tuzikov AB, Bovin NV, Gerdil C, Fanget 
B, Webster RG. 1999. Selection of receptor-binding variants of human influenza
A and B viruses in baby hamster kidney cells. Virology 262:31-38.
136. WHO. 2014. WHO information for molecular diagnosis of influenza virus 
137. WHO. 2010. Use of influenza rapid diagnostic tests.
138. Faix DJ, Sherman SS, Waterman SH. 2009. Rapid-test sensitivity for novel 
swine-origin influenza A (H1N1) virus in humans. N Engl J Med 361:728-729. 
139. Ginocchio CC, Zhang F, Manji R, Arora S, Bornfreund M, Falk L, Lotlikar
M, Kowerska M, Becker G, Korologos D, de Geronimo M, Crawford JM. 
2009. Evaluation of multiple test methods for the detection of the novel 2009 
influenza A (H1N1) during the New York City outbreak. J Clin Virol 45:191-195. 
140. Vasoo S, Stevens J, Singh K. 2009. Rapid antigen tests for diagnosis of 
























141. Drexler JF, Helmer A, Kirberg H, Reber U, Panning M, Muller M, Hofling 
K, Matz B, Drosten C, Eis-Hubinger AM. 2009. Poor clinical sensitivity of 
rapid antigen test for influenza A pandemic (H1N1) 2009 virus. Emerg Infect Dis 
15:1662-1664.
142. Centers for Disease C, Prevention. 2009. Evaluation of rapid influenza
diagnostic tests for detection of novel influenza A (H1N1) Virus - United States, 
2009. MMWR Morb Mortal Wkly Rep 58:826-829.
143. Uyeki TM. 2003. Influenza diagnosis and treatment in children: a review of 
studies on clinically useful tests and antiviral treatment for influenza. Pediatr 
Infect Dis J 22:164-177. 
144. Uyeki TM, Prasad R, Vukotich C, Stebbins S, Rinaldo CR, Ferng YH, Morse
SS, Larson EL, Aiello AE, Davis B, Monto AS. 2009. Low sensitivity of rapid 
diagnostic test for influenza. Clin Infect Dis 48:e89-92. 
145. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. 2007. Performance of six
influenza rapid tests in detecting human influenza in clinical specimens. J Clin 
Virol 39:132-135.
146. Rouleau I, Charest H, Douville-Fradet M, Skowronski DM, De Serres G. 
2009. Field performance of a rapid diagnostic test for influenza in an ambulatory
setting. J Clin Microbiol 47:2699-2703.
147. WHO. 2011. Manual for the laboratory diagnosis and virological surveillance of 
influenza.
148. Schlingemann J, Leijon M, Yacoub A, Schlingemann H, Zohari S, Matyi-
Toth A, Kiss I, Holmquist G, Nordengrahn A, Landegren U, Ekstrom B, 
Belak S. 2010. Novel means of viral antigen identification: improved detection of 
avian influenza viruses by proximity ligation. J Virol Methods 163:116-122.
149. Fredriksson S, Dixon W, Ji H, Koong AC, Mindrinos M, Davis RW. 2007. 
Multiplexed protein detection by proximity ligation for cancer biomarker 
validation. Nat Methods 4:327-329.
150. Fan S, Macken CA, Li C, Ozawa M, Goto H, Iswahyudi NF, Nidom CA, 
Chen H, Neumann G, Kawaoka Y. 2013. Synergistic effect of the PDZ and 
p85beta-binding domains of the NS1 protein on virulence of an avian H5N1 
influenza A virus. J Virol 87:4861-4871.
151. Basler CF, Aguilar PV. 2008. Progress in identifying virulence determinants of 






















152. Li Z, Chen H, Jiao P, Deng G, Tian G, Li Y, Hoffmann E, Webster RG, 
Matsuoka Y, Yu K. 2005. Molecular basis of replication of duck H5N1 influenza
viruses in a mammalian mouse model. J Virol 79:12058-12064. 
153. Manzoor R, Sakoda Y, Nomura N, Tsuda Y, Ozaki H, Okamatsu M, Kida H. 
2009. PB2 protein of a highly pathogenic avian influenza virus strain 
A/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. 
J Virol 83:1572-1578.
154. Deng YM, Spirason N, Iannello P, Jelley L, Lau H, Barr IG. 2015. A 
simplified Sanger sequencing method for full genome sequencing of multiple
subtypes of human influenza A viruses. J Clin Virol 68:43-48. 
155. Hoper D, Hoffmann B, Beer M. 2011. A comprehensive deep sequencing
strategy for full-length genomes of influenza A. PLoS One 6:e19075.
156. Kampmann ML, Fordyce SL, Avila-Arcos MC, Rasmussen M, Willerslev E, 
Nielsen LP, Gilbert MT. 2011. A simple method for the parallel deep 
sequencing of full influenza A genomes. J Virol Methods 178:243-248.
157. Laassri M, Zagorodnyaya T, Plant EP, Petrovskaya S, Bidzhieva B, Ye Z, 
Simonyan V, Chumakov K. 2015. Deep Sequencing for Evaluation of Genetic
Stability of Influenza A/California/07/2009 (H1N1) Vaccine Viruses. PLoS One
10:e0138650. 
158. Junemann S, Sedlazeck FJ, Prior K, Albersmeier A, John U, Kalinowski J, 
Mellmann A, Goesmann A, von Haeseler A, Stoye J, Harmsen D. 2013. 
Updating benchtop sequencing performance comparison. Nat Biotechnol 31:294-
296.
159. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, 
Pallen MJ. 2012. Performance comparison of benchtop high-throughput 
sequencing platforms. Nat Biotechnol 30:434-439.
160. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni
A, Swerdlow HP, Gu Y. 2012. A tale of three next generation sequencing
platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq 
sequencers. BMC Genomics 13:341.
161. Glenn TC. 2011. Field guide to next-generation DNA sequencers. Mol Ecol 
Resour 11:759-769.
162. Croville G, Soubies SM, Barbieri J, Klopp C, Mariette J, Bouchez O, Camus-
Bouclainville C, Guerin JL. 2012. Field monitoring of avian influenza viruses: 
whole-genome sequencing and tracking of neuraminidase evolution using 454 





























163. Lin Z, Farooqui A, Li G, Wong GK, Mason AL, Banner D, Kelvin AA, 
Kelvin DJ, Leon AJ. 2014. Next-generation sequencing and bioinformatic
approaches to detect and analyze influenza virus in ferrets. J Infect Dev Ctries 
8:498-509.
164. Rutvisuttinunt W, Chinnawirotpisan P, Simasathien S, Shrestha SK, Yoon 
IK, Klungthong C, Fernandez S. 2013. Simultaneous and complete genome 
sequencing of influenza A and B with high coverage by Illumina MiSeq Platform. 
J Virol Methods 193:394-404.
165. Wilker PR, Dinis JM, Starrett G, Imai M, Hatta M, Nelson CW, O'Connor 
DH, Hughes AL, Neumann G, Kawaoka Y, Friedrich TC. 2013. Selection on 
haemagglutinin imposes a bottleneck during mammalian transmission of
reassortant H5N1 influenza viruses. Nat Commun 4:2636.
166. Zhou B, Lin X, Wang W, Halpin RA, Bera J, Stockwell TB, Barr IG, 
Wentworth DE. 2014. Universal influenza B virus genomic amplification 
facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol 
52:1330-1337.
167. Luksza M, Lassig M. 2014. A predictive fitness model for influenza. Nature
507:57-61.
168. Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF,
Osterhaus AD, Fouchier RA. 2004. Mapping the antigenic and genetic evolution 
of influenza virus. Science 305:371-376.
169. Bailey EL, LP Zhao, N. Hall, JS Baroch, JA Nolting, J. Senter, L. 
Cunningham, FL Pharr, GT Hanson, L. Slemons, RD DeLiberto, TJ Wan, 
XF. 2016. Antigenic characterization of H3 subtypes of avian influenza a viruses 
from North America. Avian Dis.
170. Xu YB, E. Spackman, E. Li, T. Wang, H. Long, LP. Baroch, JA 
Cunningham, FL Lin, X. Jarman, RG DeLiberto, TJ Wan, XF. 2016. Limited 
antigenic diversity in contemporary H7 avian-origin influenza a viruses from 
North America. Sci Rep 9:20688.
171. Webby RJ, Rossow K, Erickson G, Sims Y, Webster R. 2004. Multiple
lineages of antigenically and genetically diverse influenza A virus co-circulate in 
the United States swine population. Virus Res 103:67-73.
172. Ma W, Gramer M, Rossow K, Yoon KJ. 2006. Isolation and genetic
characterization of new reassortant H3N1 swine influenza virus from pigs in the




























   
173. Lorusso A, Vincent AL, Harland ML, Alt D, Bayles DO, Swenson SL, 
Gramer MR, Russell CA, Smith DJ, Lager KM, Lewis NS. 2011. Genetic and 
antigenic characterization of H1 influenza viruses from United States swine from 
2008. J Gen Virol 92:919-930. 
174. Hause BM, Oleson TA, Bey RF, Stine DL, Simonson RR. 2010. Antigenic
categorization of contemporary H3N2 Swine influenza virus isolates using a high-
throughput serum neutralization assay. J Vet Diagn Invest 22:352-359.
175. Olsen CW, Karasin AI, Carman S, Li Y, Bastien N, Ojkic D, Alves D, 
Charbonneau G, Henning BM, Low DE, Burton L, Broukhanski G. 2006. 
Triple reassortant H3N2 influenza A viruses, Canada, 2005. Emerg Infect Dis 
12:1132-1135.
176. Richt JA, Lager KM, Janke BH, Woods RD, Webster RG, Webby RJ. 2003. 
Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 
swine influenza viruses cocirculating in the United States. J Clin Microbiol 
41:3198-3205.
177. Lewis NS, Russell CA, Langat P, Anderson TK, Berger K, Bielejec F, Burke
DF, Dudas G, Fonville JM, Fouchier RA, Kellam P, Koel BF, Lemey P, 
Nguyen T, Nuansrichy B, Peiris JM, Saito T, Simon G, Skepner E, Takemae
N, consortium E, Webby RJ, Van Reeth K, Brookes SM, Larsen L, Watson
SJ, Brown IH, Vincent AL. 2016. The global antigenic diversity of swine 
influenza A viruses. Elife 5.
178. Feng Z, Gomez J, Bowman AS, Ye J, Long LP, Nelson SW, Yang J, Martin
B, Jia K, Nolting J, Cunningham F, Cardona C, Zhang J, Yoon KJ, Slemons 
R, Wan X-F. 2013. Antigenic characterization of H3N2 influenza A viruses from 
Ohio agricultural fairs. Journal of Virology 87:7655-7667. 
179. Scholtissek C. 1990. Pigs as 'mixing vessels' for the creation of new pandemic
influenza a viruses. Medical Principles and Practice 2:64-71.
180. Karasin AI, Olsen CW, Anderson GA. 2000. Genetic characterization of an 
H1N2 influenza virus isolated from a pig in Indiana. J Clin Microbiol 38:2453-
2456.
181. Zhang G, Kong W, Qi W, Long LP, Cao Z, Huang L, Qi H, Cao N, Wang W, 
Zhao F, Ning Z, Liao M, Wan XF. 2011. Identification of an H6N6 swine
influenza virus in southern China. Infect Genet Evol 11:1174-1177. 
182. Gipson PS, B. Hlavachick, T. Berger, C. D. Lee. Explanations for recent range


























183. Sun H, Cunningham FL, Harris J, Xu Y, Long LP, Hanson-Dorr K, Baroch
JA, Fioranelli P, Lutman MW, Li T, Pedersen K, Schmit BS, Cooley J, Lin
X, Jarman RG, DeLiberto TJ, Wan XF. 2015. Dynamics of virus shedding and 
antibody responses in influenza A virus-infected feral swine. J Gen Virol 
96:2569-2578.
184. WHO. 2011. Manual for the laboratory diagnosis and virological surveillance of 
influenza. Geneva : World Health Organization, 
185. Potter CW, Oxford JS. 1979. Determinants of immunity to influenza infection in 
man. Br Med Bull 35:69-75. 
186. Wyckoff AC, Henke SE, Campbell TA, Hewitt DG, VerCauteren KC. 2009. 
Feral swine contact with domestic swine: a serologic survey and assessment of 
potential for disease transmission. J Wildl Dis 45:422-429. 
187. Rajao DS, Gauger PC, Anderson TK, Lewis NS, Abente EJ, Killian ML, 
Perez DR, Sutton TC, Zhang J, Vincent AL. 2015. Novel Reassortant Human-
Like H3N2 and H3N1 Influenza A Viruses Detected in Pigs Are Virulent and 
Antigenically Distinct from Swine Viruses Endemic to the United States. J Virol 
89:11213-11222.
188. Gorman OT, Bean WJ, Kawaoka Y, Webster RG. 1990. Evolution of the
nucleoprotein gene of influenza A virus. J Virol 64:1487-1497.
189. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. 2004. Prevention and 
control of influenza: recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Recomm Rep 53:1-40.
190. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, 
Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, 
Mishra AC, Monto A, Siqueira M, Tashiro M, Waddell AL, Wairagkar N, 
Wood J, Zambon M, Zhang W. 2012. Improving influenza vaccine virus 
selection: report of a WHO informal consultation held at WHO headquarters, 
Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 6:142-152. 
191. WHO. 1982. Concepts and procedures for laboratory-based influenza
surveillance. U.S. Dept. of Health and Human Services.
192. Hirst GK. 1941. The Agglutination of Red Cells by Allantoic Fluid of Chick 
Embryos Infected with Influenza Virus. Science 94:22-23.
193. Grund S, Adams O, Wahlisch S, Schweiger B. 2011. Comparison of 
hemagglutination inhibition assay, an ELISA-based micro-neutralization assay
and colorimetric microneutralization assay to detect antibody responses to 


























    
194. Cox NJ, Bender, C.A. 1995. The molecular epidemiology of influenza viruses. 
Seminars in Virology 6:359-370.
195. Sun H, Yang J, Zhang T, Long LP, Jia K, Yang G, Webby R, Wan X-F. 
2013. Inferring influenza virus antigenicity using sequence data. mBio 4:4.
196. Lee HK, Tang JW, Kong DH, Loh TP, Chiang DK, Lam TT, Koay ES. 2013. 
Comparison of mutation patterns in full-genome A/H3N2 influenza sequences 
obtained directly from clinical samples and the same samples after a single
MDCK passage. PLoS One 8:e79252.
197. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and 
high throughput. Nucleic Acids Res 32:1792-1797.
198. Zwickl DJ. 2006. Genetic algorithm approaches for the phylogenetic analysis of 
large biological sequence datasets under the maximum likelihood criterion. Ph.D. 
dissertation. The University of Texas Austin.
199. Swofford DL. 1998. PAUP*: Phylogenic analysis using Parsimony. Sinauer,. 
Sunderland, Massachusetts.
200. Wan XF, Nguyen T, Davis CT, Smith CB, Zhao ZM, Carrel M, Inui K, Do 
HT, Mai DT, Jadhao S, Balish A, Shu B, Luo F, Emch M, Matsuoka Y, 
Lindstrom SE, Cox NJ, Nguyen CV, Klimov A, Donis RO. 2008. Evolution of
highly pathogenic H5N1 avian influenza viruses in Vietnam between 2001 and 
2007. PLoS One 3:e3462.
201. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006. 
Kinetics of influenza A virus infection in humans. J Virol 80:7590-7599. 
202. Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, Sebastian
R, Chong M, Tam T, De Serres G. 2007. Estimating vaccine effectiveness 
against laboratory-confirmed influenza using a sentinel physician network: results 
from the 2005-2006 season of dual A and B vaccine mismatch in Canada. 
Vaccine 25:2842-2851.
203. Wilson IA, Cox NJ. 1990. Structural basis of immune recognition of influenza
virus hemagglutinin. Annu Rev Immunol 8:737-771.
204. Hampson AW. 2002. Influenza virus antigens and ‘antigenic drift’. Perspectives 
in Medical Virology 7:49-85. 
205. Noah DL, Krug RM. 2005. Influenza virus virulence and its molecular 
determinants. Adv Virus Res 65:121-145.
206. Tellier R. 2009. Aerosol transmission of influenza A virus: a review of new























   
 
  
207. Tellier R. 2006. Review of aerosol transmission of influenza A virus. Emerg
Infect Dis 12:1657-1662.
208. WHO. 2014. Global Epidemiological Surveillance Standards for Influenza, on
WHO Press. 
http://www.who.int/influenza/resources/documents/WHO_Epidemiological_Influ 
enza_Surveillance_Standards_2014.pdf?ua=1. Accessed February 16, 2017.
209. Robertson JS. 1999. An overview of host cell selection. Dev Biol Stand 98:7-11; 
discussion 73-14.
210. Henning KJ. 2004. What is syndromic surveillance? MMWR Suppl 53:5-11.
211. Hirshon JM. 2000. The rationale for developing public health surveillance
systems based on emergency department data. Acad Emerg Med 7:1428-1432.
212. Irvin CB, Nouhan PP, Rice K. 2003. Syndromic analysis of computerized 
emergency department patients' chief complaints: an opportunity for bioterrorism 
and influenza surveillance. Ann Emerg Med 41:447-452. 
213. Varney SM, Hirshon JM. 2006. Update on public health surveillance in 
emergency departments. Emerg Med Clin North Am 24:1035-1052.
214. Frenk J, Gomez-Dantes O. 2002. Globalization and the challenges to health 
systems. Health Aff (Millwood) 21:160-165.
215. Daum LT, Canas LC, Arulanandam BP, Niemeyer D, Valdes JJ, Chambers 
JP. 2007. Real-time RT-PCR assays for type and subtype detection of influenza A 
and B viruses. Influenza Other Respir Viruses 1:167-175. 
216. Fitch WM, Leiter JM, Li XQ, Palese P. 1991. Positive Darwinian evolution in 
human influenza A viruses. Proc Natl Acad Sci U S A 88:4270-4274. 
217. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. 1999. Predicting the 
evolution of human influenza A. Science 286:1921-1925. 
218. Grenfell BT, Pybus OG, Gog JR, Wood JL, Daly JM, Mumford JA, Holmes 
EC. 2004. Unifying the epidemiological and evolutionary dynamics of pathogens. 
Science 303:327-332. 
219. Reed LJ, Muench H. 1938. A SIMPLE METHOD OF ESTIMATING FIFTY
PER CENT ENDPOINTS12. American Journal of Epidemiology 27:493-497.
220. Martin BE, Jia K, Sun H, Ye J, Hall C, Ware D, Wan XF. 2015. Detection of
influenza antigenic variants directly from clinical samples using polyclonal






















221. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. 2001. Universal primer 
set for the full-length amplification of all influenza A viruses. Arch Virol 
146:2275-2289.
222. Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, 
Wentworth DE. 2009. Single-reaction genomic amplification accelerates 
sequencing and vaccine production for classical and Swine origin human 
influenza a viruses. J Virol 83:10309-10313. 
223. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for
Illumina sequence data. Bioinformatics 30:2114-2120. 
224. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. 
Nat Methods 9:357-359.
225. Zerbino DR, Birney E. 2008. Velvet: algorithms for de novo short read assembly
using de Bruijn graphs. Genome Res 18:821-829.
226. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, 
Abecasis G, Durbin R, Genome Project Data Processing S. 2009. The
Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078-2079. 
227. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz
G, Mesirov JP. 2011. Integrative genomics viewer. Nat Biotechnol 29:24-26. 
228. Hancock D, Holler S. 1995. Optimizing cutpoints of diagnostic tests. Popul Med 
Newsl 8:1-5. 
229. Barnett JL, Yang J, Cai Z, Zhang T, Wan XF. 2012. AntigenMap 3D: an 
online antigenic cartography resource. Bioinformatics 28:1292-1293.
230. Cai Z, Zhang T, Wan XF. 2010. A computational framework for influenza
antigenic cartography. PLoS Comput Biol 6:e1000949.
231. Anonymous. 2013. Update of WHO biosafety risk assessment and guidelines for
the production and quality control of human influenza vaccines against avian 
influenza A(H7N9) virus.
232. Martin BE, Bowman AS, Li L, Nolting JM, Smith DR, Hanson LA, Wan XF. 
2017. Detection of Antigenic Variants of Swine Subtype H3 Influenza A Viruses 
from Clinical Samples. J Clin Microbiol doi:10.1128/JCM.02049-16. 
233. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-
binding sites of Hong Kong influenza haemagglutinin and their involvement in 





























234. Smyth RP, Schlub TE, Grimm A, Venturi V, Chopra A, Mallal S, Davenport 
MP, Mak J. 2010. Reducing chimera formation during PCR amplification to 
ensure accurate genotyping. Gene 469:45-51.
235. de Silva A, Messer W. 2004. Arguments for live flavivirus vaccines. Lancet 
364:500.
236. Scholtissek C. 1990. Pigs as ‘Mixing Vessels’ for the Creation of New Pandemic
Influenza A Viruses. Med Principles Pract 2:65-71.
237. Scholtissek C, Burger H, Kistner O, Shortridge KF. 1985. The nucleoprotein 
as a possible major factor in determining host specificity of influenza H3N2
viruses. Virology 147:287-294. 
238. Nelson MI, Vincent AL. 2015. Reverse zoonosis of influenza to swine: new 
perspectives on the human-animal interface. Trends Microbiol 23:142-153.
239. Bowman AS, Workman JD, Nolting JM, Nelson SW, Slemons RD. 2014. 
Exploration of risk factors contributing to the presence of influenza A virus in 
swine at agricultural fairs. Emerg Microbes Infect 3:e5.
240. Feng Z, Gomez J, Bowman AS, Ye J, Long LP, Nelson SW, Yang J, Martin
B, Jia K, Nolting JM, Cunningham F, Cardona C, Zhang J, Yoon KJ, 
Slemons RD, Wan XF. 2013. Antigenic characterization of H3N2 influenza A 
viruses from Ohio agricultural fairs. J Virol 87:7655-7667. 
241. USDA. 2012. Part II: Reference of Swine Health and Health Management in the
United States, 2012. Forth Collins, CO.
242. Van Reeth KM, W. 2013. Swine influenza virus vaccines: to change or not to 
change-that's the question. Current Topics In Microbiology And Immunology. 
370(173-200. 
243. USDA-APHIS. 2009. Autogenous biologics, 9 C.F.R. Ch. 1, Washington, DC.
244. Beato MS, Xu Y, Long LP, Capua I, Wan XF. 2014. Antigenic and genetic
evolution of low-pathogenicity avian influenza viruses of subtype H7N3 
following heterologous vaccination. Clin Vaccine Immunol 21:603-612.
245. WHO. 2011. WHO information for molecular diagnosis of influenza virus in 
humans.
246. Sullivan KM, Dean A, Soe MM. 2009. OpenEpi: a web-based epidemiologic
and statistical calculator for public health. Public Health Rep 124:471-474.
247. WHO. 2011. Manual for the laboratory diagnosis and virological surveillance of 





















248. Petric M, Comanor L, Petti CA. 2006. Role of the laboratory in diagnosis of 
influenza during seasonal epidemics and potential pandemics. J Infect Dis 194 
Suppl 2:S98-110.
249. Anonymous. 1999. Rapid diagnostic tests for influenza. Med Lett Drugs Ther 
41:121-122.
250. Control CfD, Prevention NCfIaRDN. 2016. Estimated Influenza Illnesses, 
Medical Visits, Hospitalizations, and Deaths Averted by Vaccination in the 
United States.
251. Influenza WCCfRaRo, Services USDoHaH. 1982. Concepts and procedures for
laboratory-based influenza surveillance, Washington, D.C.
252. Gobet N, Ketterer S, Meier M. 2014. Design and validation of DNA libraries 
for multiplexing proximity ligation assays. PLoS One 9:e112629.
253. Lorenz R, Bernhart SH, Honer Zu Siederdissen C, Tafer H, Flamm C,
Stadler PF, Hofacker IL. 2011. ViennaRNA Package 2.0. Algorithms Mol Biol
6:26.
254. Xue KS, Hooper KA, Ollodart AR, Dingens AS, Bloom JD. 2016. Cooperation 
between distinct viral variants promotes growth of H3N2 influenza in cell culture. 
Elife 5:e13974.
178
